UNCLASSIFIED

AD NUMBER

ADB286348

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Mar 2002. Other requests shall be referred to US Army Medical Research and Materiel Comd., 504 Scott St., Fort Detrick, MD 21702-5012.

AUTHORITY

USAMRMC ltr, dtd 28 July 2003

THIS PAGE IS UNCLASSIFIED
Award Number: DAMD17-98-1-8590

TITLE: Signal Transduction Pathway in Maspin-induced Tumor Suppression of Prostate Cancer

PRINCIPAL INVESTIGATOR: Karl X. Chai, Ph.D.

CONTRACTING ORGANIZATION: University of Central Florida
Orlando, Florida 32816

REPORT DATE: March 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Mar 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number:  DAMD17-98-1-8590
Organization: University of Central Florida

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

[Signature] 01/24/03
1. AGENCY USE ONLY (Leave blank) March 2002 Final (1 Sep 98 - 28 Feb 02)

4. TITLE AND SUBTITLE
Signal Transduction Pathway in Maspin-induced Tumor Suppression of Prostate Cancer

6. AUTHOR(S)
Karl X. Chai, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Central Florida
Orlando, Florida 32816
E-mail: kxchai@mail.ucf.edu

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

11. SUPPLEMENTARY NOTES
Original contains color plates: All DTIC reproductions will be in black and white.

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Distribution authorized to U.S. Government agencies only (proprietary information, Mar 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) The original purpose was to identify a receptor for maspin, a serpin tumor suppressor of breast and prostate cancers. Prostasin and hepsin serine proteases were examined as candidates. Prostasin was found to be down-regulated in high-grade prostate cancers and absent in invasive prostate and breast cancer cells, in which prostasin promoter hypermethylation was found. Prostasin was shown to be an invasion suppressor, via its GPI-anchored membrane form. Prostasin is involved in epithelial sodium channel activation and is regulated by the serpin protease nexin-1 (PN-1). Other cellular protein changes elicited by prostasin expression were also observed. A new project has been initiated to investigate the mechanisms of prostasin's anti-invasion function. A second new project has been initiated to evaluate the potential of using prostasin as a metastasis suppressor of breast cancer. A new hypothesis is proposed for a potential indirect interaction between maspin and prostasin based on their individually confirmed roles in sodium transport regulation. We demonstrated an up-regulation of hepsin in prostate cancer, but no direct interaction was established between maspin and hepsin at the biochemical or cellular level. Drosophila genetics was and will continue to be employed to investigate hepsin's role in cancer.

14. SUBJECT TERMS
Prostate Cancer, maspin, receptor, prostasin, hepsin, Drosophila, mutation

15. NUMBER OF PAGES
156

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT
Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE
Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT
Unclassified

20. LIMITATION OF ABSTRACT
Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102
Table of Contents

Cover.................................................................................................................................
SF 298................................................................................................................................. 2
Introduction........................................................................................................................... 4
Body..................................................................................................................................... 4
Key Research Accomplishments......................................................................................... 7
Reportable Outcomes.......................................................................................................... 8
Conclusions.......................................................................................................................... 10
References........................................................................................................................... 11
Appendices.......................................................................................................................... 11

Item 1: Chen et al., 2001a
Item 2: Chen et al., 2001b
Item 3: Narikiyo et al., 2002
Item 4: Chen and Chai, 2002a
Item 5: Chen and Chai, 2002b (submitted manuscript)
Item 6: Chen and Chai, 2002c (manuscript to be submitted)
Item 7: Bayer et al., 2002 (manuscript to be submitted)
(4) INTRODUCTION:

Maspin is a serine protease inhibitor (serpin) capable of suppressing breast and prostate cancers. The investigation of maspin tumor suppression in breast and prostate cancer cells led to the speculation of maspin’s interaction with a membrane-bound serine protease in these tissues or cancers. This interaction may be an initial signaling event to the tumor suppression pathways (manifested as inhibition of tumor cells’ motility and invasiveness in *in vitro* and *in vivo* assays, as well as tumor suppression of nude mouse xenografts) (Sheng et al., 1996). We had suggested in our original proposal that a human prostate-produced serine protease, prostasin, can serve the role of a maspin receptor/interactive protease based on our evaluation of prostasin’s putative structure and its substrate preference (Yu et al., 1994). We intended to investigate whether a direct interaction between maspin and prostasin can be established using conventional biochemistry and molecular biology methods. We also intended to identify the down-stream proteins in the maspin/prostasin signal transduction pathway taking advantage of *Drosophila* genetics methods. Further, an alternative candidate protease, human hepsin, will also be investigated for the same functions.

(5) BODY:

1). **Prostasin serine protease is a novel invasion suppressor and may be a key molecule in epithelial function and signal transduction**

In the execution of the work plan, we made the observation that prostasin serine protease is down-regulated in high-grade prostate cancers (Gleason 4/5) and absent in two invasive prostate cancer cell lines, DU-145 and PC-3. Maspin’s anti-invasion properties in prostate cancer were observed in these two cell lines (Sheng et al., 1996). The observation of an absence of prostasin in these cell lines effectively eliminated the prostasin serine protease as a direct receptor/interactive protein for maspin in its role of anti-invasion in prostate cancer. The experiments to investigate prostasin’s expression in DU-145 and PC-3 cells were based on an excellent suggestion from the review comments to our original proposal. We have since modified the Statement of Work concerning the investigation on prostasin serine protease as our findings were potentially important toward the understanding of prostate cancer biology. In one published paper (Chen et al., 2001a), we demonstrated that forced re-expression of recombinant human prostasin protein in DU-145 and PC-3 cells reduced the *in vitro* invasiveness by 68% and 42%, respectively, while showing no effect on cell proliferation. The results of this experiment suggest that the prostasin serine protease itself is a prostate cancer invasion suppressor. In this paper, we also established that prostasin’s anti-invasion activity is associated with a membrane-bound form of the protease, but not with the secreted form (purified, and added back to the cells *via* the culture media). In a second published paper (Chen et al., 2001b), we used a recombinant human prostasin serine protease (r-hPro) expressed in several human cell lines, including DU-145 and PC-3, to show that r-hPro is synthesized as a membrane-bound protein, while a free-form prostasin is secreted into the culture medium. Prostasin was also identified in nuclear and membrane fractions. The membrane-bound prostasin is anchored by a glycosylphosphatidylinositol (GPI)-linkage. Further, a novel prostasin-binding protein was identified exclusively in seminal vesicle fluid. Using an indirect enzymatic activity assay involving this prostasin-binding protein, we showed that prostasin is an active serine protease in its membrane-bound form. We had previously stated in an annual report (2001) that the identification of a specific prostasin-binding protein will facilitate the investigation of prostasin’s potential natural substrates or interactive proteins, possibly including maspin, leading the project back to the originally proposed goals of prostasin-maspin interaction. On this front, we have now purified and characterized this prostasin-binding protein and submitted a manuscript to the Journal of Biological Chemistry for review (Chen and Chai, 2002b). The identity
of the prostasin-binding protein was established to be a serpin (serine protease inhibitor), previously identified as protease nexin-1 (PN-1), known to promote neurite outgrowth and inhibit thrombin serine protease (Scott et al., 1985). Also on this front, many recent reports suggest that prostasin serine protease and its homologues in *Xenopus*, mice, and rats function as a proteolytic activator (CAP-1) of the epithelial sodium channel (ENaC), thus being implicated in kidney and airway diseases (Adachi et al., 2001; Donaldson et al., 2002; Vallet et al., 2002; Vuagniaux et al., 2000). We undertook a collaboration with one of the groups that reported such findings and together showed that prostasin is directly involved in ENaC activation and that prostasin expression in the kidney is regulated by aldosterone (Narikiyo et al., 2002). Still on this front, there is recent evidence by others that both maspin and the homologue of prostasin (CAP-1) are involved in epithelial culture “dome formation”, a phenomenon viewed as *in vitro* cell differentiation (Ichigi and Asashima, 2001; Zucchi et al., 2001). Interestingly, the roles played by maspin and prostasin seemed to be on opposite ends, with prostasin/CAP-1 being the promoter for this cellular event (Ichigi and Asashima, 2001) while maspin being the inhibitor (Zucchi et al., 2001). We have now formulated a new hypothesis that there may still be an interaction between prostasin serine protease and maspin, the serpin, at the cellular level, but it involves the membrane-bound prostasin and potentially other co-factors. Prostasin, maspin, and the putative co-factors regulate epithelial differentiation, potentially involving the ENaC. This new hypothesis will be further explored in our continued research endeavors as it represents a major under-explored area of research in prostate cancer: sodium transport. Our laboratory is in an advantageous position to pursue this line of research as we have gained the experience and re-tooled to work with membrane-bound proteases and their mechanisms.

As our new finding that prostasin itself is an invasion suppressor, we looked to investigate the cellular mechanisms and pathways involved in this process and observed major cellular protein changes resulting from prostasin re-expression in DU-145 and PC-3 cells. We have indicated in a previous annual report (2001), that in DU-145 and PC-3 cells expressing a recombinant human prostasin protein, a protein band migrating at approximately 120-130 kDa range in SDS-PAGE was found to be reduced in tyrosine phosphorylation, as compared to the vector-transfected control cells. We have proposed that the tyrosine phosphorylation-reduced 120-130-kDa protein could be focal adhesion kinase (FAK, 125 kDa) or p130Cas (130 kDa), both proteins have been implicated in promoting tumor invasion via increased cell motility when tyrosine-phosphorylated (Cary and Guan, 1999). Their tyrosine phosphorylation state in the prostate cancer cells expressing recombinant human prostasin is consistent with the fact that prostasin reduced invasiveness. A further observation was that protein kinase C alpha (PKCα) protein expression is reduced as a result of forced prostasin re-expression in the prostate cancer cells, also consistent with prostasin’s anti-invasion role. Increased PKCα activity has been implicated in promoting cell motility, and in turn, tumor invasion (Timar et al., 1996). These observations formed the basis of a new research grant proposal submitted to the DoD-PCRPO1 and is now funded and active (Grant No. DAMD17-02-1-0032, “Prostasin’s Role in Prostate Cancer”). In this project, the role of prostasin in prostate epithelial biology and signal transduction (normal versus pathological) will be examined.

We further investigated the molecular genetic mechanisms of prostasin gene inactivation in prostate cancer and observed prostasin promoter DNA hypermethylation at one location in DU-145 and PC-3 cells as compared to normal prostate epithelial cells and LNCaP (as indicated in Annual Report of 2001). This study was expanded to human breast cancer cells with the purpose of establishing a more generalized molecular genetic gene inactivation mechanism for prostasin in cancer. We were able to show that prostasin is also down-regulated in highly invasive breast cancer cells as compared to normal breast epithelial cells and non-invasive breast cancer cells. Prostasin also reduced breast cancer cell invasiveness *in vitro* by 50%, and prostasin promoter DNA hypermethylation was observed at multiple locations in the highly invasive breast cancer cells. Demethylation coupled with histone deacetylase
inhibition re-activated prostasin mRNA expression in the invasive breast cancer cells, providing evidence
to a causal relationship of the methylated state of prostasin promoter and the down-regulation of
prostasin expression in cancer. These results have been published recently (Chen and Chai, 2002a). We
then returned to the prostate cancer cells (LNCaP, DU-145, and PC-3) with the tools and methods
developed in the breast cancer study. We demonstrated that prostasin promoter DNA hypermethylation,
at multiple locations, is a causal mechanism of prostasin down-regulation in the invasive prostate cancer
cell lines DU-145 and PC-3. These results have been summarized in a new manuscript to be submitted
for publication (Chen and Chai, 2002b). Our results on prostasin expression and function in breast
cancer cells formed the basis of an IDEA proposal to the DoD-BCRP01 and is now funded (Grant No.
DAMD17-02-1-0338). In this project, we will examine the potential of using prostasin serine protease to
limit human breast cancer invasion and metastasis in an animal model.

Overall, the original award that funded the research on the relationship between prostasin serine
protease and the serpin tumor suppressor maspin has resulted in an unanticipated finding of a novel
invasion suppressor (prostasin). Despite the evidence that there does not seem to be a direct
molecular interaction between prostasin and maspin, recent progress by our own group and others
points to the potential of an indirect interaction via the regulation of the epithelial sodium channel,
implicating a role for both prostasin and maspin in epithelial differentiation. The present project,
upon its completion, represents a major shift of focus in terms of the molecules under examination
(from maspin and prostasin to prostasin), but maintains its original purpose of investigating signal
transduction pathways in prostate cancer, that in the long term, will also address the maspin issue.

2). Maspin, hepsin, and prostasin transgenic flies for the elucidation of the tumor
suppression signal pathway(s):

In the collaborating laboratory (led by Dr. von Kalm), transgenic Drosophila strains expressing
human maspin, prostasin and hepsin genes were generated and was applied in Drosophila genetic
manipulations to identify interactive genes/proteins. The maspin- or prostasin-expressing strains did
not exhibit any observable phenotype, consistent with their tumor/invasion suppressor functions or
roles in normal prostate tissue physiology. The hepsin-expressing strains all had malformed eyes,
which were not corrected upon cross-breeding with the maspin-expressing strains, indicating that the
Drosophila eye may not provide all necessary cellular pathways for the examination of a potential
maspin-hepsin interaction. This observation does not rule out any potential interaction of maspin and
hepsin.

We investigated hepsin expression in prostate cancer cell lines and in prostatectomy specimens to
support the basis of a potential interaction between maspin and hepsin. In the LNCaP and PC-3 cells,
RT-PCR analysis with hepsin-specific primers demonstrated its expression, and in situ histochemistry
using an anti-sense hepsin RNA probe showed an up-regulation of hepsin in high-grade prostate
cancer in 11 cases of radical prostatectomy (as indicated in Annual Report of 2000). The up-
regulation of hepsin in prostate cancer was later corroborated by recent reports from other groups
(Dhanasekaran et al., 2001; Luo et al., 2001; Magee et al., 2001; Stamey et al., 2001). A human
hepsin antibody was obtained from Dr. Kurachi of University of Michigan for use in an investigation
of direct maspin-hepsin interaction using the human cell lines, as planned in the original Statement of
Work. This antibody reagent, however, does not recognize hepsin protein produced in the native
form (such as that from the HepG2 cells, the source of the cloned hepsin cDNA), but only reacts with
recombinant hepsin produced in E. coli. Our attempts of using recombinant hepsin for interaction
studies with maspin were hampered by the high degree of difficulty in purifying recombinant hepsin.
It is an active serine protease that tends to degrade itself upon purification, but adding protease
inhibitors is not applicable in our studies since we need to maintain the serine protease activity of hepsin to evaluate its interaction with maspin. Maspin was shown to be capable of inhibiting angiogenesis of human prostate cancer cells injected into animals by Dr. Ming Zhang’s group in Baylor College of Medicine (Zhang et al., 2000). Since hepsin is involved in angiogenesis (activating Factor VII) (Kazama et al., 1995), we collaborated with Dr. Ming Zhang to perform a yeast two-hybrid assay on maspin and hepsin. Dr. Zhang’s group was unable to establish a direct interaction between maspin and hepsin using the respective cDNA’s in a yeast two-hybrid assay. This lack of proof from the yeast two-hybrid assay, however, still does not rule out an interaction between hepsin and maspin as in the yeast two-hybrid system the proteins may not be in the correct conformation, particularly for hepsin for being a transmembrane protein.

The transgenic Drosophila strains that express hepsin in the eyes were used to identify other potential interactive proteins for hepsin, a tumor-promoting serine protease (Torres-Rosado et al., 1993) and a potential prostate cancer marker (Dhanasekaran et al., 2001; Luo et al., 2001; Magee et al., 2001; Stamey et al., 2001). Recent progress in Dr. von Kalm’s laboratory has indicated that hepsin may be hyper-activating the epidermal growth factor receptor (EGFR) signaling pathway via proteolytically cleaving the Drosophila homologue of transforming growth factor alpha (TGFα). The preliminary results were obtained when the hepsin-expressing flies that manifest malformed eyes were bred with deletion mutants for phenotype rescue. It appeared that hepsin expression in the Drosophila eye causes the cells within the eye imaginal disc to adopt an inappropriate developmental fate. Specifically, of the two cell types that are present in the disc, photoreceptor cells and pigment cells, hepsin expression causes a conversion of photoreceptor cells to pigment cells. Since photoreceptor cell formation requires properly regulated EGFR signaling, it is consistent with the observation that a deletion mutant of the Drosophila homologue of TGFα can rescue the hepsin eye-malformation phenotype. These preliminary results will form the basis of a future joint research proposal between our two laboratories as EGFR signaling is highly relevant to prostate cancer (Kim et al., 1999).

3). Stubble, a membrane-bound serine protease in Drosophila, provides a model for studying signal pathway(s):

Based on our new hypothesis, prostasin’s anti-invasion mechanism may involve regulation of cell motility, in turn, the regulation of the structure and potential changes of structure of the cytoskeleton. In Drosophila, the stubble, a potentially membrane-bound serine protease, has been shown by genetic means to affect cytoskeleton organization, in that fly legs are malformed in stubble mutants (von Kalm et al., 1995). Dr. von Kalm’s laboratory has now further demonstrated that the stubble serine protease plays a role in RhoA signaling, which is involved in cell motility (Wittmann et al., 2001). The data from Dr. von Kalm’s group are summarized in a manuscript to be submitted for publication (Bayer et al., 2002). Also, the stubble project is now potentially funded by the National Institutes of Health (Grant proposal No. 1R15GM65884-01; “Serine Protease Action in Drosophila Development”). The ultimate goal of this line of research is to help understand the roles played by membrane-bound serine proteases in cytoskeleton regulation, providing insights to prostate cancer relevant cytoskeleton and cell motility research.

(6) KEY RESEARCH ACCOMPLISHMENTS:

- Prostasin expression is found to be down-regulated in high-grade (Gleason 4/5) prostate cancers.
Prostasin was shown to be a novel invasion suppressor of prostate and breast cancers.

Prostasin down-regulation in invasive prostate and breast cancer cells is the result of promoter DNA hypermethylation at multiple locations.

Prostasin's sub-cellular localization has been thoroughly investigated and prostasin's membrane anchorage was confirmed.

A prostasin-binding protein has been identified in mouse seminal vesicle. Using this serpin-like protein (in the context of the seminal vesicle extract mixture), we were able to show that the membrane-bound prostasin is an active serine protease.

The prostasin-binding protein has been purified and characterized. It is identified as a serpin type serine protease inhibitor, previously known as protease nexin-1 (PN-1).

Prostasin is involved in proteolytic activation of the epithelial sodium channel (ENaC), implicating a role for prostasin in epithelial differentiation, also implicating an interaction with maspin.

Prostasin re-expression in human prostate cancer cell lines DU-145 and PC-3 elicited cellular protein changes that potentially could implicate prostasin in regulating cell motility. These cellular protein changes are the reduction of tyrosine phosphorylation of a 120-130-kDa protein, suspected to be FAK or p130Cas; and the down-regulation of PKCa protein expression.

The speculated role of prostasin in regulating cell motility led to the undertaking of transgenic fly work to investigate membrane serine proteases' roles in cell signaling. *Drosophila* strains expressing human hepsin have been established and used to probe prostate cancer-relevant cell signaling events in flies.

(7) REPORTABLE OUTCOMES:

- manuscripts, abstracts, presentations;

The following papers have been published (reprints attached to report):


The following manuscript has been submitted for publication (attached to report):

The following manuscripts will be submitted for publication (attached to report):

1. Chen LM, Chai KX. The prostatin gene promoter is hypermethylated in invasive human prostate cancer cells.


The following presentations were made at the meeting indicated:


- patents and licenses applied for and/or issued;

1. A full utility patent application under the title of “A Method of Identifying and Treating Invasive Carcinomas” has been filed with the USPTO. Co-inventors: Karl X. Chai, Li-Mei Chen, Lee Chao, and Julie Chao.

- degrees obtained that are supported by this award;


- funding applied for based on work supported by this award;

1. DoD-PCRP01, “Prostasin’s Role in Prostate Cancer”
   
   Principal Investigator: Karl X. Chai, Ph.D.
   Co-investigator: Li-Mei Chen, M.D., Ph.D.
   Grant Number: DAMD17-02-1-0032
   Type: Idea Award
   Period: 11/19/2001 - 12/28/2004
   Total Direct Cost: $353,167

2. National Institutes of Health, “The Role of Serine Protease Inhibitors in Fertility”,
   Principal Investigator: Li-Mei Chen, M.D., Ph.D.
   Grant Number: HD40241
3. DoD-BCRP01, “Prostasin Serine Protease as A Breast Cancer Invasion Marker And A Metastasis Suppressor”
Principal Investigator: Karl X. Chai, Ph.D.
Co-investigators: Li-Mei Chen, M.D., Ph.D.; Ying Zhang, Ph.D.
Grant Number: DAMD17-02-1-0338
Type: Idea Award
Period: 07/01/2002 – 06/30/2005
Total Direct Cost: $232,776 (pending final negotiation)

The following proposal has been reviewed and is likely to be funded (Priority Score 151):
Principal Investigator: Laurence H. von Kalm, Ph.D.
Proposal Number: 1R15GM65884-01
Period: 07/01/02 – 06/30/05
Total Direct Cost: $100,000

List of personnel receiving pay
Li-Mei Chen, M.D., Ph.D.
Cynthia A. Bayer, Ph.D.

(8) CONCLUSIONS:

We have demonstrated that prostasin serine protease is a novel invasion suppressor of prostate and breast cancers and have discovered a molecular mechanism for its down-regulation in cancer, promoter DNA hypermethylation. We have investigated prostasin’s cellular and biochemical properties and paved the way for an in-depth investigation of the mechanisms of prostasin’s biological functions. We have also established a model system in the fruit fly for an in-depth investigation of hepsin signaling as hepsin is now recognized as a potential prostate cancer marker.

“So What Section” The currently completed research has the following implications toward the diagnosis or treatment of human prostate cancer:

1). An assay (test) may be established to determine the level of production of human prostasin in prostate cancer using an immunological reagent (antibody) for diagnosis or prognosis of the invasiveness of prostate cancer since we have demonstrated a correlation between prostasin’s down-regulation and prostate cancer grade.

2). A molecular genetic assay (test) may also be established to determine the methylation state of the prostasin promoter in prostate cancer and the result may be applicable to prostate cancer diagnosis or prognosis.

3). Our demonstration of prostasin serine protease activity in the membrane-bound form may lead us to the identification of prostate cancer relevant molecules. The identification and investigation of these molecules will offer us better understanding of the progression of prostate cancer and may lead to the development of diagnostics and drugs.
REFERENCES:


(c) Chen LM, Chai KX. The prostasin gene promoter is hypermethylated in invasive human prostate cancer cells. 2002, to be submitted.


Down-Regulation of Prostasin Serine Protease:  
A Potential Invasion Suppressor in Prostate Cancer

Li-Mei Chen,1 G. Byron Hodge,2 Luis A. Guarda,3 James L. Welch,4 Norman M. Greenberg,5 and Karl X. Chai*1

1Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida  
2Walt Disney Memorial Cancer Institute, Florida Hospital, Orlando, Florida  
3Department of Pathology, Florida Hospital, Orlando, Florida  
4Urologic Oncology, M.D. Anderson Cancer Center, Orlando, Florida  
5Department of Cell Biology, Baylor College of Medicine, Houston, Texas

BACKGROUND. Prostasin is a serine protease predominantly expressed in normal prostate epithelial cells. The biological function of prostasin has not been determined.

METHODS. Western blot and RT-PCR analyses were used to examine the expression of prostasin in prostate cancer cell lines. Immunohistochemistry was used to evaluate prostasin protein expression in human prostate cancer. An in vitro Matrigel invasion assay was used to test the invasiveness of prostate cancer cell lines forced to express recombinant prostasin.

RESULTS. Both prostasin protein and mRNA were found to be expressed in normal human prostate epithelial cells and a non-invasive human prostate cancer cell line, the LNCaP, but neither was found in invasive human prostate cancer cell lines DU-145 and PC-3. Prostasin mRNA expression was absent in invasive prostate cancer cell lines of a transgenic mouse model. Immunohistochemistry analysis showed that prostasin protein expression is down-regulated in high-grade prostate cancer. Transfection of DU-145 and PC-3 cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 68 and 42%, respectively.

CONCLUSIONS. Our data indicate that prostasin may be implicated in normal prostate biology and is able to suppress prostate cancer invasion in vitro. Prostate 48:93–103, 2001. © 2001 Wiley-Liss, Inc.

KEY WORDS: cell line; gene expression; immunohistochemistry; prostatectomy; transfection

INTRODUCTION

For men in the US, prostate cancer is the most commonly diagnosed cancer, and the second leading cause of cancer-related death [1]. The primary goals of prostate cancer research are to find new markers or assays for early detection, and new methods to control invasion and metastasis. Our laboratory’s research focus is on the roles played by serine proteases and serine protease inhibitors in the development or progression of cancer. In this report we describe the results on a serine protease, prostasin [2].

The conventional paradigm of protease involvement in the development and progression of cancer has been the assignment of a usually negative role to the proteases, such as promoting tumor invasion [3]. In turn, the conventional paradigm of protease inhibitors in relation to cancer is usually a regard of...
a beneficial effect for the presence of these molecules [4]. Recently, however, the picture of a new paradigm is beginning to emerge for several serine proteases in breast, prostate, and testicular cancers. A "normal epithelial cell specific-1" (NES1) serine protease was found to be down-regulated in breast and prostate cancers, and it functions as a tumor suppressor [5]. A prostate-specific serine protease, prostase [6], was shown to be expressed in normal prostate but not in prostate cancer cell lines DU-145 and PC-3. The expression of a testis-specific serine protease, testisin, was shown to be lost in testicular cancer through either a loss of gene [7] or methylation in the promoter [8]. Further, transfection of human testicular cancer cells with a testisin cDNA reduced the tumor growth of xenografts of these cells in nude mice, suggesting a tumor suppressor function for testisin [8]. The testisin serine protease is potentially membrane-bound as suggested by its structure and confirmed by immunohistochemistry [7].

Prostasin serine protease is an acidic protein (pI 4.5-4.8) of approximately 40 kDa in molecular mass [2]. It is predominantly made in the prostate gland (~140 ng/mg protein), with lesser amounts (2-6 ng/mg protein) also found in the bronchi, colon, kidney, liver, lung, pancreas, and the salivary glands [2]. Prostasin is secreted in the prostatic fluid, and can be detected in the semen (~9 μg/ml). Prostasin expression is localized to the epithelial cells of human prostate gland by in situ hybridization histochemistry using an antibody or an anti-sense RNA probe [2,9]. Molecular cloning of a full-length human prostasin cDNA revealed that its predicted amino acid residue sequence contains a carboxyl-terminal hydrophobic region that can potentially anchor the protein on the membrane [9]. At the amino acid level, prostasin is similar to plasma kallikrein, coagulation factor XI, hepsin, plasminogen, acrosin, prostase, and, in particular, testisin (sharing 44% sequence identity) [6,7,9]. A membrane-bound, Xenopus kidney epithelial cell sodium channel-activating protease (CAP1) was shown to be highly homologous to human prostasin as well (sharing 53% sequence identity at the amino acid level) [10]. Prostasin is encoded by a single-copied gene, which is located on human chromosome 16p11.2 [11].

The secreted prostasin cleaves synthetic substrates in vitro preferentially at the carboxyl-terminal side of Arg residue, and is thus considered a trypsin-like serine protease [2]. The physiological function of prostasin, however, has remained unknown. In an effort to define the physiological function of prostasin, we examined the expression of this protease in primary human prostate epithelial cells or human prostate cancer cell lines. Our findings indicated a potential down-regulation of prostasin in highly invasive prostate cancer cells. Three prostate cancer cell lines derived from the transgenic adenocarcinoma of the mouse prostate (TRAMP) model [12] were also shown to have null or reduced prostasin expression at the mRNA level. A down-regulation of prostasin protein expression was demonstrated in immunohistochemistry studies of prostate cancer tissue sections. These results implicate a function for prostasin serine protease in normal prostate, and its loss of expression may contribute to tumor progression. To test our hypothesis, we transfected invasive human prostate cancer cells with a full-length human prostasin cDNA, and showed that a restoration of prostasin expression reduces the invasiveness of the cancer cells in vitro.

MATERIALS AND METHODS

Cell Culture

All tissue culture media, sera, and supplements were purchased from LifeTechnologies (Gaithersburg, MD), except for those noted otherwise.

A normal human prostate epithelial cell primary culture (CC-2555) was obtained from Clonetics (San Diego, CA), and maintained in the supplied medium (prostate epithelial cell basal medium, containing bovine pituitary extract, hydrocortisone, human epidermal growth factor, epinephrine, transferrin, insulin, retinoic acid, tri-iodothyronine, gentamicin, and amphotericin). The culture was kept at 37°C with 5% CO₂ and used for experiments at the third passage.

Human prostate cancer cell lines LNCaP, DU-145, and PC-3 were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The PC-3 cells were maintained in F-12K medium supplemented with 10% fetal bovine serum (FBS) while the LNCaP and the DU-145 cells were maintained in RPMI-1640 medium supplemented with 10% FBS and 1 mM sodium pyruvate, and all were kept at 37°C with 5% CO₂.

The TRAMP-C1, C2, and C3 cell lines derived from the TRAMP model were cultured as previously described [12], in D-MEM with high glucose and L-glutamine, but without sodium pyruvate; supplemented with 5% Nu-serum (Collaborative Biochemical, Bedford, MA), 5% FBS, 5 μg/ml insulin, and 10⁻⁸ M dihydrotestosterone (DHT, Sigma-Aldrich Co., St Louis, MO), at 37°C with 5% CO₂.

RNA Preparation and Analysis by RT-PCR–Southern Blot

Prostates of C57BL/6 mice (Harlan, Indianapolis, IN), or confluent cell cultures were used for total RNA
extraction using the RNeasy kit from QIAGEN (Valencia, CA). The use of animals was approved by the IACUC of the University of Central Florida.

The human prostasin-specific RT-PCR (reverse transcription-polymerase chain reaction)/Southern blot analysis was performed as described previously [9]. One microgram of total RNA was used in the RT-PCR with two human prostasin gene-specific oligonucleotide primers [9], a Southern blot of the resolved RT-PCR samples was probed with a third prostasin gene-specific oligonucleotide [9], detecting an amplified 232 bp fragment.

The mouse prostasin-specific RT-PCR was performed using the following oligonucleotide primers: upstream, 5'-ATC ACC GGT GGT GGC AGT GC-3', downstream, 5'-TGG CTG CAG GGA GGC AGA TG-3' which were derived from a mouse prostasin mRNA (cDNA) sequence (GenBank Accession Number: A1527990). This reported mouse prostasin cDNA sequence is 73% identical to the reported human prostasin cDNA sequence [9]. The sequence of the downstream RT-PCR primer is complementary to both the human and mouse prostasin mRNA, while the upstream PCR primer is unique to the mouse prostasin mRNA. The PCR fragment that was amplified with these two primers is 342 bp in length. We probed the amplified PCR product with a full-length human prostasin cDNA to confirm the identity of the amplified PCR fragment as the mouse prostasin homolog. One microgram of RNA was used in the RT (at 37°C for 1 h followed by 94°C for 5 min) and the PCR with the following program: 94°C/1 min–60°C/1 min–72°C/2 min for 30 cycles. One-fifth of the PCR product for each sample was resolved RT-PCR samples was probed with a third one microgram of RNA was used in the RT-PCR with two human prostasin gene-specific oligonucleotide primers [9], a Southern blot of the resolved RT-PCR samples was probed with a third prostasin gene-specific oligonucleotide [9], detecting an amplified 232 bp fragment.

The mouse prostasin-specific RT-PCR was performed using the following oligonucleotide primers: upstream, 5'-ATC ACC GGT GGT GGC AGT GC-3', downstream, 5'-TGG CTG CAG GGA GGC AGA TG-3' which were derived from a mouse prostasin mRNA (cDNA) sequence (GenBank Accession Number: A1527990). This reported mouse prostasin cDNA sequence is 73% identical to the reported human prostasin cDNA sequence [9]. The sequence of the downstream RT-PCR primer is complementary to both the human and mouse prostasin mRNA, while the upstream PCR primer is unique to the mouse prostasin mRNA. The PCR fragment that was amplified with these two primers is 342 bp in length. We probed the amplified PCR product with a full-length human prostasin cDNA to confirm the identity of the amplified PCR fragment as the mouse prostasin homolog. One microgram of RNA was used in the RT (at 37°C for 1 h followed by 94°C for 5 min) and the PCR with the following program: 94°C/1 min–60°C/1 min–72°C/2 min for 30 cycles. One-fifth of the PCR product for each sample was resolved in a 0.8% agarose gel, Southern-transferred to an Immobilon-N membrane (Fisher Scientific, Pittsburgh, PA), and probed with a full-length human prostasin cDNA labeled by nick-translation using a reagent kit (LifeTechnologies). Following the hybridization, the membrane was washed to a final stringency of 1xSSPE/0.1% SDS (1xSSPE: 0.18 M NaCl, 10 mM NaH2PO4, 1 mM Na2EDTA, pH 7.4), at 60°C before an exposure of 30 min at –80°C to an X-ray film without an intensifying screen.

In both the human and mouse prostasin-specific RT-PCR, the following primers were used to co-amplify the β-actin mRNA for control of RNA quality and quantity: upstream, 5'-GAA CCC TAA GGC CAA CCG TG-3', downstream, 5'-TGG CAT AGA GGT CTT TAC GG-3'.

**Tissue Specimens and Immunohistochemistry**

Human prostate tissues were obtained from radical prostatectomies performed at the Florida Hospital South Orlando location, Orlando, FL, or the Orlando Regional Medical Center (ORMC), Orlando, FL. The procurement of human tissues was approved by the Institutional Review Boards (IRB) of Florida Hospital, ORMC, and the University of Central Florida. None of the subjects examined in our study underwent prior hormonal, radiation, or chemotherapy. Tissues were fixed in formalin, paraffin-embedded, and sectioned at 4 μm thickness. The sections used in our study contained both benign and neoplastic tissues, as evaluated upon hematoxylin/eosin staining of the adjacent sections.

Immunohistochemistry was performed according to Yu et al. [2] with some modifications. Briefly, the human prostate sections were de-paraffinized in Hemo-De (Fisher Scientific) followed by rehydration in a decreasing series of alcohol. The prostate sections were subjected to a standard antigen retrieval procedure (BD Pharmingen, San Diego, CA) in citrate buffer, pH 6.0, followed by treatment in 3% H2O2. After blocking the sections with 10% goat serum (LifeTechnologies) in TBS-T (10 mM Tris–HCl, pH 7.6, and 150 mM NaCl, containing 0.1% Triton X-100), a prostasin-specific antibody [2] (diluted at a ratio of 1:500 in the blocking solution) was added for an incubation of 2 h, followed by an incubation of 1 h with the secondary antibody, goat anti-rabbit IgG (Sigma-Aldrich Co., used at 20 μg/ml). The sections were then incubated with the peroxidase: anti-peroxidase complex (Sigma-Aldrich Co., 1:200) for 1 h. Sections were washed in TBS/0.1% Tween-20 between steps. The color reaction was performed by incubating the sections with 3,3'-diaminobenzidine tetrahydrochloride (0.5 mg/ml, LifeTechnologies) and H2O2 (0.03%) for 15 min. The prostate sections were then counterstained with hematoxylin, dehydrated in an increasing series of alcohol, and mounted with Permount (Fisher Scientific). Control sections were treated with the same procedures as described above, except that a pre-immune rabbit serum was used in place of the prostasin-specific antiserum.

**Evaluation of Immunohistochemical Staining**

Sections from 39 radical prostatectomy specimens were subjected to prostasin immunostaining. For each section used in prostasin immunostaining, an adjacent section was stained with hematoxylin/eosin and evaluated by a pathologist (L.A.G.) to determine tumor Gleason grades [13]. Prostasin immunostaining in each tumor area with a distinct Gleason grade was recorded as a separate observation (n). For each case, we selected 1–4 sections to examine the different regions of the prostate from the patient. In total, 128 sections were evaluated. Prostasin immunostaining in
the prostate sections was evaluated by adopting, with modifications, the scoring system used for HercepTest™ (DAKO Corporation, Carpinteria, CA). A score of 0 is assigned to areas with no staining. A score of 1 (+) is assigned to areas with faint epithelial staining and/or staining in fewer than 10% of cells. Scores 0 and 1 are defined as negative for the data summarized in Table I. A score of 2 (++) is assigned to areas with moderate epithelial staining in more than 10% of cells, and a score of 3 (+++) is assigned to areas with strong staining in more than 10% of cells. Scores 2 and 3 are defined as positive for the data summarized in Table I. Areas selected for scoring were viewed under 100× magnifying power. The differences in prostasin-specific staining mean scores between tumor grades were examined by analysis of variance (ANOVA, defining P < 0.05 as being significant).

**Transfection of Cell Lines with Plasmid DNA and Selection of Stable Transfectants**

A pREP-8 (Invitrogen, Carlsbad, CA) plasmid carrying a full-length human prostasin cDNA [9] was provided by Dr. Julie Chao of the Medical University of South Carolina (Charleston, SC). This plasmid was used to transfect the DU-145 cells. For transfection of the PC-3 cells, we re-engineered the plasmid as follows. The histidinol-resistance element of this human prostasin cDNA plasmid was removed via a Bgl II digestion (a 3,475 bp fragment), and replaced with a neomycin (G418)-resistance element, via an EcoRI V-Dra I fragment (3,439 bp) of the pcDNA3 vector (Invitrogen). The resulting plasmid contains a full-length human prostasin cDNA under the control of the RSV promoter, a G418-resistance element, and the EBNA-1 element for episomal expression in primate cells. A similar drug-resistance gene rearrangement was made for the pREP-8 plasmid without the human prostasin cDNA, and the resulting plasmid was used as a vector control in our experiments. Drug-resistance genes were rearranged to make the new prostasin cDNA plasmid carry a G418-resistance element, because in our earlier experiments we found that the PC-3 cell line was not sensitive to the histidinol drug selection.

Transfection was carried out using a BTX-600 Electro-Cell-Manipulator (Gentronics, San Diego, CA) according to the recommended procedures. Briefly, 1,000,000 pelleted cells were re-suspended in 0.3 ml of the culture medium, and mixed with 50 μg of plasmid DNA dissolved in 0.1 ml of sterile distilled water. The cell/DNA mixture was then transferred to a 4 mm cuvette and pulsed at 200 V, 1600 μF, 72 μ, and 500 V/C setting on the BTX-600. Following the pulse, cells remained in the cuvette at room temperature for 30 min before being transferred to a 25 cm² tissue culture flask containing the proper culture medium.

At 24 h post-electroporation, the culture medium was replaced with fresh medium containing either 5 mM histidinol (for DU-145 selection) or 800 μg/ml G418 (for PC-3 selection) and maintained in the presence of the drugs until colonies appeared (5–7 days). Colonies (100–200) were then dispersed via trypsinization, and maintained in the presence of drugs as a polyclonal culture without colony isolation. Cells transfected with the human prostasin cDNA plasmids were assayed in Western blot analysis for expression of the prostasin protein, using vector-transfected cells as negative control.

**Western Blot Analysis**

Cells grown to 80–100% confluence were washed three times in 1× PBS (phosphate-buffered saline, pH 7.4), and then lysed in TBS containing 1% Triton X-100 on ice for 30 min. The total lysates were
centrifuged at 14,000 rpm for 30 min at 4°C to remove the pellet. Protein concentration was determined using a DC (detergent compatible) protein assay kit (Bio-Rad, Hercules, CA). The samples were then subjected to SDS-PAGE followed by Western blot analysis using a prostasin-specific antibody [2]. Briefly, cell lysates were resolved in 10% gels under reducing conditions before electrotransfer to nitrocellulose (NC) membranes (Fisher Scientific). Upon complete protein transfer, the NC membranes were blocked in BLOTTO (5% non-fat milk made with TBS/0.1% Tween-20, pH 7.6), incubated with the prostasin-specific antibody diluted at a ratio of 1:2,000 in BLOTTO, followed by an incubation with the secondary antibody, goat anti-rabbit IgG conjugated to HRP (horseradish peroxidase) (Sigma-Aldrich Co.; used at 1:10,000). The bound secondary antibody was detected using enhanced-chemiluminescence (ECL) reagents (Pierce, Rockford, IL) according to the supplier's recommendations. All procedures were performed at room temperature, and the membranes were washed between steps.

**Matrigel Chemoinvasion Assay**

An in vitro Matrigel chemoinvasion assay was performed as follows. Basement membrane Matrigel stock (10 mg/ml, Collaborative Biochemical, Bedford, MA) was thawed overnight on ice in a refrigerator (0-4°C). Transwell invasion chambers (Costar, Cambridge, MA) with 8 μm pore polycarbonate filters (growth area 0.33 cm²) were coated with a diluted Matrigel (50 μg/filter, a 1:3 dilution of the stock with chilled serum-free medium was used for coating). The gel was solidified by incubating the coated filters at 37°C for 60 min in a moist chamber. The lower chambers of the Transwell plates were filled with 0.6 ml serum-free medium, supplemented with 25 μg/ml fibronectin (Sigma-Aldrich Co.). Ten thousand cells in 0.1 ml serum-free OPTI-MEM I medium were placed onto each Matrigel-coated filter. The filter cartridge was then inserted into the lower chamber and the assembled plates were incubated at 37°C for 24 h. After removing the medium, the filters were washed three times in 1 x PBS, fixed at room temperature for 20 min in 4% paraformaldehyde made with 0.1 M phosphate buffer (pH 7.4), and then washed three times with the phosphate buffer. The filters were then stained with 1% toluidine blue (LabChem, Inc., Pittsburgh, PA) for 2 min. The cells on the Matrigel surface were removed with a Q-tip, and all cells on the underside of each filter were counted under a light microscope after mounting the filter on a glass slide. The invasion assays were done in triplicates per cell type for three times.

**RESULTS**

**Prostasin Expression Is Absent in Invasive Prostate Cancer Cell Lines**

Normal human prostate epithelial cells and three human prostate cancer cell lines were subjected to Western blot analysis using a prostasin-specific antibody. As shown in Figure 1 (upper panel), prostasin is detected as a 40 kDa band in normal human prostate epithelial cells (CC-2555) and in the non-invasive prostate cancer cell line LNCaP. The prostasin protein was not detected in two highly invasive human prostate cancer cell lines, DU-145 and PC-3, when the same amount of total cellular protein was analyzed.

By means of RT-PCR/Southern blot analysis, we demonstrated a corresponding difference of prostasin mRNA expression in these cells as well. Prostasin mRNA is detected in the CC-2555 and LNCaP cells, but not in the DU-145 or PC-3 cells (Fig. 1, middle panel). A co-amplification of a house-keeping gene, β-actin, message (Fig. 1, lower panel) was used as a control for the quantity and quality of the RNA used.
Prostasin protein was detected in the cytoplasm and on the plasma membrane (apical) of benign epithelial cells lining the secretory lumen as well as in the secretion inside the lumen (Fig. 3A and B, score 3, or ++), confirming the results of Yu et al. [2]. When a pre-immune rabbit serum was used in place of the prostasin antiserum, no staining was observed in either the non-tumor epithelia (Fig. 3C and D) or tumor epithelia (Fig. 3E). Tumor epithelia displayed various degrees of prostasin immunostaining as shown in Figure 3F-L. In Gleason grade 1–2 tumors, moderate prostasin staining was seen in the cytoplasm and on the plasma membrane of some epithelial cells, as well as in the secretion in the lumen (Fig. 3G and H, score 2, or ++). In Gleason grade 3 tumors, a lesser number of epithelial cells displayed the moderate level prostasin staining (Fig. 3I and J). In Gleason grade 4–5 tumors, most epithelial cells did not show any prostasin staining, while some prostasin staining can be seen in rare, sporadic tumor cells (Fig. 3K and L, as indicated by the arrow, score 0).

Re-expression of Human Prostasin Protein in Invasive Human Prostate Cancer Cells Reduces Invasiveness In Vitro

Following the electroporation and drug selection, 100–200 colonies formed for each transfected cell type. All colonies for each transfected cell type were kept in a mixed culture as polyclonal transfectants for the ensuing experiments. Polyclonal DU-145 and PC-3 cells transfected with the human prostasin cDNA (designated DU-145/Pro, and PC-3/Pro, respectively) were confirmed to express the human prostasin protein, as shown in the Western blot analysis of the cell lysates (Fig. 4, upper panel). The vector-transfected cells, designated DU-145/Vector or PC-3/Vector, respectively, were used as negative control in

---

Prostasin

342 bp

β-Actin

560 bp

Fig. 2. Mouse prostasin mRNA expression. Total RNA (1 μg) from a normal mouse prostate (whole), and the TRAMP-C cells were subjected to an RT-PCR using two mouse prostasin-specific oligonucleotide primers (see Materials and Methods). The amplified mouse prostasin message (a cDNA band of 342 bp) was then probed with a full-length human prostasin cDNA, as shown in the autoradiogram in the upper panel. Note the strong signal of mouse prostasin message in the normal prostate RNA sample but not in RNA samples of the TRAMP-C cells. Co-amplification of a 560 bp mouse β-actin message (as shown in the gel photograph in the lower panel) confirmed the quality and the quantity of the RNA applied in each RT-PCR.

The data indicate that prostasin expression is lost in highly invasive human prostate cancer cell lines. Loss of prostasin expression was also seen in mouse prostate cancer cell lines. Since the human prostasin antibody does not cross-react with the mouse prostasin protein (data not shown), we examined mouse prostasin expression in the cell lines by RT-PCR/Southern blot hybridization with a human prostasin cDNA probe. Mouse prostasin mRNA was detected in normal mouse prostate, but was not detected in the TRAMP-C cell lines (Fig. 2, upper panel). Again, a co-amplification of a mouse house-keeping gene, β-actin, message was used as a control for RNA quantity and quality (Fig. 2, lower panel). A weak amplified mouse prostasin mRNA signal could be seen in the nontumorigenic [12] TRAMP-C3 cells after a prolonged exposure, but not in the tumorigenic and invasive [12,14] TRAMP-C1 and TRAPM-C2 cells (data not shown).

Expression of Prostasin Protein Is Reduced in Human Prostate Cancer

Prostatectomy specimens from 39 patients (128 sections) were subjected to immunohistochemistry using a prostasin-specific antibody. Overall, in nontumor or benign prostate epithelia, 89.0% of the examined areas demonstrated positive staining for prostasin protein and 11.0% were considered negative (see MATERIALS AND METHODS for scoring criteria). In tumor specimens that were examined, prostasin was detected in 93.3% of the low Gleason grade areas (<grade 2), 44.4% of Gleason grade 3 areas, and 15.4% of Gleason grade 4–5 areas (data summarized in Table 1). The mean prostasin immunostaining score was found significantly decreased in high-grade prostate tumors as compared to that of non-tumor or low-grade (1–2) areas (ANOVA, P < 0.0001).

Representative staining images of non-tumor (benign) areas and prostate tumor areas are shown in Figure 3. The prostasin protein was detected in the cytoplasm and on the plasma membrane (apical) of benign epithelial cells lining the secretory lumen as well as in the secretion inside the lumen (Fig. 3A and B, score 3, or ++), confirming the results of Yu et al. [2]. When a pre-immune rabbit serum was used in place of the prostasin antiserum, no staining was observed in either the non-tumor epithelia (Fig. 3C and D) or tumor epithelia (Fig. 3E). Tumor epithelia displayed various degrees of prostasin immunostaining as shown in Figure 3F-L. In Gleason grade 1–2 tumors, moderate prostasin staining was seen in the cytoplasm and on the plasma membrane of some epithelial cells, as well as in the secretion in the lumen (Fig. 3G and H, score 2, or ++). In Gleason grade 3 tumors, a lesser number of epithelial cells displayed the moderate level prostasin staining (Fig. 3I and J). In Gleason grade 4–5 tumors, most epithelial cells did not show any prostasin staining, while some prostasin staining can be seen in rare, sporadic tumor cells (Fig. 3K and L, as indicated by the arrow, score 0).
Fig. 3. Immunoperoxidase staining of prostatic in human prostate. Paraffin-embedded human prostate sections were stained for prostatic protein expression evaluation using a specific antibody [2] as described in MATERIALS AND METHODS. Prostatic-positive staining (brown color) was detected in the cytoplasm and apical membrane in non-tumor or benign epithelial cells (image A, or B: the boxed area of A). When prostatic antibody was omitted in the immunohistochemistry procedures, neither non-tumor (image C, or D: the boxed area of C), nor tumor epithelial cells (image E) displayed any staining. Tumor epithelial cells showed reduced prostatic staining (image F) as compared to non-tumor epithelial cells in adjacent areas (image F). Representative areas in which prostatic staining is reduced in tumor epithelial cells are shown in image G, or H: the boxed area of G (Gleason grade 2); image I, or J: the boxed area of I (Gleason grade 3), and image K, or L: the boxed area of K (Gleason grade 4). Magnification: A, C, E, I, and K: 25×; G: 100×; B, D, F, H, J and L: 200×.
Fig. 3. (Continued)
Prostasin Down-Regulation in Prostate Cancer

**DISCUSSION**

Human prostasin serine protease was discovered in 1994 but its function was not defined [2]. We present evidence in this report to demonstrate prostasin as a potential invasion suppressor of prostate cancer.

In the prostate, prostasin is synthesized by the epithelial cells and may assume a membrane-bound form in these cells [2,9]. The demonstration of prostasin protein and mRNA expression in normal human prostate epithelial cells (Fig. 1) suggested that prostasin may have a function in normal prostate biology. On the other hand, a loss of prostasin expression in prostate cancer may also suggest a role for prostasin in suppressing prostate cancer progression. In the present study, the following results support our hypothesis: (1) Two highly invasive human prostate cancer cell lines, the DU-145 and the PC-3 [15], do not express prostasin at either the protein level or the mRNA level, while a non-invasive human prostate cancer cell line, the LNCaP [15], expresses this serine protease at both the mRNA and the protein levels (Fig. 1). (2) A loss of mouse prostasin mRNA expression was demonstrated in the tumorigenic and invasive [12,14] prostate cancer cell lines TRAMP-C1 and -C2 (Fig. 2). (3) Immunohistochemistry analysis of human prostate cancer demonstrated a downregulated pattern of prostasin protein expression in high-grade prostate tumors (Fig. 3, and Table I).

Genetically, prostate tumors are heterogeneous and multi-focal in nature, in that one patient's gross-anatomy tumor comes from multiple initial lesions which are caused by different initial transformation events and progress to different stages by different ensuing transformations [16]. The Gleason grading, when used as a percentage of each cancer occupied by Gleason grade 4-5 areas, is independently associated with prostate cancer progression [17]. We demonstrated a significant decrease of prostasin expression in the high-grade, i.e., the more progressively transformed tumors. In the case of mouse prostate adenocarcinomas in the TRAMP model, the tumors are induced by expression of the SV40 T-antigen as an initial transformation event [18]. The TRAMP-C cell lines were established from a primary prostate tumor of a TRAMP mouse at 32 weeks of age, and represent different stages of the prostate epithelial cell tumor transformation process [12]. In this mouse prostate cancer cell line model, the more progressively transformed cells (TRAMP-C1 and -C2) did not express the prostasin mRNA (Fig. 2). A weak level of mouse prostasin mRNA expression was detected only in TRAMP-C3 cells following a prolonged exposure of the Southern blot in Figure 2 (data not shown), the significance of such a weak level of expression...
is presently unclear. In both the human prostate cancer cell lines and the primary tumors, as well as the mouse prostate cancer cell lines, however, the down-regulation of prostasin may be linked to the transformation stage and progression of prostate cancer.

An immediate step that could be taken to address prostasin's potential function in the prostate was to restore prostasin expression in the prostate cancer cell lines that lost expression. We used the human prostate cancer cell lines as a model to begin investigating prostasin's potential function. We forced the expression of prostasin in the DU-145 and PC-3 cells via transfection with a human prostasin cDNA. We found that a forced re-expression of the prostasin protein in DU-145 and PC-3 reduced the in vitro invasiveness of the cells by 68 and 42%, respectively (Fig. 4). We also tested our transfectants to determine if a forced re-expression of prostasin protein had any anti-proliferation effects on these cells grown in tissue culture. No significant difference was found between the growth rates of DU-145/Pro or PC-3/Pro cells and that of the vector-transfected cells, DU-145/Vector or PC-3/Vector (data not shown). This observation also validates the observed reduction of invasiveness in the invasion assay. We can attribute the reduced number of DU-145/Pro or PC-3/Pro cells invading through the Matrigel membrane to a change of their intrinsic invasive properties, not to a significantly slower growth rate over the assaying period. We further tested if the anti-invasion activity of prostasin may be attributed to the plasma membrane-bound, or to the secreted form of prostasin by adding purified recombinant human prostasin (the secreted form, at 0.5 μM final concentration) in an invasion assay using the PC-3 cells. Our results indicated that the secreted prostasin did not reduce the invasiveness of PC-3 cells (data not shown).

CONCLUSIONS

The observation of down-regulation of prostasin expression in human and mouse prostate cancer suggests that prostasin serine protease may have a function in normal prostate, or play a role in suppressing prostate cancer progression. The in vitro anti-invasion activity of prostasin suggests that prostasin may be a potential invasion suppressor of prostate cancer.

ACKNOWLEDGMENTS

The authors thank Drs. Gary Pearl, Darian Kameh, and Diana Yin of the Department of Pathology at the Orlando Regional Medical Center; Drs. James Schoeck, Clark Kessel, Stan Sujka, and Marshall Melcer of Orlando Urology Associates for their assistance in prostate specimen procurement; Mr. Scott Howe and the Florida Hospital Pathology/Histology Laboratory for providing tissue sectioning service. We acknowledge Dr. Ratna Chakrabarti for providing the PC-3 and the LNCaP cells, Dr. Julie Chao for providing the human prostasin antibody and the prostasin cDNA plasmid. We are especially grateful to Dr. Gary Meadows for his critique of the manuscript during its preparation.

REFERENCES

8. Boucaut K, Douglas M, Clements J, Antalis T. The serine proteinase testisin may act as a tumor and/or growth suppressor in the testis and may be regulated by DNA methylation [abstract]. In Cancer Genetics and Tumor Suppressor Genes Meeting Program, August 16-20, 2000 Cold Spring Harbor Laboratory.
15. Hoosein NM, Logothetis CJ, Chung IW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide,


A recombinant human prostasin serine protease was expressed in several human cell lines. Subcellular fractionation showed that this serine protease is synthesized as a membrane-bound protein while a free-form prostasin is secreted into the culture medium. Prostasin was identified in nuclear and membrane fractions. Membrane-bound prostasin can be released by phosphatidylinositol-specific phospholipase C treatment, or labeled by [3H]ethanolamine, indicating a glycosylphosphatidylinositol anchorage. A prostasin-binding protein was identified in mouse and human seminal vesicle fluid. Both the secreted and the membrane-bound prostasin were able to form a covalently linked 82-kDa complex when incubated with seminal vesicle fluid. The complex formation between prostasin and the prostasin-binding protein was inhibited by a prostasin antibody, heparin, and serine protease inhibitors. Prostasin's serine protease activity was inhibited when bound to the prostasin-binding protein in mouse seminal vesicle fluid. This study indicates that prostasin is an active serine protease in its membrane-bound form.

Prostasin is a serine protease discovered in ejaculated human semen in 1994 (1). The molecular mass of prostasin is 40 kDa when examined by SDS-polyacrylamide gel electrophoresis (PAGE) under reducing conditions. Prostasin displays trypsin-like enzymatic activities by hydrolyzing peptidyl fluorogenic substrates such as n-Pro-Pho-Arg-AMC. This trypsin-like enzymatic activity can be inhibited by aprotinin, antipain, leupeptin, and benzamidine. Prostasin is present at high levels in normal human semen (8.61 ± 0.43 µg/ml) and in the prostate gland (145.7 ± 15.9 ng/mg). Lower amounts of prostasin can also be detected in other tissues. In the prostate gland, the prostasin protein is present in the epithelial cells as well as in the secretion inside the lumen. The full-length human prostasin mRNA has been deduced (2). The predicted mature prostasin peptide sequence has a potential carboxyl-terminal hydrophobic membrane anchorage domain followed by a short cytoplasmic tail. The translated amino acid residue sequence of prostasin is similar to those of human prostate, testis, plasma kallikrein, coagulation factor XI, hepsin, plasminogen, and acrosin (2–4). A membrane-bound Xenopus kidney epithelial cell sodium channel-activating protease (CAP1) was found highly homologous to human prostasin, sharing 53% sequence identity at the amino acid level (6). Recently, the mouse counterpart of CAP1, mCAP1, has been cloned from a cortical collecting duct cell line (6). mCAP1 shares 77% amino acid sequence identity with human prostasin.

Serine proteases play important roles in a diverse range of the body's normal physiological processes, and they are implicated in various pathological processes such as cardiovascular disorders and cancers (7). The prostate produces a number of serine proteases such as prostate-specific antigen (8), human glandular kallikrein (9), and the most recently discovered prostate (3). Some of these serine proteases are suspected to affect fertility or semen liquefaction (10), and others are implicated in normal prostate development or prostatic diseases (11–14). For example, both prostate-specific antigen and human glandular kallikrein have become important diagnostic and prognostic markers for prostate cancer. Serine proteases are usually regulated at the post-translational level in addition to the transcriptional regulation at their gene level. The body's own strategy of regulating the serine proteases is to bind the serine proteases with a protein inhibitor such as the inhibitors of the serpin class (15). These serpin-serine protease pairs are highly specific with regard to the two molecules involved; examples include α1-antitrypsin and elastase (15), kallistatin and kallikrein (16, 17), α1-antichymotrypsin and prostate-specific antigen (18). The mechanism of serpin inhibition of serine proteases involves the formation of a covalently linked complex at a 1:1 stoichiometry (19). Such a complex exhibits resistance to treatment with SDS or boiling (16, 17).

The physiological functions of prostasin are not fully understood. In a recent study (20) we showed that prostasin expression is significantly down-regulated in high grade prostate tumors and is lost in highly invasive human and mouse prostate cancer cell lines. Transfection of two human prostate cancer cell lines DU-145 and PC-3 with human prostasin cDNA reduced in vitro invasiveness of the cells, suggesting an invasion suppressor role for prostasin. This anti-invasion activity is apparently conferred by the cellular prostasin but not the secreted prostasin. In the present study, we determined that prostasin is a GPI-anchored membrane protein in addition to being a secreted protease. The subcellular localization of prostasin was investigated in cells expressing native or recombinant protein.
nant prostasin. We have also identified a prostasin-binding protein (PBP), a potentially serpin class serine protease inhibitor specific for prostasin. We further demonstrated that the membrane-bound prostasin is an active serine protease. These results will provide structural and regulatory information for further investigation of the functions of prostasin in normal prostate development, prostatic diseases, as well as reproductive biology.

**EXPERIMENTAL PROCEDURES**

**Cell Lines and Plasmid DNA Transfection—**A human embryonic kidney epithelial cell line, 293-EBNA (Invitrogen, Carlsbad, CA), was maintained in the manufacturer's modified Eagle's medium supplemented with 10% fetal bovine serum. Human prostate cancer cell lines LNCaP, DU-145, and PC-3 were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The LNCaP and the DU-145 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1 mM sodium pyruvate; the PC-3 cells were maintained in F-12K medium supplemented with 10% fetal bovine serum. All cells were kept at 37 °C with 6% CO₂. All tissue culture media, sera, and supplements were purchased from Life Technologies, Inc.

A full-length human prostasin cDNA of 1,598 base pairs (including a 290-base pair 5′-untranslated region, 1,083-base pair of the coding region, and a 655-base pair 3′-untranslated region) was generated by reverse transcription-polymerase chain reaction with the following two primers, 5′-AGA CGG CCG TGG TGA CTC GT-3′ and 5′-TGT GCT CAA ACA ATC TTA TO-3′, using the total RNA of LNCaP cell line.

The amplified cDNA was cloned into a cytomegalovirus expression vector, pREP-8 (Invitrogen), in its polylinker site. Transfection of the prostasin cDNA plasmid into 293-EBNA cells was carried out using electroporation. The electroporated cells were then subcultured for selection of transfectants (293/Pro) using 5 μM histidinol (Sigma) in the culture medium for 2 weeks. The 293/Pro vector plasmid was transfected into 293-EBNA cells and subjected to histidinol selection to establish the control cells (293/Ve).

The DU-145 and the PC-3 cells, which do not express prostasin (20), were also transfected using plasmid containing the full-length human prostasin cDNA. The methods for plasmid engineering and establishment of transfectants that express human prostasin have been described previously (20). The resulting cell lines that express human prostasin were designated DU-145/Pro and PC-3/Pro.

**SDS-PAGE and Western Blot Analysis—**These procedures were carried out for all experiments unless stated otherwise. Samples were suspended in 1 × SDS sample buffer (62.5 mM Tris-HCl at pH 6.8, 2% v/v glycerol, 2% w/v SDS, and 2% β-mercaptoethanol), boiled for 5 min, and resolved in a 10% polyacrylamide gel. The resolved proteins were then transferred to a nitrocellulose membrane. The membrane was stained with India ink for 15 min (1:1,000 in TBS-T: 20 mM Tris at pH 7.6 containing 0.137 M NaCl and 0.1% Tween 20), blocked in 5% non-fat milk at room temperature to ensure the purity of the detergent wash, then transferred to a nitrocellulose membrane. The membrane was incubated at 37 °C for 3 min, and centrifuged at 300 g for 5 min, resulting in the heavy membrane phase (pellet) from the first centrifugation was resuspended in 500 μl Tris at pH 7.6 containing 0.137 M NaCl and 0.1% Tween 20, blocked in 5% non-fat milk for 1 h, and incubated with the primary antibody for 30 min in a tray or a Surf-Blot apparatus (Idea Scientific, Inc., Minneapolis). After washing, the membrane was incubated with a secondary antibody conjugated with horseradish peroxidase (Sigma, used at a 1:10,000 dilution) for 30 min. Signals were detected using ECL (enhanced chemiluminescence) with WestPico reagents (Pierce) following the supplier’s protocol. The membrane was then exposed to Kodak x-ray film. The primary antibodies used were as follows: polyclonal antibodies against prostasin (recombinant or native, used at 1:1,000), a monoclonal antibody against β3-integrin (used at 1:1,000), and a monoclonal antibody against poly(ADP-ribose) polymerase (used at 1:500). Antibodies against β3-integrin and poly(ADP-ribose) polymerase were from BD Transduction Laboratories (San Diego).

**Purification of Recombinant Human Prostasin—**The 293/Pro cells were grown to a confluent monolayer in Dulbecco's modified Eagle’s medium and 10% fetal bovine serum containing 5 μM histidinol. Cells were then placed in Opti-MEM I serum-free medium (Life Technologies, Inc.) for 2 h before collection of the conditioned medium. The collected medium was tested for recombinant prostasin by Western blot analysis using a prostasin-specific antibody (1). For purification of the secreted prostasin, the serum-free medium was centrifuged at 10,000 rpm for 20 min to remove dead cells or debris and then passed through an aprotinin-agarose column (1.5 × 20 cm, Sigma) equilibrated with 25 mM Tris, pH 7.6, at a flow rate of 3 ml/min. The flow was then adjusted to remove any unbound proteins, the bound prostasin was eluted with 0.1 M glycine (pH 3.0) containing 0.1 M NaCl at a flow rate of 60 ml/h. The eluted prostasin was immediately neutralized with appropriate amounts of 1 M Tris, combined, concentrated with Centricon-10 concentrators (Amicon Inc., Beverly, MA), and stored at ~20 °C before use in other assays.

**Preparation of a Polyclonal Antiserum against Recombinant Prostasin—**Commercial grade bovine serum albumin (PBS, pH 7.4) was emulsified with an equal volume of complete Freund's adjuvant (Sigma) and was injected subcutaneously into a 1.5-kg female New Zealand White rabbit (Charles River Laboratories, Wilmington, MA). Booster injections with 100 μg of r-hPro (emulsified with incomplete Freund's adjuvant, Sigma) were performed at 3-week intervals. Preimmune rabbit serum was collected before the initial immunization.

**Immunocytochemistry—**The PC-3/Pro or LNCaP cells were seeded on glass coverslips (Fisher Scientific) at a density of 5 × 10⁵/coverslip and grown for 24–36 h prior to a double immunostaining. Briefly, cells were rinsed three times in 1 × PBS, fixed in 4% paraformaldehyde and permeabilized with 0.18% Triton X-100 in PBS for 10 min. After blocking in 10% normal goat serum (Life Technologies, Inc.) in 1 × PBS, cells were incubated with the primary antibodies for 45 min, washed, incubated with the appropriate secondary antibodies at room temperature for 30 min, and then washed three times for 10 min each in 1 × PBS. A rabbit polyclonal antibody against prostasin was used at a dilution of 1:100. A monoclonal antibody against poly(ADP-ribose)-ribose polymerase was used as a nuclear specific marker at a dilution of 1:75. A goat anti-rabbit IgG conjugated with fluorescent dye (1:500, Life Technologies, Inc.) and a goat anti-mouse IgG conjugated with Cy3 (1:800, Jackson Immunoresearch, West Grove, PA) were used as the secondary antibodies. The coverslips were mounted with GelMount (Fisher Scientific) and analyzed on a Carl Zeiss LSM510 laser scanning microscope.

**Differential Centrifugation—**Subcellular fractionation was performed as described in Krajewski et al. (21) and Pemberton et al. (22). Briefly, confluent cells in 4 × 150-mm² flasks (estimated 5–10 × 10⁶ cells/tube) were washed three times with 1 × PBS and removed by mechanical force for the 293/Pro cells or trypsin treatment (0.026% with 1 mM EDTA) for the PC-3/Pro and LNCaP cells. The cells were resuspended in 7 ml of cold MES buffer (17 mM at pH 7.4, 2.5 mM EDTA, and 360 mM sucrose) containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 μg/ml aprotinin, 2 μg/ml leupeptin, and 2 μg/ml antipain). The following steps were performed at 4 °C. Cell suspension was homogenized with a Dounce homogenizer for 6 strokes followed by centrifugation twice at 500 × g for 10 min, resulting in the crude nuclear fraction in the pellet. The supernatant was centrifuged twice at 10,000 × g for 15 min, resulting in the heavy membrane fraction in the pellet containing mitochondria, lysosomes, and peroxisomes. The supernatant from each centrifugation were washed with 2 × 10 ml of MEB to eliminate carryovers.

Differential extraction of membrane fractions was carried out according to Pei et al. (23). Briefly, pellet/membrane fractions were divided equally into three portions and were extracted with 1% Triton X-114 in Tria buffer (10 mM Tris-HCl, pH 7.6) or high salt (350 mM NaCl in Tri buffer), or alkal (50 mM glycine/NaOH, pH 11.0) for 1 h on ice. The samples were centrifugated at 100,000 × g for 30 min. The resulting pellet was dissolved in 1 × SDS sample buffer for gel electrophoresis. The supernatant was subjected to a trichloroacetic acid precipitation to recover proteins for gel electrophoresis.

**Detergent Phase Separation and Phosphatidylinositol-specific Phos- pholipase C (PHL-C) Treatment—**The procedure was adapted from those described by Bordier (24) and Rosenberg (25). Briefly, cells (5 × 10⁹) were lysed in 1 ml of ice-cold TBS (10 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA) containing 1% Triton X-114 (Sigma) and protease inhibitors for 2 h with gentle shaking at 4 °C. The lysate was then centrifugated at 14,000 rpm for 30 min. The supernatant (500 μl, or 700–800 μl of total protein) was overlaid onto a 300-μl sucrose cushion (6% w/v sucrose in TBS containing 0.08% Triton X-114). The solution was incubated at 37 °C for 5 min and centrifuged at 380,000 × g for 30 min at room temperature to separate the detergent phase (pellet) and the aqueous phase. The aqueous phase was removed and extracted further with 0.5% Triton X-114 and 2% Triton X-114. The aqueous phase after the final centrifugation contains the soluble proteins. The detergent phase (pellet) from the first phase was removed. After extensive washing, the final detergent fraction was resuspended in 0.5 ml of ice-cold TBS, incubated at 37 °C for 3 min, and centrifugated at 300,000 × g for 3 min at room temperature to ensure the purity of the detergent phase.
The detergent phase was resuspended in 100 μl of ice-cold TBS. 10 μl of the resuspended detergent phase was subjected to PI-PLC (Sigma) digestion at 37 °C for 1 h with gentle shaking in a total volume of 100 μl of reaction buffer (10 mM Tris-HCl at pH 7.5, 144 mM NaCl). 100 μl of ice-cold TBS containing 2% Triton X-114 was then added to the digestion mixture and subjected to phase separation as described above. At the final step, both the aqueous and detergent phases were precipitated with 6% w/v trichloroacetic acid and 0.013% sodium deoxycholate. The precipitates were resuspended in 30 μl of 1 × SDS sample buffer, neutralized with ammonium hydroxide (microliter amounts), boiled, and subjected to SDS-PAGE and Western blot analysis.

Human prostates removed by radical prostatectomy performed at Orlando Regional Medical Center (Orlando, FL) were sectioned with a cryostat at 20-μm thickness. 80 sections were collected and rinsed with PBS twice to remove prostasic fluid. The washed prostate sections were lysed in 1 ml of TBS containing 1% Triton X-114 at 4 °C overnight with rocking. The lysed prostate tissues were centrifuged and subjected to the same phase separation and PI-PLC treatment procedures as described above. Several representative prostate sections (7 μm) cut at intervals of the 20-20 μm sections were subjected to standard hematoxylin and eosin staining for confirmation of benign prostate morphology. The use of human tissues was approved by the Institutional Review Boards of Orlando Regional Medical Center and the University of Central Florida.

**Results**

**Expression and Purification of Recombinant Human Prostasin**—Serum-free conditioned medium from 293/Pro cell culture was prepared and passed through an DEAE-cellulose column for a one-step affinity-chromatographic purification of the recombinant prostasin as described under "Experimental Procedures" (see also Ref. 1). A Coomassie Blue staining of the purified recombinant prostasin is shown in Fig. 1, left panel (r-hPro). The r-hPro migrates at 40 kDa on an SDS-PAGE under reducing conditions. Because of glycosylation of the prostasin molecule (1, 2), it appeared as a rather diffused band on the gel. We prepared a polyclonal antibody (r-Pro Ab) using the purified recombinant prostasin molecule (1, 2), it appeared as a rather diffused band on the gel. We prepared a polyclonal antibody (r-Pro Ab) using the purified recombinant prostasin (secreted form), the recombinant prostasin is shown in Fig. 1, left panel (r-hPro) and is recognized by an antibody made against the purified recombinant prostasin (IB: r-Pro Ab, lane 1) as well as a prostasin-specific antibody made against purified native prostasin (IB: n-Pro Ab, lane 1, Ref. 1). The quantity of purified prostasin in lanes 1 is 0.5 μg. Samples from the 293/Pro cell lysate (lanes 2, 20 μg), 293/Vec (lanes 3, 20 μg) cell lysate, and human semen (lanes 4, 30 μg) were immunoblotted with r-Pro antibody (upper right panel, 1:1,000 dilution) and n-Pro antibody (lower right panel, 1:1,000 dilution). Both antibodies recognize the recombinant prostasin as well as the native prostasin but do not have cross-reactivity with 293/Vec proteins.

**Membrane Overlay Zymography**—The membrane overlay zymography was carried out using the protocols of Enzyme System Products (Livermore, CA) and Beals et al. (26). Briefly, samples were first resolved in a 10% polyacrylamide gel without SDS or β-mercaptoethanol. After electrophoresis, the gel was equilibrated in a reaction buffer (50 mM Tris-HCl, pH 9.0) for 15 min. Pre-wet acetate-cellulose membrane impregnated with the protease substrate Z-Pro-Avc-AFC (Enzyme System Products) was then carefully laid over the gel without entrapping air bubbles. The membrane-overlay gel was placed in a moist chamber at 37 °C for 3-5 h. The reaction was monitored using an ultraviolet lamp and photographed.
The majority of the prostasin protein is GPI-anchored to the GPI moiety that is linked to prostasin (Fig. 5, lanes 1-30). After phase separation, the aqueous phase (Fig. 5, lane 293/Pro cells) is associated with the membrane, which was treated with PI-PLC to test if prostasin is a GPI-anchored membrane protein. The 293/Pro cells were lysed in TBS containing 1% Triton X-114. After phase separation, the detergent phase (lane 2) contained total protein. Approximately 80–100 μg of total protein was subjected to detergent (TX), high salt (HiS), or alkali (Alk) treatment followed by centrifugation to separate the supernatant and the pellet for SDS-PAGE and Western blot analysis. Prostasin in all fractions can be detected in the nuclear fraction (P1), heavy membrane fraction (P2), light membrane fraction (P3), and cytosol (S) of 293/Pro. Purified r-hPro (0.5 μg) was used as a positive control.

Fractionation analysis on prostasin cDNA-transfected human prostate cancer cell line PC-3 (PC-3/Pro) and the human prostate cancer cell line LNCaP, which expresses endogenous prostasin (2, 20). As shown in Fig. 3A, prostasin is detected in P1, P2, and P3 fractions, but not in the cytosol (S) of PC-3/Pro. In the LNCaP cells, endogenously expressed prostasin is detected only in the P3 fraction. The membrane fractions from PC-3/Pro cells were then immunoblotted with a monoclonal antibody against a nuclear protein poly(ADP-ribose) polymerase or a monoclonal antibody against a plasma membrane-bound protein β1-integrin to ensure the purity of each fraction. The results showed that the prostasin protein exists in a membrane-bound form in all cell lines tested. The cells transfected with the vector DNA alone (293/Vec and PC-3/Vec) were subjected to the same fractionation procedures followed by SDS-PAGE/Western blot analysis. No prostasin was detected (data not shown). We further subjected PC-3/Pro and LNCaP cell extracts to a double immunostaining and analyzed the subcellular localization of prostasin using confocal microscopy. The confocal microscopic analysis of PC-3/Pro cells localized prostasin (green) to the ER-Golgi complex (Fig. 3B), consistent with the cell fractionation results shown in Fig. 3A. Because the nuclear membrane is practically a prominent component of the ER (27), it is not surprising that this portion of prostasin appeared in the P1 fraction. The LNCaP cells, however, did not show punctate or nuclear-ER-Golgi complex staining, again, consistent with the cell fractionation results shown in Fig. 3A.

To test if prostasin is truly a membrane-anchored protein rather than a membrane-associated protein, we subjected the P1, P2, and P3 fractions of the PC-3/Pro cells to treatment with a detergent, high salt, or alkali. As shown in Fig. 4, membrane-bound prostasin (pellet) was released into the supernatant only by the detergent treatment but not the high salt or alkali treatment. The detergent released prostasin and the membrane-bound prostasin had similar molecular weight. The results indicated that prostasin is a true membrane-anchored protein.

Membrane Prostasin Is GPI-anchored—A comparison of the potential carboxy-terminal membrane-anchorage domain of prostasin (2) with GPI-anchored proteins (28) predicts a GPI linkage for prostasin as well (data not shown). Such a linkage may be susceptible to cleavage by PI-PLC, GPI-specific phospholipase D, or nitrous acid (25). In our studies, we first chose P1-PLC to test if prostasin is a GPI-anchored membrane protein. The 293/Pro cells were lysed in TBS containing 1% Triton X-114. After phase separation, the aqueous phase (Fig. 5, lane 1, 30 μg of total protein) and the detergent phase (lane 2, 3 μg of total protein) were analyzed by Western blot using the prostasin-specific antibody. The majority of the prostasin protein in the supernatant is detected. The majority of the prostasin protein in the supernatant is detected. The majority of the prostasin protein in the supernatant is detected.
brane-bound prostasin in DU-145/Pro and LNCaP is resistant identification of membrane-associated proteins (equivalent to 1/10 of the total starting membrane-associated proteins) was further treated with PI-PLC followed by additional phase separation. The soluble proteins (lane 1, 30 µg) and the detergent phase proteins (lane 2, 3 µg) before PI-PLC treatment and the soluble proteins extracted from the detergent phase after PI-PLC treatment were subjected to SDS-PAGE and Western blot analysis using a prostasin-specific antibody. The membrane-bound prostasin is released from the membrane after PI-PLC digestion as it was detected in the post-PLC soluble phase. The amounts of PI-PLC used in the reactions were lane 3, 0.25 unit; lane 4, 0.125 unit; and lane 5, 0 unit in a total reaction volume of 100 µl. The results indicate that prostasin is anchored to membrane via GPI. The size difference between the membrane-bound prostasin and the soluble prostasin (lanes 1 and 2) may be attributed to the GPI moiety that is linked to prostasin.

One question that remained unclear was whether the native prostasin in the prostate tissue epithelial cells is membrane-bound by GPI anchorage as well. We selected a panel of prostate cancer cell lines and 293/Pro cells that express either recombinant or endogenous prostasin, and normal human prostate tissues in our next experiment. Cell lines that express recombinant prostasin were 293/Pro, PC-3/Pro, and DU-145/Pro. The human prostate cancer cell line LNCaP and normal human prostate tissues were used for testing native cellular prostasin. All samples (300 µg of total protein as the starting quantity) were subjected to detergent phase separation before and after PI-PLC digestion as described under "Experimental Procedures." PC-3 transfected with a vector plasmid (PC-3/Ve) was used as negative control. The results are presented in Fig. 6A. Without PI-PLC treatment, both the recombinant and native prostate tissues are mainly membrane-anchored (found in the detergent phase). Soluble prostasin is detected in 293/Pro and prostate tissues. After PI-PLC treatment, the membrane-anchored prostasin is released into the soluble fraction from 293/Pro, PC-3/Pro, and LNCaP in all fractions tested. Because of a high level prostasin expression in the 293/Pro cells, a portion of prostasin remained in the detergent phase after PI-PLC digestion. Panel B, incorporation of [3H]ethanolamine into prostasin. PI-PLC of PC-3/Pro or LNCaP cells were incubated with 100 µCi of [3H]ethanolamine in 1 ml of Opti-MEM I serum-free medium for 24 h in 5% O2 at 37 °C. The cell lysates were subjected to immunoprecipitation using the prostasin antibody (purified IgG fraction, 2 µg/ml) and protein A-Sepharose beads as described under "Experimental Procedures." After SDS-PAGE separation of the samples, the labeled protein was detected by fluorography using Amplify fluorographic reagent and exposure to an x-ray film at −80 °C with an intensifying screen for 14 days.

Identification of a Prostasin-binding Protein—An incubation of the purified r-hPro with mouse or human seminal vesicle fluid yielded a higher molecular weight form of prostasin-containing band as analyzed by SDS-PAGE and immunoblotting. The result presented in Fig. 7A indicated that the purified r-hPro formed an 82-kDa complex with a mouse seminal vesicle protein (named as the mouse prostasin-binding protein, or mPBP). The complex was apparently covalently linked and not via a disulfide bond because it was SDS- and heat-stable and...
The complex formation between prostasin and its binding partners was investigated further by incubating the purified r-hPro with serine protease inhibitors (Fig. 8, lanes 2–5) or the prostasin antibody (lanes 7 and 8) for 15 min at room temperature before an incubation with mouse seminal vesicle fluid for another 60 min at 37°C. Or, mouse seminal vesicle fluid was first incubated with heparin before the addition of r-hPro (Fig. 8, lane 6). The complex formation between prostasin and mPBP was inhibited by serine protease inhibitors such as aprotinin at 5 μg/ml and 5 μg/ml, phenylmethylsulfonyl fluoride at 1 μM and 1 μM, and human seminal vesicle fluid was inhibited by aprotinin, phenylmethylsulfonyl fluoride, heparin, and the antibody against prostasin. The asterisk (*) indicates the IgG heavy chain and light chain recognized by the goat anti-rabbit secondary antibody used in the Western blot analysis. Excess unbound prostasin is indicated by the lower arrow. Complex formation between r-hPro and mPBP in mouse seminal vesicle fluid without any other reagent was used as positive control (lane 1).
Membrane Overlay Immunoblotting

1 2 3 4 1 2 3 4

FIG. 9. Membrane overlay zymography. Samples from a prostates binding assay were resolved on a 10% native acrylamide gel without SDS/boiling or β-mercaptoethanol. The gel was then either overlaid with a membrane impregnated with a prostates substrate (D-Pro-Phe-Arg-AFC) (left panel) or transferred for prostates immunoblotting (right panel). Lane 1, 5 μl of mouse seminal vesicle fluid alone; lane 2, 0.5 μg of purified r-hPro alone; lane 3, mixture of r-hPro and mouse seminal vesicle fluid; lane 4, same as lane 3 except r-hPro was preincubated with 5 μg/ml aprotinin for 15 min before the addition of mouse seminal vesicle fluid. The fluorogenic substrate impregnated in the membrane was hydrolyzed by prostates in the gel, and isoprostasin patterns in the membrane appear as fluorescent bands. The results suggest that mPBP not only binds to prostates at the serine active site but also inhibits prostates's serine protease activity in vitro.

active site and that heparin may alter mPBP binding property. The properties displayed by mPBP are shared by the serpin class serine protease inhibitors. We have observed similar properties for the serpin, kallistatin (16, 17). The predicated molecular mass of PBP (mouse or human) is estimated at ~47 kDa, given the 40-kDa apparent molecular mass of prostates and considering the fact that serpin molecules lose a carboxy-terminal fragment of ~5 kDa when complexed with a serine protease (31).

mPBP Inhibits the Serine Protease Activity of Prostasin—We performed a membrane overlay zymography analysis to test if mPBP inhibits prostates activity in vitro. The prostates binding assay was carried out by incubating the purified r-hPro with mouse seminal vesicle fluid in the absence of the serine protease inhibitor aprotinin (Fig. 9, lane 3) or in the presence of aprotinin (lane 4). Each sample was then divided into two equal portions and subjected to a native PAGE analysis (i.e., SDS and β-mercaptoethanol were not included in the gel solution or the samples, and the samples were not heated before loading) followed by membrane overlay zymography (left panel) or Western blot analysis using the prostates antibody (right panel).

Mouse seminal vesicle fluid proteins alone (Fig. 9, lane 1) displayed no enzymatic activities toward the synthetic substrate D-Pro-Phe-Arg-AFC (left panel) nor cross-reactivity with the prostates antibody (right panel). The purified r-hPro alone (lane 2) demonstrated enzymatic activity toward D-Pro-Phe-Arg-AFC (left panel) and was recognized by the prostates antibody (right panel). When prostates formed a complex with mPBP in the mouse seminal vesicle fluid, it no longer cleaves D-Pro-Phe-Arg-AFC because no fluorescence is present at the complex band location in lane 3 of the left panel, whereas the complex is identified by the prostates antibody as the upper band in lane 3 of the right panel. The remaining unbound prostates yielded, expectedly, lesser fluorescence (left panel, lower band in lane 3 compared with lane 2) and was recognized by the prostates antibody (right panel, lane 3). When the purified r-hPro was preincubated with the serine protease inhibitor aprotinin before incubation with the mouse seminal vesicle fluid, no complex was detected (right panel, lane 4). A reduced level of fluorescence appeared at the prostates band in lane 4 of the left panel because of the presence of aprotinin. Because the binding of aprotinin to prostates is reversible while proteins were being resolved in the gel, the inhibition of prostates activity seen in lane 4 was not complete. The results suggested that mPBP not only binds to prostates at the serine active site but also inhibits the serine protease activity of prostates in vitro. Two bands were observed in the prostates alone sample in the immunoblot (Fig. 9, right panel, lane 2), the differential mobility may be caused by differential glycosylation (1). Aprotinin binding to prostates changes the charge/mass ratio of the protein; therefore, migration of the aprotinin-bound prostates in a native PAGE could change as well, potentially causing the multiple banding pattern seen in lane 4 of the immunoblot (Fig. 9, right panel).

Membrane Prostasin Binds to mPBP—To test if the membrane-bound prostates has binding activity toward mPBP, the 293/Pro and PC-3/Pro cells were subjected to differential centrifugation as described under "Experimental Procedures" except that no protease inhibitors were added during membrane fractionation. Immediately after centrifugation, an aliquot of each membrane fraction (30–40 μg of total protein) was incubated with an aliquot of mouse seminal vesicle fluid (5 μl) at 37°C for 1 h. The binding mixture was then analyzed by Western blot analysis using a prostates-specific antibody. In Fig. 10, the left panel shows that the membrane-bound prostates in 293/Pro cells (P2 and P3 fractions) formed an 82-kDa complex when incubated with mouse seminal vesicle fluid. The prostates protein in the crude nuclear fraction (P1) and the cytosol (S) did not form any detectable complex. The purified r-hPro from the conditioned medium (i.e. the secreted prostates) was used as positive control for the binding assay. In Fig. 10, right panel, we show that the membrane-bound prostates in PC-3/Pro cells also formed a complex with mPBP, and this reaction was inhibited by the serine protease inhibitor aprotinin.

DISCUSSION

The prostates serine protease is predominantly synthesized in the prostate in human (1). Recently our laboratory demonstrated that prostates expression is significantly down-regulated in high grade prostate tumors and absent in invasive human and mouse prostate cancer cell lines. We have also shown, in an in vitro Matrigel invasion assay, that cellular prostates may be an invasion suppressor of prostate cancer.

**FIG. 10.** Membrane-bound prostates forms a complex with mPBP. Membrane fractions of 293/Pro and PC-3/Pro cells (30–40 μg of total protein) were incubated with 5 μl of mouse seminal vesicle fluid at 37°C for 1 h. Right panel, samples where indicated, were preincubated with aprotinin before the addition of mouse seminal vesicle fluid. All sample mixtures were analyzed on an SDS-PAGE under reducing conditions followed by prostates immunoblotting. P1, nucleus fraction; P2, heavy membranes; P3, light membranes; S, cytosolic proteins; and r-hPro, purified recombinant prostates. The membrane-bound prostates in heavy or light membrane fractions formed a complex (upper arrow) when incubated with mouse seminal vesicle fluid, whereas prostates in P1 and cytosolic fractions showed no complex formation. r-hPro was used as a positive control in the in vitro binding assay. Excess unbound prostates is indicated by the lower arrow. The addition of aprotinin at 6 μg/ml inhibited complex formation as shown in the right panel.
GPI-anchored Prostasin

(20). In the present study, we intended to investigate the intracellular distribution of prostasin and to determine whether the cellular prostasin is an active serine protease, to provide clues to the potential mechanisms of prostasin's cellular function.

We first established a mammalian expression system to produce a recombinant human prostasin. The purified secreted recombinant prostasin displayed biochemical characteristics similar to those of the native prostasin (purified from human semen, Ref. 1), such as the molecular mass on SDS-PAGE, immunological reactivity (Fig. 1), enzymatic activity toward the synthetic substrate \( \text{o-Pro-Phe-Arg-AFC} \) (Fig. 9), and responsiveness to serine protease inhibitors (Figs. 8 and 9). We then used a polyclonal antibody specific for human prostasin to determine whether prostasin can exist in a membrane-bound form because its predicted structure suggested this possibility (2). By means of sequential centrifugation of the 293/Pro and PC-3/Pro cell components (as shown in Figs. 2 and 3A), we were able to identify prostasin in various subcellular compartments such as the crude nuclei, heavy membranes (including mitochondria, lysosomes, and peroxisomes), and light membranes (including plasma membrane, microsomes, and endoplasmic reticulum). A confocal microscopy analysis of the PC-3/Pro cells (Fig. 3D) revealed prostasin's subcellular localization to be primarily at the nuclear-ER-Golgi complex (27). The immunofluorescently localized prostasin at the nuclear-ER-Golgi complex is believed to be that identified in the Western blot analysis of the nuclear fraction P1. The endogenously expressed prostasin in the LNCaP cells, however, was only detected in the light membrane fraction P3 (Fig. 3A) at the nuclear-ER-Golgi complex (Fig. 3B). The different subcellular localization of prostasin between the recombinant expression system and the endogenous expression system may be caused by expression level differences. Cells expressing recombinant prostasin produced high amounts of prostasin with the 293/Pro being the highest followed by PC-3/Pro and DU-145/Pro. The prostasin expression level in the LNCaP cells was considerably lower than that in these transfected cell lines. The expression levels were determined by a semiquantitative Western blot analysis (data not shown). Alternatively, different cell lines may have different protein sorting mechanisms, leading to different subcellular localization patterns (32). On the other hand, GPI-anchored prostasin might be associated with sterols and therefore can be found in many compartments of the cell including the plasma membrane, the Golgi apparatus, ER, nucleus, lysosomes and mitochondria, and in lipid particles (33). Prostasin in the nuclear fraction P1 did not show binding activity to PBP (Fig. 10). It is presently unclear why prostasin in this fraction was unable to form a complex with mPBP. The functional significance of prostasin in the nuclear-ER-Golgi complex is also unclear at present and will be investigated in the future.

Despite the apparently different subcellular localization of prostasin in overexpressing cells versus endogenously expressing cells, prostasin is found in an membrane-bound form in all cell lines tested as well as in normal human prostate tissues (Fig. 6A). The membrane-bound prostasin was released when extracted with a detergent but remained membrane-bound when treated with high salt or alkali (Fig. 4), ruling out the possibility that prostasin is associated with another membrane-bound protein via noncovalent linkages. We also demonstrated that the membrane-bound and the detergent-released prostasin have similar molecular mass (Fig. 4), ruling out the possibility that prostasin is covalently linked to another membrane-bound protein.

The native prostasin in normal prostate tissue and the recombinant prostasin in 293/Pro and PC-3/Pro cells were easily released from the membrane with PI-PLC treatment (Figs. 5 and 6A), suggesting that prostasin is bound to the membrane via a GPI anchor rather than through a true transmembrane domain. The membrane-bound prostasin in LNCaP cells (native) or DU-145/Pro cells (recombinant), however, was resistant to PI-PLC treatment (Fig. 6A). As reported in Englund (34) and Hiroshi et al. (35), not all GPI-anchored proteins are susceptible to PI-PLC digestion. The membrane-anchored prostasin in LNCaP and DU-145/Pro could potentially be susceptible to other phospholipases such as GPI-phospholipase D (34, 35). Our results from the \( \text{PH} \)ethanolamine biosynthetic labeling experiment with PC-3/Pro and LNCaP cells, however, provided direct evidence that in the prostate epithelial cells recombinant or native prostasin is GPI-anchored, regardless of its sensitivity to PI-PLC treatment (Fig. 6B).

Among all four human cell lines that express either recombinant or native prostasin, as well as normal human prostate tissue, prostasin exists mainly as a membrane-bound protein (Fig. 6A). A small portion of prostasin in the 293/Pro cells is in the cytosolic fraction. This cytosolic prostasin could be a misprocessed or misfolded form that was exported from the ER before GPI anchor attachment, a mechanism documented previously (36). The presumably misfolded prostasin in the cytosol had no binding activities when it was incubated with mouse seminal vesicle fluid, possibly because of the misfolding. The secreted recombinant prostasin, when purified from the 293/Pro culture medium, however, is enzymatically active and able to form a complex with mPBP (Figs. 9 and 10), indicating that the cytosolic prostasin is not the source of secreted prostasin. The soluble fraction of prostasin seen in the human prostate tissues (Fig. 6A) before PI-PLC treatment may also be a misfolded form by the same mechanism described above or may be attributed to residual prostatic fluid caused by possible incomplete washing before tissue lysis.

We identified a PBP in mouse and human seminal vesicles (Fig. 7). Prostasin forms an 82-kDa, SDS- and heat-stable complex when incubated with seminal vesicle fluid as determined by SDS-PAGE under reducing conditions followed by prostasin immunoblottting. This complex is apparently covalently formed between prostasin and PBP and not via a disulfide linkage. We have chosen to use mouse seminal vesicles for an in-depth analysis of PBP because of easier availability. Complex formation between prostasin and mPBP was inhibited by the polyclonal prostasin antibody, heparin, and serine protease inhibitors. In a membrane overlay zymography analysis (Fig. 9), the prostasin-mPBP complex showed no activities to a synthetic substrate \( \text{o-Pro-Phe-Arg-AFC} \), whereas unbound prostasin was active. These results suggest that mPBP may be a serpin class serine protease inhibitor. The true nature of the mechanism of prostasin inhibition by mPBP will be investigated upon purification and sequence analysis of this protein. An incubation of mouse or human plasma with r-hPro did not result in formation of any covalently-bound complex. This result would rule out the possibility of mPBP being one of the known members of the serpin family present normally in the blood, such as \( \alpha_1 \)-antitrypsin, \( \alpha_2 \)-antichymotrypsin, kallistatin, plasminogen activator inhibitor, and protein C inhibitor. At present, the functional significance of PBP with respect to prostate biology is unclear. Future studies will be aimed at determining the prostasin binding site in PBP, which could potentially reveal clues to prostasin's natural protein substrate.

One of our goals for the present study was to determine whether the membrane-anchored prostasin is an active serine protease. To accomplish this, we needed a prostasin-specific
enzymatic activity assay that is applicable for membrane-bound prostasin because this form of prostasin exists in a complex mixture. The membrane overlay zymography assay was not applicable for the membrane-anchored prostasin because lipid-associated proteins cannot be well resolved in non-denaturing native gel electrophoresis. The identification of mPBP offered an indirect but prostasin-specific assay to address this question. As presented in Fig. 10, the membrane-bound human prostasin also displayed binding activity to mPBP, and the binding is inhibited by a serine protease inhibitor (aprotinin) that competes for the serine active site, suggesting that the membrane-bound prostasin is likely an active serine protease. Demonstration of membrane-bound prostasin being an active serine protease will provide clues for investigating the signal transduction pathway(s) involved in the anti-invasion activity of prostasin because this anti-invasion activity is conferred by the cellular prostasin but not the secreted prostasin (20).

Prostasin is made in the prostate and secreted as an active serine protease (1), whereas PBP is made in the seminal vesicles. The fact that prostasin forms a complex with PBP suggests that the two proteins interact with each other when semen is ejaculated, thereby implicating a role for both proteins in semen coagulation and liquefaction. Prostasin and PBP in male reproductive tracts may serve together in a partnership (21-24).

REFERENCES
PROSTASIN SERINE PROTEASE INHIBITS BREAST CANCER INVASIVENESS AND IS TRANSCRIPTIONALLY REGULATED BY PROMOTER DNA METHYLATION

Li-Mei CHEN and Karl X. CHAI* 

Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, FL, USA

We have shown that prostasin serine protease is downregulated in high-grade prostate tumors and inhibits invasiveness of prostate cancer cell lines upon enforced reexpression. In our study, prostasin mRNA and protein were shown to be expressed in normal human mammary epithelial cells (NHMEC), the poorly invasive breast carcinoma cell line MCF-7 and the nonmetastatic breast carcinoma cell line MDA-MB-453, but absent in highly invasive and metastatic breast carcinoma cell lines MDA-MB-231 and MDA-MB-435s. Enforced expression of prostasin in MDA-MB-231 and MDA-MB-435s reduced the in vitro invasiveness of either cell line by 50%. Examination of the prostasin gene promoter and first exon revealed a GC-enriched region that contains transcription regulatory elements. The promoter and exon 1 region of the prostasin gene was investigated for DNA methylation in NHMEC and the carcinoma cell lines. The results revealed a methylation pattern that correlates with prostasin expression in these cells. Demethylation coupled with histone deacetylation inhibition resulted in reactivated expression of the prostasin mRNA in MDA-MB-231 and MDA-MB-435s cells. These results suggest that prostasin expression in breast cancer cells may be regulated by DNA methylation and that an absence of prostasin expression may contribute to breast cancer invasiveness and metastatic potential. 

Key words: prostasin; serine protease; invasion suppressor; breast cancer; transcription regulation; DNA methylation

Prostasin, a prostate-abundant serine protease originally discovered in human seminal fluid,1 has recently been shown to be downregulated in high-grade (Gleason 4/5) prostate cancers and to have the ability of inhibiting invasion in vitro upon enforced reexpression in highly invasive human prostate cancer cells DU-145 and PC-3.2 Prostasin is a glycosylphosphatidylinositol (GPI)-anchored active serine protease expressed in normal prostate epithelial cells and can also be secreted into the prostate fluid.3 The membrane-anchored but not the secreted prostasin confers the invasion suppression of prostate cancer cells.4 Enforced reexpression in these cells is not affected by cell proliferation.2 Together with normal epithelial specific 1 (NES1),4 prostasin5 and testisin,6 these 4 and potentially more serine proteases form the foundation of a new paradigm of serine proteases and cancer.2 First, these serine proteases are expressed in either normal prostate epithelia or cells (prostasin, NES1 and prostasin),5,6 normal breast epithelial cells (NES1)3 or the pachytae spermatocytes in normal testis (testisin).6 But they are absent or expression level-reduced in tumors or tumor cell lines of these tissues.4-6 Second, NES1 and testisin have been shown to be tumor suppressors5,7 and prostasin may be a potential invasion suppressor.2 These new roles of serine proteases in cancer are in sharp contrast to the view held of serine proteases' role in cancer by the conventional paradigm, that they are usually upregulated in cancer and promote cancer invasion and metastasis.8 A classical example of the conventional paradigm of serine proteases' role in prostate and breast cancers is given with the urokinase-type plasminogen activator (uPA). uPA is upregulated in prostate and breast cancers and promotes tumor invasion.9,10 In breast cancer cell lines, uPA expression was observed in the highly invasive, hormone-insensitive MDA-MB-231, but not in the poorly invasive, hormone-sensitive MCF-7, T-47D or normal human mammary epithelial cells (NHMEC).11 uPA expression in breast cancer cells is regulated by promoter DNA methylation.11 Prostasin's expression was mainly found in the prostate while a lesser amount was found in various tissues.1-12 Prostasin expression in the breast, however, has not been examined. Several prostate-abundant serine proteases, for example, prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2), have been shown to be expressed in human breast cancer cell lines.13 In our study, we have examined prostasin expression in NHMEC and a panel of human breast carcinoma cell lines, including the poorly invasive MCF-7, the nonmetastatic MDA-MB-453 and the highly invasive and metastatic MDA-MB-231 and MDA-MB-435s. Enforced reexpression of a recombinant human prostasin protein in the invasive cell lines was performed and the effect of prostasin reexpression on in vitro invasiveness was examined. Prostasin gene promoter in these cell lines was examined for DNA methylation, and the effect of demethylation coupled with histone deacetylation inhibition on prostasin expression in the MDA-MB-231 and MDA-MB-435s cells was investigated.

MATERIAL AND METHODS

Cell culture maintenance

All cell culture media, sera and supplements were purchased from Life Technologies (Gaithersburg, MD), except for those noted otherwise. A normal human mammary epithelial cell primary culture (catalog number CC-2551) was obtained from Clonetics (San Diego, CA) and maintained in the mammary epithelial basal medium (supplemented with bovine pituitary extract, recombinant human epidermal growth factor, bovine insulin and hydrocortisone) according to the supplier's protocols. The culture was kept at 37°C with 5% CO2 and used for experiments at the 9th overall passage. Human breast carcinoma cell lines MCF-7, MDA-MB-453, MDA-MB-231 and MDA-MB-435s were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The MCF-7 cells were maintained in DMEM supplemented with 10% FBS and kept at 37°C with 5% CO2. The MDA-MB-231 and MDA-MB-453 cells were maintained in Lebowitz-15 (L-15) medium supplemented with 10% FBS and kept at 37°C without CO2. The MDA-MB-435s cells were maintained in L-15 medium supplemented with 15% FBS and 10 μg/ml bovine insulin and kept at 37°C without CO2.

Transfection of cell lines with plasmid DNA and selection of stable transfectants

Construction of a plasmid containing a full-length human prostasin cDNA under the control of a Rous sarcoma virus (RSV) promoter

---

Grant sponsor: Department of Defense Prostate Cancer Research Program; Grant number: DAMD17-98-1-8590.

*Correspondence to: Department of Molecular Biology and Microbiology, University of Central Florida, 4000 Central Florida Boulevard, Orlando, FL 32816-2360, USA. Fax: +407-823-3095.

E-mail: kxchai@mail.ucf.edu

Received 23 April 2001; Revised 27 July 2001; Accepted 6 August 2001

DOI 10.1002/ije.1601
promoter and transfection of cells were carried out as described previously. Briefly, 1,000,000 MDA-MB-231 or MDA-MB-435s cells were resuspended in 0.3 ml of the culture medium and mixed with 50 μg of plasmid DNA dissolved in 0.1 ml of sterile distilled water. The cell/DNA mixture was then transferred to a 4 mm cuvette and pulsed at 200 volts, 1,600 μF, 72 ohms and 500 V/Capacitance setting on a BTX-600 Electro-cell manipulator (Genetronics, San Diego, CA). Selection of transfactants was carried out in the presence of 800 μg/ml G418 (final concentration) until colonies appeared (5–7 days). Colonies (~200 in number) were then dispersed via trypsinization and maintained in G418-containing culture medium without colony-isolation. Cells transfected with the human prostasin cDNA construct were assayed in Western blot analysis for expression of the prostasin protein, using vector-transfected cells as controls.

**RNA preparation and analysis by RT-PCR/Southern blot**

Cells grown to 80% confluence (in 60 mm tissue culture dish) were lysed directly with 1 ml of the Trizol Reagent (Life Technologies) and RNA was isolated according to the manufacturer’s protocol. The human prostasin-specific RT-PCR/Southern blot analysis was performed as described previously. One microgram of total RNA was used in the RT-PCR with 2 human prostasin gene-specific oligonucleotide primers, and a Southern blot of the resolved RT-PCR samples was probed with a third prostasin gene-specific oligonucleotide, detecting an amplified 324 bp fragment. A co-amplification of the β-actin mRNA for control of RNA quality and quantity was performed as described previously.

**Western blot analysis**

Cells grown to 80–100% confluence (in 60 mm tissue culture dish) were lysed directly in 1 X PBS (pH 7.4) and then lysed in RIPA buffer (1 X PBS, pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). The total lysate were centrifuged at 14,000 rpm for 30 min at 4°C to remove the pellet. Protein concentration was determined using a DC (detergent-compatible) protein assay kit (Bio-Rad, Hercules, CA). The samples were then subjected to SDS-PAGE followed by Western blot analysis using a prostasin-specific antibody. Briefly, cell lysate were resolved in 10% gels under reducing conditions before electrotransfer to nitrocellulose (NC) membranes (Fisher Scientific, Pittsburgh, PA). Upon complete protein transfer, the NC membranes were blocked in BLOTTO (5% nonfat milk made with 72 ohms and 500 and all cells on the underside of the filters were counted under a light microscope after mounting the filter on a glass slide. All invasion assays were done in triplicate for at least 3 times.

**Genomic Southern blot analysis of prostasin promoter methylation**

High molecular weight genomic DNA was isolated from various cell lines as described previously. Genomic DNA from each cell line was digested with the following restriction enzyme combinations: XhoI/BamH I (X/B), XhoI/BamH I/Hha I (X/B/Hh), XhoI/BamH I/Aci I (X/B/A), XhoI/BamH I/Bsa A I (X/B/Bs), XhoI/BamH I/Msp I (X/B/M) or XhoI/BamH IHpa II (X/B/H) using 10 μg of DNA per digestion combination. The X/B cutting sites flank the CpG sites to be investigated for differential methylation by the methylation-sensitive restriction endonucleases. The digests were resolved in a 0.8% agarose gel and analyzed by Southern blot hybridization as described previously. A nick-translated prostasin promoter probe (bases 703–1,649 of the prostasin gene sequence, GenBank accession number U33446) was used for the hybridization. The base numbering of the prostasin gene sequence was described in Yu et al.

**Demethylation of prostasin gene promoter and reactivation of prostasin expression**

For demethylation of prostasin gene promoter, MDA-MB-231 and MDA-MB-435s cells were seeded in 100 mm dishes at an initial density of 50% confluence and cultured in the presence of 500 nM 5-aza-2'-deoxycytidine (5-aza-2'-dC; Sigma-Aldrich) for 8 days, with renewal of medium and 5-aza-2'-dC performed at 2-day intervals. Genomic DNA was then isolated for Southern blot analysis as described. For reactivation of prostasin expression, MDA-MB-231 and MDA-MB-435s cells were seeded in 60 mm dishes at 80% confluence and cultured in the presence of 500 nM 5-aza-2'-dC for 24 hr, and were then treated for an additional 24 hr with either 1 μM trichostatin A (TSA; Sigma-Aldrich) or an equal volume of 5% ethanol used to dissolve TSA. For measuring time-dependence of prostasin gene reactivation, cells were treated as described above but were harvested at 6 or 12 hr after the addition of TSA. RNA was isolated for prostasin-specific RT-PCR/Southern blot analysis as described. The MCF-7 and the MD-MB-453 cell lines were subjected to the same 5-aza-2'-dC/TSA treatment and prostasin RT-PCR/Southern blot analysis procedures.

**RESULTS**

**Prostasin expression in breast cancer cell lines**

Expression of prostasin protein and mRNA in NHMEC and human breast carcinoma cell lines was examined by Western blot analysis using a prostasin-specific antibody or RT-PCR/Southern blot analysis as described. For our study, we chose 4 human breast carcinoma cell lines based on their differences in invasiveness and metastatic potential. The MCF-7 cell line is poorly invasive and nonmetastatic. The MDA-MB-231 and MDA-MB-435s cells are both highly invasive and metastatic. The 2 breast cancer cell lines that express the prostasin protein (MCF-7 and MDA-MB-453) appeared to show a greater level of expression than the NHMEC. It is presently unclear what factors
may have contributed to this apparent difference of prostasin protein expression levels in these cells. Expression of prostasin mRNA in these cells corresponds with the presence of prostasin protein expression. As shown in Figure 1 (middle panel), a 232 bp amplified prostasin message was detected in total RNA of NHMEC, MCF-7 and MDA-MB-453, but not MDA-MB-231 or MDA-MB-435s. A co-amplification of a 556 bp human β-actin message (as shown in the gel photograph in the bottom panel) confirmed the quality and the quantity of the RNA applied in each RT-PCR.

Reexpression of recombinant human prostasin in invasive breast cancer cells reduced in vitro invasiveness

Following the electroporation and drug selection, ∼200 colonies formed for each transfected cell type. All colonies for each transfected cell type were kept in a mixed culture as polyclonal transfectants for the ensuing experiments. Polyclonal MDA-MB-231 and MDA-MB-435s cells transfected with the human prostasin cDNA were confirmed to express the recombinant human prostasin protein, as shown by Western blot analysis of the cell lysate (Fig. 2, top panel). The vector-transfected cells were used as negative control in the Western blot analysis. In the in vitro Matrigel chemoinvasion assays (Fig. 2, bottom panel), transfected MDA-MB-231 or MDA-MB-435s cells expressing the recombinant human prostasin protein showed a significantly reduced level of invasiveness, at 50% of that of their vector-transfected controls, respectively.

Prostasin gene promoter is hypermethylated in invasive breast cancer cell lines

Examination of the prostasin gene locus by genomic Southern blot-RFLP (restriction fragment length polymorphism) analysis did not reveal any evidence of gene loss or gross rearrangement in the cell lines that did not show prostasin expression, namely, MDA-MB-231 and MDA-MB-435s (data not shown). We then considered the possibility of prostasin gene-silencing by epigenetic mechanisms. Postsynthetic methylation of cytosine residues in the 5′-CpG islands is often involved in long-term silencing of certain genes during mammalian development and in the progression of cancers.23 An examination of the prostasin promoter and exon 1 region sequence (GenBank accession number U33446) identified 28 CpG dinucleotides in a segment defined by an Xho I site (base number 1,101 to the BamH I site (1,649), at a length of 549 bp and has a GC content of 58.6%. The 549 bp GC-enriched domain contains 19 CpG dinucleotides, but failed to qualify as a true CpG island by the standards of Gardiner-Garden and Frommer.24
Genomic DNA methylation state of this Xho I-BamH I segment in the prostasin promoter-exon 1 region was investigated by Southern blot analysis using methylation-sensitive restriction endonucleases, which cut at unmethylated sites that contain CpG dinucleotide. The sites being investigated were an Hha I site at base number 615 (of U33446, same below)/*807 (relative to the transcription initiation site, same below), an Aci I site at 1,102/*320, a BsaA I site at 1,156/*266, an Hpa II site at 1,326/*96 and an Aci I site at 1,445/*24 (Fig. 3a). The results of the genomic Southern blot analysis are presented in Figure 3b and summarized in Table I.
In all 4 breast cancer cell lines and the NHMEC, Xho I/BamH I/ Hha I digestion yielded a 1,275 bp prostasin promoter band seen in the Xho I/BamH I digestion (Fig. 3b, upper panel), indicating that the -807 Hha I site-CpG is homogeneously methylated.

In the NHMEC, digestion with Xho I/BamH I/Aci I yielded a 1,072 bp, a 727 bp and a 345 bp band, but no 1,275 bp band, indicating that the -320 Aci I site-CpG is heterogeneously methylated, but the -24 Aci I site-CpG is homogeneously unmethylated. In MCF-7, MDA-MB-453, and MDA-MB-231, digestion with Xho I/BamH I/Aci I yielded only the 1,072 bp band, indicating that the -320 Aci I site-CpG is homogeneously methylated, but the +24 Aci I site-CpG is homogeneously unmethylated. In MDA-MB-453, digestion with Xho I/BamH I/Aci I yielded only the 1,072 bp band, indicating that both the -320 and the +24 Aci I site-CpG's are homogeneously methylated.

In the NHMEC, digestion with Xho I/BamH I/BsaA I yielded a 782 bp and a 343 bp band, indicating that the -266 BsaA I site-CpG is homogeneously unmethylated. In MCF-7 and MDA-MB-453, digestion with Xho I/BamH I/BsaA I yielded the 782 bp and the 493 bp bands, but also the 1,275 bp band, indicating that the -266 BsaA I site-CpG is heterogeneously methylated. In MDA-MB-231 and MDA-MB-435s, digestion with Xho I/BamH I/BsaA I yielded only the 1,275 bp band, indicating that the -266 BsaA I site-CpG is homogeneously methylated.

In the NHMEC and MCF-7 cells, the 1,275 bp Xho I/BamH I band can be digested by the methylation-insensitive Msp I as well as by the methylation-sensitive Hpa II, yielding an 951 bp band, indicating that the CpG at the -96 M/H restriction site is homogeneously unmethylated. In MDA-MB-453, the 1,275 bp band can be fully digested by Msp I, but only partially by the methylation-sensitive Hpa II, indicating a heterogeneous methylation of the -96 M/H site-CpG. In MDA-MB-231 and MDA-MB-435s, the 1,275 bp band was undigested by Hpa II while having been completely digested by Msp I, indicating that the -96 M/H site-CpG is homogeneously methylated.

Overall, in the prostasin-expressing cells, the NHMEC is the least methylated in this region and the methylation is restricted to beyond -266, relative to the transcription initiation site. The prostasin gene promoter-exon 1 region in MCF-7 and MDA-MB-453 cells is methylated to a higher extent than that in the NHMEC. In the MCF-7, methylation is restricted to beyond -96, while in the MDA-MB-453, methylation is observed at the -96 position and beyond. In the cells that do not express prostasin, the promoter-exon 1 region is the most heavily methylated. While in MDA-MB-231 the methylation is still restricted to the 5'-flanking region, all CpG sites examined, including 1 of exon 1 (+24 Aci I site-CpG) were found to be homogeneously methylated in the MDA-MB-435s cells. Our results showed that the prostasin gene promoter-exon 1 region CpG methylation patterns correlate with the absence of prostasin expression in the human breast cells examined in our study.

Prostasin expression was reactivated by demethylation and histone deacetylase inhibition in the invasive and metastatic breast cancer cell lines

Methylated promoter DNA may contribute to repression of gene expression by interfering with the binding of transcription factors,35 or by interacting with various methyl-CpG binding proteins, such as the MeCP1 complex, MeCP2 and the MBD's,26-29 depending on cell type, sequence of the methylated regulatory region and binding of other transcription factors.30 Histone deacetylation enzymes may be recruited by the methyl-CpG binding proteins to co-repress gene expression via chromatin restructuring.31-35 Histone deacetylases act synergistically with DNA methylation in the co-repress-

| Table 1 - Summary of CPG Methylation States in the Prostasin Gene Promoter-exon 1 Region in Human Breast Cells |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Cell type      | Prostasin expression | Hha I (-807) | Aci I (-320) | BsaA I (-266) | Msp I/Hpa II (-96) | Aci I (+24) |
| NHMEC          | Yes              | Methy | Hetero-metyl | Un-methyl | Un-methyl | Un-methyl |
| MCF-7          | Yes              | Methy | Methy       | Hetero-metyl | Un-methyl | Un-methyl |
| MDA-MB-453     | Yes              | Methy | Methy       | Hetero-metyl | Hetero-metyl | Un-methyl |
| MDA-MB-231     | No               | Methy | Methy       | Methy       | Methy       | Methy       |
| MDA-MB-435/Aza | Yes              | Methy | Hetero-metyl | Hetero-metyl | Hetero-metyl | Un-methyl |
| MDA-MB-435/Aza | Yes              | Methy | Hetero-metyl | Hetero-metyl | Hetero-metyl | Un-methyl |

Methyl, homogeneously methylated; Hetero-methyl, heterogeneously methylated; Un-methyl, homogeneously unmethylated. Prostasin mRNA expression was detected when these cell lines were further treated with TSA (Fig. 4a).

**Figure 3** - (a) Schematic illustration of the promoter-exon 1 region of the prostasin gene. The solid horizontal line represents the promoter-exon 1 region of the human prostasin gene (GenBank U33446).1 The Xho I site is located at base number 374, and the BamH I site is located at base number 1,649 of the U33446 sequence, respectively. The methylation-sensitive restriction sites used for differential methylation analysis, Hha I (615/-807), Aci I (1,102/-320 and 1,445/+24), BsaA I (1,156/-266) and Msp I/Hpa II (1,326/-96) are indicated by arrows. Four additional Aci I sites and a second Msp I/Hpa II site are present between the +24 Aci I site and the BamH I site, but not shown in the figure since they do not affect the results of the genomic DNA Southern blot analysis. The transcription initiation site (1) is indicated by the triangle on an extended vertical bar. Thin vertical bars map the location of the 28 CpG dinucleotides identified in this region. A 549 bp GC-enriched domain is indicated by the filled rectangular box. The extended vertical bars with open square boxes indicate the locations of the consensus GC boxes. The location of the probe used in the genomic DNA Southern blot analysis is shown by the open rectangular box. (b) Genomic Southern blot analysis of DNA from NHMEC and human breast cancer cell lines. Panels of genomic DNA Southern blot analysis results are as indicated for each cell type. Restriction endonucleases used in each digestion mixture are identified as follows: X, Xho I; B, BamH I; H, Hha I; A, Aci I; B, BsaA I; M, Msp I; H, Hpa II. Hha I, Aci I, BsaA I and Hpa II only cut unmethylated DNA, while Msp I, an isoschizomer of Hpa II, cuts unmethylated or methylated DNA. Genomic DNA (10 µg) from each cell type was cut with X/B or with X/B/M to serve as controls for the detection of differential methylation. In the upper panel, prostanin promoter DNA will yield a 1,275 bp X/B fragment. When Hha I was added to the X/B digestion mixture, a fragment of 1,037 bp was expected depending on the methylation pattern of the -807 Hha I site-CpG. When Msp I was added to the X/B digestion mixture, 3 smaller bands might be expected depending on the methylation pattern of the -320 Aci I site-CpG. When Aci I was added to the X/B digestion mixture, 2 smaller bands might be expected depending on the methylation pattern of the -807 Hha I site-CpG. When BsaA I was added to the X/B digestion mixture, a fragment of 1,037 bp was expected if the -807 Hha I site-CpG was not methylated. When Hpa II was added to the X/B digestion mixture, a fragment of 1,275 bp was expected if the methylation pattern of the -96 M/H site-CpG was not methylated. When Msp I was added to the X/B digestion mixture, 3 smaller bands might be expected depending on the methylation pattern of the -96 M/H site-CpG.
sion, with DNA methylation being the dominant force for stable maintenance of gene silencing in cancer. Treatment of cancer cells with the demethylation agent 5-aza-2'-deoxycytidine (5-aza-2'-dc) may restore a minimal expression for genes silenced by promoter methylation, and the combined treatment of 5-aza-2'-dc with the histone deacetylase inhibitor, trichostatin A (TSA), may further stimulate restored expression. We next investigated if demethylation and/or histone deacetylase inhibition could reactivate prostasin gene expression in the MDA-MB-231 and MDA-MB-435s cells.

After 8 days of treatment with the DNA methyltransferase inhibitor 5-aza-2'-dc, a significant level of demethylation was observed in the prostasin promoter-exon 1 region in the MDA-MB-231 and MDA-MB-435s cells, as genomic DNA of this region in these cells was partially digested by Hha I at -807, Aci I at -320, BsaAI at -266 and HpaII at -96 (Fig. 3c). The +24 Aci I was also partially digested in MDA-MB-435s following demethylation (Fig. 3c). Examination of total RNA of these cells by RT-PCR/Southern blot analysis following the 8-day 5-aza-2'-dc treatment, however, failed to detect prostasin mRNA expression (data not shown).

We then further investigated the combined effect of treating the cells with 5-aza-2'-dc and TSA, an inhibitor of histone deacetylase. As shown in Figure 4a (upper panel), by RT-PCR/Southern blot analysis, a time-dependent reactivated expression of prostasin mRNA was observed in both the MDA-MB-231 and the MDA-MB-435s cells after a treatment with 5-aza-2'-dc for 24 hr followed by a treatment with TSA for 6, 12 or 24 hr. Treatment of the cells with 5-aza-2'-dc alone, TSA alone or 5-aza-2'-dc followed by 95% ethanol (solvent for TSA) did not result in prostasin mRNA reexpression. A co-amplification of the β-actin message confirmed the quality and quantity of the total RNA used in each RT-PCR (Fig. 4a, lower panel). When MCF-7 and MDA-MB-453 cells were subjected to the same 5-aza-2'-dc/TSA treatment and prostasin RT-PCR/Southern blot analysis procedures, no increase of prostasin mRNA expression was observed for either cell line (Fig. 4b).

**DISCUSSION**

Prostasin serine protease has recently been shown to be an *in vitro* invasion suppressor of prostate cancer and to be downregulated in high-grade (Gleason 4/5) prostate tumors. Carcinomas of the prostate and of the breast drew close comparisons of each other as both originate from secretory epithelial cells and respond to changes of sex hormone levels in the body. On a molecular basis, carcinomas of these 2 sites have been shown to have common upregulated proteins that promote tumor progression and invasiveness and also common downregulated proteins that have been shown to be suppressors of tumorigenesis and/or invasiveness. For example, uPA, a serine protease that promotes tumor invasion, is upregulated in both of these cancers. The mechanism of uPA's tumor-invasion-promoting activity is believed to be 2-fold, since it is capable of degrading the extracellular matrix (ECM) and also increasing cell motility. NESP1, a serine protease and a tumor suppressor, is downregulated in both of these cancers. Further, a tumor/invasion suppressor serine protease inhibitor, maspin, is effective in inhibiting *in vitro* tumor invasion in both of these cancers by inhibiting cell motility. These findings suggest that in addition to the anatomical and physiological similarities between prostate and breast carcinomas, the cellular pathways that regulate tumor cell behaviors, such as invasiveness, may also be similar in these cancers. We have demonstrated that prostasin is a GPI-anchored active serine protease, prompting the reasoning that it may serve as a cell signaling molecule, as the importance of signaling via GPI-anchored proteins is increasingly appreciated in nonhematopoietic cells. For example, the cell motility-promoting action elicited by uPA is signaled via its cell surface receptor, uPAR. uPAR is a GPI-anchored protein and interacts with integrin during cell motility signal transduction. In our study, we demonstrated for the first time prostasin protein expression in normal human mammary epithelial cells and the loss of prostasin protein and mRNA expression in invasive and metastatic human breast cancer cell lines. This observation led to our transfection experiments of 2 invasive and metastatic breast cancer cell lines, MDA-MB-231 and MDA-MB-435s, to establish cell lines that reexpress the prostasin protein. We further demonstrated that enforced prostasin reexpression in these highly invasive breast cancer cell lines resulted in significant (50%) inhibition of *in vitro* invasiveness. Our findings suggest that prostasin serine protease may be a breast cancer invasion suppressor and its expression in breast tumors should be investigated in future studies.
mRNA expression reactivation was observed when MDA-MB-231 and MDA-MB-435s cells were treated with TSA following a treatment with 5-aza-2'-dC for only 24 hr, while TSA treatment alone did not reactivate prostasin mRNA expression (Fig. 4a). The same 5-aza-2'-dCTSA treatment procedures did not result in a prostasin mRNA expression increase when applied to the MCF-7 and MDA-MB-435 cells, confirming that the reactivation of prostasin mRNA expression in the MDA-MB-231 and MDA-MB-435s cells was the result of these inhibitors working on the silent prostasin promoter. These observations suggest that DNA methylation in the prostate gene promoter defined by the region of −266 to −96 may be relevant to prostasin gene silencing in the invasive breast cancer cell lines MDA-MB-231 and MDA-MB-435s. Examination of MDA-MB-231 and MDA-MB-435s cells treated with 5-aza-2'-dC for 8 days followed by TSA treatment for 24 hr in a Western blot analysis or following an immunoprecipitation using a prostasin-specific antibody did not reveal any expression of the prostasin protein (data not shown). It is possible that expression of prostasin in the breast is regulated by transcription factors that are lost in these highly invasive breast cancer cells and the reactivated prostasin mRNA expression detected by RT-PCR/Southern blot analysis represents the basal expression.

The finding that prostasin gene may be silenced by promoter DNA methylation in invasive breast cancer cells provides the molecular basis of a potential method of differentially diagnosing invasive breast cancer. Further, the prostasin gene may also provide the molecular basis for a gene-reactivation approach to treating invasive breast cancer.

REFERENCES

Regulation of prostasin by aldosterone in the kidney

Takefumi Narikiyo, Kenichiro Kitamura, Masataka Adachi, Taku Miyoshi, Kozo Iwashita, Naoki Shiraishi, Hiroshi Nonoguchi, Li-Mei Chen, Karl X. Chai, Julie Chao, and Kimio Tomita

1Third Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan
2Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida, USA
3Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, USA

Received for publication May 10, 2001, and accepted in revised form December 27, 2001.

Prostasin is a serine protease present in mammalian urine that increases the activity of the epithelial sodium channel (ENaC) when the two are coexpressed in Xenopus oocytes. To determine if aldosterone, one of the principal regulators of urinary Na reabsorption by the distal nephron, affects prostasin expression, we examined prostasin mRNA and protein in a cultured mouse cortical collecting duct cell line (M-1), whole rats, and patients with primary aldosteronism. Aldosterone treatment of M-1 cells substantially increased prostasin expression and stimulated 22Na uptake. Urinary excretion of prostasin in rats that were infused with aldosterone likewise increased by ~4-fold when compared with the vehicle-infused rats. Finally, urinary excretion of prostasin in patients with primary aldosteronism was substantially increased when compared with normal patients. Adrenalectomy reduced urinary prostasin excretion to control levels, whereas urinary prostasin levels were not altered in patients undergoing surgery for other reasons. In patients with primary aldosteronism, reduction in the urinary excretion of prostasin correlated with the increase in the urinary Na/K ratio. These findings, together with our previous report that prostasin activates the amiloride-sensitive Na currents through ENaC, demonstrate that prostasin regulates Na balance in vivo by virtue of its heightened expression in the presence of aldosterone.


Introduction

Aldosterone is the primary hormone that regulates Na balance, extracellular fluid volume, and blood pressure (1–3). Aldosterone increases the rate of Na reabsorption across epithelia at the distal nephron, the distal colon, and the ducts of exocrine glands by increasing Na transport through the epithelial Na channel (ENaC), one of the principal physiologic targets of aldosterone (4, 5). Regulation of ENaC by aldosterone has been extensively studied in the A6 renal cell line (6). In A6 cells, the effect of aldosterone on ENaC is characterized by a three-phase response: (a) a latent period, lasting 45 minutes; (b) an early response, lasting about 3 hours, in which Na transport increases and the transepithelial electrical resistance falls; and (c) a late response, lasting 12 to 24 hours, during which Na transport further increases while transepithelial resistance does not change significantly. The early and late effects of aldosterone appear to be mediated by transcriptional mechanisms because actinomycin D fully inhibits both actions (7). In addition to transcriptional regulation, May et al. reported that aldosterone increases the rate of de novo synthesis of ENaC α subunit 60 minutes after treatment, raising the possibility that aldosterone may exert its early phase action on ENaC through translational mechanisms (6). Furthermore, Weisz et al. reported the importance of aldosterone-induced trafficking and turnover of individual ENaC subunits in A6 cells (8). They demonstrated that long-term treatment with aldosterone stimulated Na influx by the selective insertion of βENaC at the apical membrane of A6 cells.

In 1997, a novel mechanism by which serine proteases regulate ENaC activity was identified. Vallet et al. cloned a new serine protease, xCAP-1, from A6 cells (9, 10). They showed that coexpression of xCAP-1 and ENaC in Xenopus oocytes increased the amiloride-sensitive Na current (I_{Na}) by two- to threefold. Chraibi et al. also reported that low concentrations of trypsin (2 μg/ml) increased I_{Na} by two- to fivefold in oocytes expressing ENaC (11). The precise molecular mechanisms of activation of ENaC by serine proteases are not fully understood. Vuagniaux et al. isolated a cDNA clone of mCAP-1 from a mouse cortical collecting duct (CCD) cell line and suggested that CAP-1 is an orthologous gene for prostasin (12). They also demonstrated that mCAP-1/prostasin activates ENaC when expressed in oocytes. Recently, we isolated a cDNA clone of rat prostasin, a serine protease that is expressed in the same epithelial tissues as ENaC, from the rat kidney (13). We demonstrated that prostasin is expressed in rat kidney collecting ducts and that coexpression of rat prostasin with rat ENaC increased I_{Na}. 

The Journal of Clinical Investigation | February 2002 | Volume 109 | Number 3
two- to threefold in Xenopus oocytes. We proposed that prostasin might play an important role in Na handling in the kidney by activating ENaC. However, regulation of prostasin mRNA, protein, or activity by physiologic stimuli, or under pathophysiologic conditions, is not yet established. Therefore, we investigated the regulation of prostasin expression by aldosterone because aldosterone is one of the principal regulators of Na reabsorption in the distal nephron.

We found that treatment of a mouse CCD cell line with aldosterone increased the secretion of prostasin protein into culture media and that aldosterone stimulated 22Na uptake by increasing prostasin expression. We also found that increased aldosterone levels in rats markedly increased the urinary excretion of prostasin. Furthermore, we demonstrated that the urinary excretion of prostasin was substantially increased in patients with primary aldosteronism and that adrenalectomy significantly reduced urinary prostasin excretion. These results indicate that prostasin is an important physiologic regulator of Na handling in the kidney.

Methods

Cloning of mouse prostasin cDNA. A partial cDNA fragment of mouse prostasin was obtained by PCR with two degenerate primers that correspond to amino acid sequences of human prostasin as described previously (13-15). A first-strand cDNA was synthesized from mouse kidney total RNA by the oligo (dT) primer method and amplified by these primers. The amplified DNA fragment was subcloned into pGEM-T Easy vector (Promega Corp., Madison, Wisconsin, USA) and sequenced. The 5' and 3' ends of mouse prostasin cDNA was cloned by the 5' and 3' rapid amplification of cDNA ends (RACE) system (Life Technologies Inc., Rockville, Maryland, USA), following the manufacturer's protocol. Briefly, mouse kidney total RNA was reverse-transcribed with antisense primer 5A-m1 (5'-CCCAACTCA-CATGTCGTCGCAA-3') for the 5'-RACE reaction. The cDNA that was generated was amplified by nested anti-sense primers, 5A-m2 (5'-ACCCCGCCGCTTCTCCTGC-3') and 5A-m3 (5'-CGGCTGATGAGTGGTACCTC-3'), sequentially with the abridged anchor primer and the abridged universal amplification primer (AUAP). For the 3' RACE reaction, total RNA was reverse-transcribed and amplified by nested PCR with two sense primers, 35-m1 (5'-GAGGTACCTCAGGAGCTGCAA-3') and 35-m2 (5'-GCCCACTTTCTCCTGGCCA-3'), and the AUAP primer. Both 5' and 3' RACE products were subcloned into pGEM-T Easy vector and sequenced. A full-length cDNA of mouse prostasin and rat β-actin was individually cloned with horseradish peroxidase) for 1 hour at 37°C and 5% CO2. Experiments were performed when cells were confluent. Serum and dexamethasone were removed 48 hours before experiments. All studies described in this paper were performed on cells between the 5th and 20th passages.

Preparation of proteins and TCA precipitation. After incubation under experimental conditions, culture medium was precipitated by trichloroacetic acid (TCA) (final concentration: 15%). The samples were centrifuged at 12,000 g and the pellets were washed three times with ice-cold 80% acetone. The precipitated proteins were dried and solubilized at 100°C for 5 minutes in 1x TCA buffer (200 mM unbuffered Tris, 1% SDS, 10% glycerol, 1% β-mercaptoethanol). For preparation of membrane and cytosolic fractions of M-1 cells, confluent M-1 cells were washed twice in PBS, scraped into lysis buffer (25 mM Tris-HCl, pH 7.5, 4 μg/ml aprotinin, 4 μg/ml leupeptin, 1 mM PMSF, and 4 μg/ml pepstatin A), and lysed in a glass Dounce homogenizer. The homogenate was centrifuged at 800 g to remove nuclei, and the supernatant was centrifuged at 12,000 g to separate the membrane and cytosolic fractions. The membrane fraction was then dissolved in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% vol/vol Triton-X 100, 2 mM EDTA, 4 μg/ml aprotinin, 4 μg/ml leupeptin, 1 mM PMSF, and 4 μg/ml pepstatin A). All these procedures were performed at 4°C.

Immunoblotting. Samples were resolved on 12% SDS-PAGE and transferred onto nitrocellulose filters. After blocking with 5 g/dl nonfat dry milk, the blots were probed with a polyclonal Ab against prostasin (15) in Tris-buffered saline with 0.05% Tween-20 for 1 hour, followed by a secondary Ab (goat anti-rabbit IgG conjugated with horseradish peroxidase) for 1 hour at room temperature. Bands were visualized using chemiluminescence substrate (ECL; Amersham Pharmacia Biotech, Amersham, United Kingdom) followed by exposure to x-ray film. The band densities were quantitated by densitometry (Densitograph 4.0; ATTO Co., Tokyo, Japan).

22Na influx studies. The activities of ENaC in M-1 cells were determined by measurement of amiloride-sensitive 22Na uptake (16). Preliminary experiments determined that amiloride-sensitive uptake of 22Na was linear for up to 15 minutes. After incubation under experimental con-
ditions, cells on six-well dishes were rinsed twice and preincubated for 15 minutes at 37°C in a Na-free solution composed of 137 mM N-methylglucamine (NMDG), 5.4 mM KCl, 1.2 mM MgSO\(_4\), 2.8 mM CaCl\(_2\), and 15 mM HEPES (pH 7.4). At the end of the preincubation, the Na-free solution was replaced by the uptake solution composed of 14 mM NaCl, 35 mM KCl, 96 mM NMDG, and 20 mM HEPES (pH 7.4) containing 1 mM ouabain and 1.5 μCi/ml of \(^{22}\)NaCl (specific activity: 748 μCi/mg Na; New England Nuclear, Boston, Massachusetts, USA) in the presence or absence of 1 mM amiloride. After a 5-minute incubation, uptake was stopped by washing the cells four times with 1 ml/well of an ice-cold solution containing 120 mM NMDG and 20 mM HEPES (pH 7.4). The cells were then solubilized in 0.5% Triton X-100. Tracer activities were measured in a gamma scintillation counter. The amount of protein per well was measured using the BCA kit (Pierce Chemical Co., Rockford, Illinois, USA). All assays were performed in duplicate. ENaC activity was determined as the difference between \(^{22}\)Na uptake in the presence or absence of amiloride. The results were normalized for protein concentration and expressed as percentage of control.

**Aldosterone infusion studies.** Experiments were conducted in male Sprague-Dawley rats (160–170 g) from Charles River Laboratories (Wilmington, Massachusetts, USA). Rats were anesthetized with pentobarbital sodium (Nembutal; Abbott Laboratories, North Chicago, Illinois, USA) before subcutaneous implantation of osmotic minipumps (model 2001; Alza Corp., Palo Alto, California, USA) that delivered 100 μg/100 g body weight aldosterone per day (17). Aldosterone (Sigma Chemical Co., St. Louis, Missouri, USA) was dissolved in DMSO and diluted with isotonic saline. Control rats received vehicle alone. All rats were kept in metabolic cages, and 24-hour urine collections were made. Urine samples, corrected for creatinine excretion, were concentrated by TCA precipitation, and the amount of prostasin was determined by immunoblotting as described above. Blood samples were obtained at the end of the experiments to measure plasma aldosterone, serum potassium, and serum bicarbonate concentrations. All animal procedures were approved by the institutional ethics committee.

**Patients with primary aldosteronism.** Three patients with primary aldosteronism and three patients undergoing surgery for other reasons with general anesthesia were enrolled in the study. Institutional approval was received from the Kumamoto University Human Subject Review Board, and written informed consent was obtained from each patient prior to the studies. All patients with primary aldosteronism were treated with adrenalectomy, and 24-hour urine collections were obtained before and after surgery. The prostasin excretion level in urine samples was determined by the same method as described above.

**Results**

**Cloning of full-length mouse prostasin cDNA.** To evaluate the level of prostasin mRNA expression in the M-1 cell line by Northern blotting, we isolated a full-length prostasin cDNA from mouse kidney using RT-PCR, 5' and 3' RACE methods. The prostasin cDNA encodes a 339-amino-acid polypeptide, including a 29-amino-acid signal peptide, a 15-amino-acid light chain, and a 295-amino-acid heavy chain. The catalytic triad that is highly conserved among the serine proteases is also found in mouse prostasin (His\(^{85}\), Asp\(^{134}\), and Ser\(^{238}\)). Vuagniaux et al. proposed that mCAP-1, xCAP-1, and human prostasin are orthologous genes (12). Our cloning of mouse prostasin cDNA also revealed that mouse prostasin is identical to the mCAP-1 at the amino acid level.

**Effect of aldosterone on prostasin expression in M-1 cells.** Previously, we demonstrated that expression of prostasin stimulates ENaC in Xenopus oocytes (13). May et al. also reported that aldosterone increases ENaC activity as well as ENaC protein translation in A6 cells (6). These findings motivated us to study the effect of aldosterone on the expression of prostasin. We used M-1 cells to study the regulation of prostasin by aldosterone because both prostasin and ENaC are expressed in the CCD segment (12, 13, 18) and aldosterone modulates Na transport in M-1 cells (19). We measured prostasin mRNA abundance in M-1 cells following aldosterone treatment. Figure 1 shows the time course of prostasin mRNA induction by aldosterone. Prostasin transcripts were readily detected under basal conditions. Aldosterone induced an increase in prostasin mRNA after 6 hours of stimulation. Maximum induction occurred at 24 hours (1.9-fold ± 0.2-fold), and elevated mRNA levels were still present for up to 48 hours.

We then determined the distribution of prostasin protein between M-1 cell membranes and cytosol. Based on its predicted secondary structure, prostasin is presumed to be a secreted and/or a glycosylphosphatidylinositol-anchored protein, so we also determined if it was present in cell culture medium. Proteins in the membrane and cytosolic fractions of M-1 cells and culture media were precipitated by TCA and subjected to immunoblotting. As shown in Figure 2a, the antiprostasin Ab detected a single band of 40 kDa only when we immunoblotted 80 μg of protein. While prostasin protein was shown to be secreted when synthesized in the prostate (15), recent findings also indicated that it can assume a membrane-anchored form via glycosylphosphatidylinositol in prostate epithelial cells that naturally express prostasin (20). In the M-1 cells, it is possible that the distribution of the membrane-anchored versus the secreted prostasin protein for the total pool of prostasin protein synthesized is
The blot is representative of five separate experiments. Aldosterone, aldosterone-TCA-precipitated culture medium from M-1 cells were subjected to 404 experiments. Values are mean ± SEM (n = 4). *P < 0.02.

Figure 1
Effect of aldosterone on the expression of prostasin mRNA in M-1 cells. M-1 cells, which were serum deprived for 48 hours, were treated with 1 µM aldosterone and harvested at various time points (0, 6, 12, 24, and 48 hours) for isolation of total RNA. Each lane contains 20 µg of total RNA. The abundance of prostasin mRNA was normalized for β-actin (bottom). Aldosterone induced an increase in prostasin mRNA after 6 hours of stimulation. Maximum induction occurred at 24 hours (1.9-fold ± 0.2-fold increase), and this effect was observed for up to 48 hours. This blot is representative of four separate experiments. Values are mean ± SEM (n = 4). *P < 0.02.

Figure 2
Effect of aldosterone on the expression of prostasin protein in M-1 cells. (a) Cellular distribution of prostasin protein in M-1 cells. Forty micrograms of membrane and cytosolic proteins as well as 3 ml of TCA-precipitated culture medium from M-1 cells were subjected to SDS-PAGE. Blots were probed with the antiprostasin Ab and with Ab preadsorbed with the immunizing peptide. Prostasin was detected as a 40-kDa band in the culture medium only. (b) Effect of aldosterone on the expression of prostasin protein in M-1 cells. M-1 cells were treated with 1 µM aldosterone or vehicle for 24 and 48 hours. Proteins in the culture medium were TCA precipitated and subjected to SDS-PAGE. Treatment with 1 µM aldosterone increased prostasin protein expression by 3.5-fold ± 0.6-fold (for 24 hours) and 3.3-fold ± 0.3-fold (for 48 hours) when compared with the controls during 24-hour and 48-hour incubations. This stimulatory effect of aldosterone on prostasin protein expression was dose dependent over the range of 0-10-6 M (Figure 3c). Even after treatment with aldosterone, we could not detect prostasin protein in either membrane or cytosolic fractions (data not shown). These findings demonstrate that aldosterone stimulates expression of prostasin at the levels of mRNA as well as protein in M-1 cells.

Effect of aprotinin on aldosterone-induced 22Na uptake in M-1 cells. To determine if the aldosterone-induced increase in prostasin protein abundance in M-1 cells indeed has a role in activating ENaC, we measured amiloride-sensitive 22Na uptake. M-1 cells were treated for 24 hours with 1 µM aldosterone or vehicle in the presence or absence of 28 µg/ml aprotinin, a potent prostasin inhibitor (IC50 of aprotinin for prostasin is 11.7 ng/ml) (15), and then amiloride-sensitive 22Na uptake was measured. As shown in Figure 3a, treatment with aprotinin decreased the amiloride-sensitive 22Na uptake by 25% ± 9% under basal conditions. Nakhoul et al. reported that aprotinin reduced the Na current in M-1 cells by 49% ± 9% (19). The difference in the magnitude of the aprotinin-sensitive component in the basal Na current in M-1 cells could have resulted from the differences of the methods used. Aldosterone increased the 22Na uptake by 189% ± 25%, and aprotinin significantly reduced the Na influx in aldosterone-treated cells. Interestingly, aprotinin-insensitive Na uptake was markedly increased by twofold in aldosterone-treated cells when compared with the control. Also, aldosterone increased the aprotinin-insensitive component. To address the question if sufficient
with the findings that aldosterone increases prostasin protein expression in M-1 cells, demonstrate that M-1 cells have aprotinin-sensitive Na uptake under basal conditions that is probably due to prostasin expression and that aldosterone substantially increases the prostasin-dependent Na uptake by increasing prostasin protein abundance. Furthermore, these findings strongly support our hypothesis that aldosterone-induced increase in prostasin protein has a key role in the aldosterone-induced activation of ENaC.

**Effect of amiloride on aldosterone-induced prostasin expression in M-1 cells.** Aldosterone activates Na transport in M-1 cells (19) and distal tubules of other species (2) through activation of ENaC. Prostasin expression could be increased by mechanisms that are a consequence of activation of ENaC, such as an increase in the intracellular Na concentration. To determine whether an increase in prostasin expression is secondary to an event following the activation of ENaC by aldosterone, we studied the effect of amiloride, a potent ENaC inhibitor, on the aldosterone-induced increase in prostasin expression in the cell culture media. M-1 cells were preincubated with 5 μM amiloride for 30 minutes, and then aldosterone (final 1 μM) was added to the media in the presence of amiloride. Twenty-four hours after incubation, medium was collected and subjected to immunoblotting. As shown in Figure 4, amiloride treatment had no effect on either basal or aldosterone-induced prostasin protein expression. These results suggest that the induction of prostasin by aldosterone is not mediated by an amiloride-sensitive mechanism that is secondary to ENaC activation. We then studied the effect of prostasin on the aldosterone sensitivity of ENaC. The \( K_{m} \) of ENaC in the absence of prostasin (0.10 ± 0.006 μM; \( n = 12 \)) did not significantly differ from the \( K_{m} \) in the presence of prostasin (0.094 ± 0.005 μM; \( n = 14 \)).

**Aldosterone-infusion studies.** To study the stimulatory effect of aldosterone on prostasin expression in vivo, we infused rats with aldosterone through subcuta-

---

**Figure 3**

Role of prostasin in the aldosterone-induced increase in \(^{22}\)Na uptake in M-1 cells. (a) Effect of aprotinin on aldosterone-induced \(^{22}\)Na uptake in M-1 cells. M-1 cells were treated with 1 μM aldosterone or vehicle for 24 hours in the presence or absence of 28 μg/ml aprotinin. Aminoide-sensitive \(^{22}\)Na uptake was determined in the presence of 1 mM amiloride and 1 mM ouabain. Treatment with aprotinin partially inhibited the basal Na influx as well as the aldosterone-induced Na influx. Aldosterone significantly increased the aprotinin-sensitive Na uptake twofold. Aprotinin-sensitive Na uptake values are mean ± SEM (\( n = 6 \)). (b) Effect of recombinant prostasin on aldosterone-induced \(^{22}\)Na uptake in M-1 cells. M-1 cells were treated with 1 μM aldosterone or vehicle for 24 hours, then cells were treated with 2 μg/ml of recombinant prostasin. Aminoide-sensitive \(^{22}\)Na uptake was determined as described above. Treatment with recombinant prostasin further increased the basal Na influx as well as the aldosterone-induced Na influx (1.35-fold and 1.56-fold, respectively). Values are mean ± SEM (\( n = 7 \)). *\( P < 0.05 \).

**Figure 4**

Effect of amiloride on aldosterone-induced expression of prostasin protein in M-1 cells. M-1 cells were treated with 1 μM aldosterone or vehicle in the presence or absence of 5 μM amiloride for 24 hours. Prostasin protein abundance was determined by immunoblotting. Treatment of M-1 cells with amiloride had no effect on the secretion of prostasin in the culture media (aldosterone: 1.9-fold ± 0.2-fold, aldosterone + amiloride: 1.8-fold ± 0.7-fold, not significant). This figure is representative of four separate experiments. Am, amiloride. Values are mean ± SEM (\( n = 4 \)). NS, not significant; *\( P < 0.02 \).
The effect of aldosterone was time dependent, and maximum induction was observed at day 7 (4.3-fold increase over control). These findings indicate that aldosterone induces prostasin expression in the kidney in whole animals as well as in cultured cells and that it may play an important role in the impaired Na handling in patients with hyperaldosteronism.

**Urinary prostasin levels in patients with primary aldosteronism.** To determine whether aldosterone increases prostasin protein expression in humans, we measured urinary prostasin protein expression in patients with primary aldosteronism before and after adrenalectomy. The diagnosis of an aldosterone-secreting adenoma was made on the basis of measurement of plasma renin activity and plasma aldosterone levels and by radiologic examinations, including computed tomography and magnetic resonance imaging scans. Patient profiles, plasma renin activities, plasma aldosterone concentration (PAC), and serum potassium levels of the patients are shown in Table 1. To study urinary prostasin excretion, 24-hour urine collections were obtained before and 7 days after adrenalectomy. Figure 6a shows the results of Western blot analysis of urinary prostasin excretion before and after adrenalectomy from patient number 1. Adrenalectomy resulted in a marked decrease in urinary prostasin protein abundance. PAC was also reduced to the normal range after the operation (Table 1). Interestingly, the urinary Na/K ratio correlated with the expression level of prostasin, suggesting that aldosterone-induced prostasin plays a role in activation of ENaC (Figure 6a). Patients with high PAC level (numbers 1–3) had substantially higher urinary prostasin excretion when compared with normal PAC level patients (numbers 4–6) (Figure 6b). In all three patients with primary aldosteronism, adrenalectomy resulted in a significant decrease in the urinary prostasin excretion, while no change in urinary prostasin excretion was observed in the three patients with normal PAC levels (Figure 6b). These results indicate that prostasin is regulated by aldosterone in humans as well as in rats.

**Table 1**
Clinical profiles of the patients with primary aldosteronism and other diseases

<table>
<thead>
<tr>
<th>Patients</th>
<th>Sex</th>
<th>Age (years old)</th>
<th>Height (cm)</th>
<th>BW (kg)</th>
<th>PRA (ng/ml/h) before/after</th>
<th>PAC (pg/ml) before/after</th>
<th>p-K (mEq/l)</th>
<th>Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>22</td>
<td>175</td>
<td>69.6</td>
<td>&lt;0.1/0.1</td>
<td>330/50</td>
<td>2.8</td>
<td>PA</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>51</td>
<td>155</td>
<td>51.1</td>
<td>&lt;0.1/0.2</td>
<td>189/51</td>
<td>3.2</td>
<td>PA</td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>43</td>
<td>160</td>
<td>57.6</td>
<td>&lt;0.1/0.1</td>
<td>778/34</td>
<td>2.0</td>
<td>PA</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>26</td>
<td>171</td>
<td>89.0</td>
<td>0.6/0.5</td>
<td>80/58</td>
<td>4.2</td>
<td>Achalasia</td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>51</td>
<td>151</td>
<td>45.0</td>
<td>0.5/0.2</td>
<td>91/49</td>
<td>3.9</td>
<td>PHP</td>
</tr>
<tr>
<td>6</td>
<td>Male</td>
<td>37</td>
<td>178</td>
<td>92.5</td>
<td>1.8/1.3</td>
<td>94/110</td>
<td>4.2</td>
<td>Cholelithiasis</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. Plasma renin activities PRA and PAC were measured before and 7 days after the operation in each patient. BW, body weight; p-K, serum potassium; PA, primary aldosteronism; PHP, primary hyperparathyroidism; PRA, plasma renin activities.
Discussion

Serine proteases such as CAP-1, trypsin, and chymotrypsin have been shown to stimulate $I_{Na}$ in *Xenopus* oocytes expressing ENaC, although the precise mechanisms of activation are not known (10-12). We cloned a rat prostasin cDNA and demonstrated that expression of rat prostasin increased the Na current through ENaC (13). Prostasin is expressed in epithelial tissues that are known to be the sites of amiloride-sensitive transepithelial Na transport. Therefore, we hypothesized that prostasin may play an important role in Na handling by the kidney through the activation of ENaC. In the present studies, we addressed the question of whether aldosterone, a major natriferic hormone that increases Na uptake in the distal nephron by activation of ENaC, could regulate the expression of prostasin in mammals. We showed that aldosterone stimulates Na uptake by increasing the expression of prostasin mRNA and protein in cultured mouse CCD cells. We also showed that urinary excretion of prostasin is increased in aldosterone-infused rats and in patients with primary aldosteronism.

Regulation of prostasin by aldosterone. In the study presented here, we showed that aldosterone induces a twofold increase in prostasin mRNA in M-1 cells. Because we have not yet measured the rate of transcription of this gene, we do not know whether the increased abundance of mRNA is mediated by a direct transcriptional effect and/or by an effect on mRNA turnover. The stimulatory effect of aldosterone on the accumulation of prostasin protein in the culture media or urine was proportional to the effect on mRNA abundance. Aldosterone significantly induced prostasin excretion in rat and human urine by approximately twofold. In the current study we have not addressed the question of whether aldosterone could regulate the assembly of prostasin in the endoplasmic reticulum, its transport to the plasma membrane, its release from the plasma membrane, and the stability of the released protein in the culture media or urine; each step could be separate sites of hormonal regulation.

Possible involvement of prostasin in aldosterone-induced Na absorption. Here we demonstrated that treatment of M-1 cells increases aprotinin-sensitive, further, prostasin-sensitive, Na uptake by increasing the prostasin protein abundance. Until this report, there was no direct evidence showing that serine proteases are involved in Na reabsorption in the distal nephron. However, data in several papers support the concept that serine proteases may play a key role in Na uptake in the kidney (9-13). Nakhou et al. demonstrated that aprotinin added to the luminal side of M-1 cells induces a 50% decrease in the $I_{Na}$, suggesting that serine proteases such as prostasin could stimulate ENaC activity since aprotinin is a potent inhibitor of prostasin activity (19). More recently, Masi-Giannini et al. reported that aldosterone infusion in rats resulted in a molecular weight shift of γENaC from 85 kDa to 70 kDa (21). They speculated that proteolytic cleavage of the γENaC by serine proteases such as CAP-1 might be responsible for this phenomenon. Since prostasin is expressed in the collecting ducts and is excreted into urine, it may participate in the molecular weight shift of γENaC and subsequent activation of ENaC in mammals. Nafamostat mesilate (NM), a synthetic serine protease inhibitor, inhibits various serine proteases including trypsin, thrombin, activated factor X, and activated complement. Although NM has been shown to be effective in the treatment of pancreatitis and disseminated intravascular coagulation, it is associated with hyponatremia and hyperkalemia in some cases (22). Muto et al. reported that perfusion of rabbit CCD with NM inhibited $I_{Na}$, resulting in inhibition of potassium secretion (23, 24). They suggested that hyponatremia and/or hyperkalemia associated with NM treatment could be caused in part by inhibition of amiloride-sensitive Na conductance. This finding also implies physiologic involvement of serine proteases such as prostasin in Na handling in renal tubules.

Aldosterone stimulates Na reabsorption by multiple actions on multiple proteins involved in Na transport or its regulation. Aldosterone stimulates the transcription of ENaC in the kidney and increases the channel number at the apical membrane of the collecting duct, leading to an enhanced Na reabsorption in the distal nephron segment. Sgk, a serine/threonine kinase that activates electrogenic Na transport by increasing the number of Na channels (ENaC) at the cell surface, is also an aldosterone-induced protein and may play a key role in the aldosterone-mediated...
regulation of Na absorption (25). Our current study suggests an additional mechanism by which aldosterone could stimulate Na transport through ENaC by way of increasing the expression of prostasin in the kidney. Our results provide a new insight into the regulation of distal nephron Na transport and pathogenesis of hypertension and provide the rationale for development of new therapeutic agents for hypertension and Na-retaining states.

Acknowledgments

We thank Shizuka Iida (Kurume University School of Medicine) and Junnosuke Inoue (Jikei Hospital) for sharing the urine samples of the primary aldosteronism patients. This work was supported by the Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Culture in Japan (11770599 and 13770602 to K. Kitamura and 10671000, 11470219, and 11877177 to K. Tomita), The Salt Science Research Foundation (to K. Tomita), and Department of Defense Prostate Cancer Research Program Grants (DAMD 17-98-1-8590 and DAMD 17-02-1-0032 to K.X. Chai).

Appendix 5

Submitted to J. Biol. Chem. Manuscript No. M2-02491

Purification and Characterization of the Prostasin-binding Protein

Li-Mei Chen and Karl X. Chai

Department of Molecular Biology and Microbiology, University of Central Florida,
Orlando, FL 32816

Running title: prostasin-binding protein

This work was supported by Department of Defense Prostate Cancer Research Program grants No. DAMD17-98-1-8590 and DAMD17-02-1-0032 to KXC, and by National Institutes of Health grant No. HD 40241 to LMC.

§To whom request for reprints should be addressed at:

Dr. Karl X. Chai
Department of Molecular Biology and Microbiology
University of Central Florida
4000 Central Florida Boulevard, Orlando, FL 32816-2360
Phone: (407) 823-6122, Fax: (407) 823-3095, e-mail: kxchai@mail.ucf.edu
Summary

Prostasin serine protease is synthesized as a glycosylphosphatidylinositol (GPI)-anchored membrane protein, and can be secreted via an unknown mechanism. Prostasin has been implicated for a function in the regulation of epithelial sodium channel activity and in cancer biology. A prostasin-binding protein was identified in mouse and human seminal vesicles. In this study, we have purified the prostasin-binding protein from mouse seminal vesicle (mPBP). The purified mPBP formed a covalent complex with purified recombinant human prostasin in a time-dependent and pH-dependent manner. The complex formation was detected after 30 seconds, with the optimum pH at 9.0. A polyclonal antibody against mPBP was generated. The antibody recognized a free-form mPBP and the complex of mPBP-prostasin. The purified mPBP inhibits prostasin's activity toward a synthetic substrate. A trypsin-digested fragment of mPBP was sequenced, the amino acid sequence matched a region in the serpin protease nexin-1 (PN-1) sequence. Recombinant mouse or human PN-1 was shown to form a covalent complex with prostasin. Together, these data indicate that the prostasin-binding protein is PN-1. The identification of an interaction between prostasin and PN-1 suggests new functions and mechanisms where these molecules are present.
Introduction

Serine proteases play important roles in a diverse range of essential physiological processes and are implicated in various pathological processes such as cardiovascular disorders, inflammation, and cancers; hence, methods to inhibit these proteases have been explored for potential therapeutic applications (1). A subgroup of serine proteases with trypsin-like activities has attracted great attention because of their potential or confirmed membrane-anchorage. Examples are prostasin, testisin, and gamma-tryptases (2-5). These membrane-anchored serine proteases may potentially act in very different ways than the classical secreted serine proteases such as trypsin. In our laboratory, we are interested in defining the physiological functions of prostasin, and identifying its regulators. Human prostasin was discovered in 1994 (2). The function of prostasin was unknown until Vallet et al. (6) identified a sodium channel activator in a *Xenopus* kidney epithelial cell line (A6), *Xenopus* CAP-I (xCAP-1), which shared 53% sequence homology at the amino acid level with human prostasin. The CAP-1 is regarded as the homologue of prostasin. Later, Vuagniaux et al. (7) isolated mouse CAP-1 (mCAP-1) from a mouse cortical collecting duct (CCD) cell line. The mCAP-1 shares >80% sequence homology at the nucleic acid level with human prostasin. They further demonstrated that mCAP-1 activates the epithelial sodium channel (ENaC). A rat prostasin cDNA was also cloned (8). Co-expression of rat prostasin with rat ENaC increased the sodium current by two- to three-fold in *Xenopus* oocytes. In human airways, prostasin has now been suggested to be a regulator of the ENaC (9). Its role in airway ENaC activation is thought to be dependent on its serine protease activity as the serine protease inhibitor aprotinin had an opposing effect. In a
recent study (10), Narikiyo et al. demonstrated that aldosterone increased the secretion of prostasin protein into the culture medium of mouse CCD cell line, and also in urinary excretion in rats treated with aldosterone. Patients with primary aldosteronism showed increased prostasin level in the urine, and adrenalectomy significantly reduced the urinary prostasin excretion. The role of prostasin in sodium balance regulation in the kidney is also associated with its serine protease activity as the sodium current changes in response to aldosterone were inhibited by aprotinin (10). Most recently, Vallet et al. (11) further demonstrated that the glycosylphosphatidylinositol (GPI)-anchorage of xCAP/prostasin is required for its sodium channel activating function. A catalytic mutant of xCAP-1/prostasin decreased the ENaC activation by 90% but did not fully abolish it, suggesting that alternative mechanisms may also be involved (11). These results indicate that prostasin, most likely through its serine protease activity, is an important physiologic regulator of sodium balance.

We have shown that prostasin is a glycosylphosphatidylinositol (GPI)-anchored active serine protease expressed in normal prostate epithelial cells, and that prostasin can also be secreted into the prostatic fluid or culture media (12). Prostasin expression is down-regulated in high-grade (Gleason 4/5) prostate cancers, and in highly invasive human prostate and breast cancer cell lines (13-14). Enforced re-expression of prostasin in prostate and breast cancer cells reduced the invasiveness of these cells in vitro (13-14). The down-regulation of prostasin in the invasive human breast cancer cell lines is due to promoter DNA methylation (14). At present it remains to be determined whether the anti-invasion function of prostasin is dependent on its serine protease activity.
Serine protease inhibitors, or the serpins, are natural specific inhibitors of serine proteases. The serpins bind to the serine proteases to form a covalent complex at the serine active site, thereby inhibiting the protease (15). The process of serpins binding to their target proteases is usually rapid. Some serpins, however, are not good inhibitors alone, but become quite excellent inhibitors when they are complexed with cofactors, such as heparin. Examples of this type of serpins are antithrombin III, heparin cofactor II, protease nexin-1 (PN-1), and protein C inhibitor (16-19). Heparin is believed to cause a conformational change in the serpin molecule, in turn, facilitating the interaction of the protease and the serpin. While prostasin's physiological functions are not fully characterized at present, the knowledge of its potential inhibitors is also lacking. In a previous study, we identified a prostasin-binding protein in mouse and human seminal vesicles. In the present study, we have purified and characterized this prostasin-binding protein, and provided evidence to show that the prostasin-binding protein is a serpin, previously identified as protease nexin-1 (PN-1) (20).
Experimental Procedures

Purification of Prostasin-binding Protein

Sample preparation – The procedure was carried out as described previously (12) with modifications. Briefly, mouse seminal vesicle fluid was expressed in buffer A (20 mM sodium phosphate, pH 6.8) at a ratio of one pair of seminal vesicles per 1.0 ml of buffer. The sample was then centrifuged at 10,000 x g for 30 min at 4°C to remove insoluble material.

The following chromatography steps were performed at room temperature.

Anion-exchange chromatography – Two milliliters of the mouse seminal vesicle supernatant were applied onto an anion-exchange Econ-Cartridge (Q, 1 ml; Bio-Rad, Hercules, CA) equilibrated with buffer A, at a flow rate of 1 ml/min. After washing with 10 ml buffer A, the cartridge was eluted with 10 ml of 1 M NaCl/buffer A. Prostasin-binding activity was monitored by means of a prostasin-binding assay as described (12).

Hydroxylapatite chromatography – Fractions containing the prostasin-binding activity from the Q cartridge were applied onto a hydroxylapatite Econ-Cartridge (HTP, 1 ml; Bio-Rad) equilibrated with buffer A. The cartridge was washed with buffer A (10 ml), and eluted with 0.2 M sodium phosphate buffer (pH 6.8, 10 ml), followed by 0.5 M sodium phosphate buffer (pH 6.8, 10 ml).

Cation-exchange chromatography – Fractions containing the prostasin-binding activity from the HTP cartridge were diluted with buffer A and applied onto a cation-exchange Econ-Cartridge (CM, 1 ml; Bio-Rad) equilibrated with buffer A. After washing with buffer A, the cartridge was eluted with a 0 – 0.75 M linear NaCl gradient in buffer A
(20 ml). Fractions containing prostasin-binding activity were collected and concentrated through a Centricon-10 concentrator (Millipore, Bedford, MA) with several changes of PBS (phosphate-buffered saline, pH 7.4, LifeTechnologies, Gaithersburg, MD), and then stored at −20°C before further characterization.

Scaled-up purification was performed as described above, except that the first anion-exchange chromatography was performed using the DEAE CL-6B agarose (2.5 x 20 cm, Amersham Pharmacia Biotech, Piscataway, NJ). The subsequent purification steps were carried out by using 5-ml cartridges (Bio-Rad).

Preparation of A Polyclonal Antiserum

An antiserum against mPBP was prepared according to the procedure described in Chen et al. (12). Briefly, 0.5 ml of the purified mPBP (250 µg) was emulsified with an equal volume of complete Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO), and injected subcutaneously into a 1.5-kg New Zealand White female rabbit (Charles River Laboratories, Wilmington, MA). Booster injections were made with 100 µg of mPBP (emulsified with incomplete Freund’s adjuvant, Sigma-Aldrich) for 3 times at 3-week intervals. Pre-immune rabbit serum was collected before the initial immunization.

Prostasin-binding Assay and Western Blot Analysis

The procedures were performed according to Chen et al. (12). Briefly, purified recombinant prostasin (12) was incubated with samples from each purification step or the final purified mPBP at 37°C for 1 hour or for various times as indicated. The binding
reaction was stopped by the addition of SDS-sample buffer [1x SDS sample buffer = 62.5 mM Tris-HCl at pH 6.8, 2% (v/v) glycerol, 2% SDS (w/v), and 2% β-mercaptoethanol]. The reaction mixtures were then boiled for 5 min, and resolved in 10% SDS-polyacrylamide gels. The resolved proteins were then transferred to nitrocellulose membranes, and analyzed with either a prostasin antibody (12) or the mPBP antibody. Signals were detected using an ECL detection procedure with the WestPico reagents (Pierce, Rockford, IL) following the manufacturer’s protocol. The membrane was then exposed to X-ray film (Midwest Scientific, St. Louis, MO). The prostasin antibody was used at 1:2,000 dilution, the mPBP antibody was used at 1:10,000 dilution, and the secondary antibody (goat anti-rabbit IgG, Sigma-Aldrich) was used at 1:10,000 dilution. All antibodies were diluted in 5% non-fat milk in TBS-T (TBS-T = 20 mM Tris-HCl at pH 7.6, 0.14 M NaCl, and 0.1% Tween-20).

**Amino Acid Sequence Analysis**

The purified mPBP (6 µg) was incubated with various amounts of trypsin (LifeTechnologies) at 37°C for 1 hour. Samples were then mixed with SDS-sample buffer containing β-mercaptoethanol, incubated at 37°C for 30 min, and subjected to Tricine/SDS-PAGE (21) followed by transferring to the Immobilon-P membrane (Fisher, Pittsburgh, PA). One membrane was subjected to immunodetection with the mPBP antibody, an identical membrane was stained with 0.02% Coomassie blue R-250 in 40% methanol and 5% acetic acid for 30 seconds. The membrane was then destained in 40% methanol and 5% acetic acid for 1 min, rinsed in distilled water for 3 x 5 min to remove the destaining solution, and air dried. A stained band at ~10 kDa, which was
recognized by the mPBP antibody, was sent for amino acid sequence analysis at the Protein Core Facility of the University of Florida (Gainesville, FL).

Enzymatic Assay

Recombinant human prostasin was purified as described previously (12). A synthetic substrate, N-t-Boc-Gln-Ala-Arg-7-amido-4-methyl coumarin (QAR-AMC) was purchased from Sigma-Aldrich. The purified mPBP (concentration range 0–0.4 μM) was incubated with prostasin (0.8 μM) for 30 min at 37°C. The binding reaction mixture (20 μl) was then added to 80 μl of 50 mM Tris-HCl (pH 8.0)/0.1% bovine serum albumin containing the QAR-AMC substrate (final concentration: 100 μM) in 96-well microtiter plates (Costar 3903, Costar, Cambridge, MA). The velocity of substrate hydrolysis was measured using a Wallac 1420 Victor² multilabel counter at λ_{ex} 355 nm and λ_{em} 460 nm. The residual activity of prostasin (velocity of the inhibited enzyme reaction/velocity of the uninhibited enzyme reaction) was plotted versus the mPBP concentration.

Molecular Cloning, Expression and Purification of Recombinant Mouse and Human Protease Nexin-1 (PN-1, Spi-4)

A cDNA encoding the mature peptide of mouse protease nexin-1 (PN-1, or Spi-4) was cloned from mouse seminal vesicle mRNA by reverse-transcription-polymerase chain reaction (RT-PCR). Total RNA of mouse seminal vesicle was isolated using a procedure described previously (22), an Oligotex mRNA Mini Kit from QIAGEN (Valencia, CA) was used to isolate the mRNA. The following oligonucleotide primers
were used in the RT-PCR to generate the mouse PN-1 cDNA: upstream: 5'-GGAATTCTCC CAG TTC AAC TCT CTG TC -3'; and downstream: 5'- CCGCCTCGAG TCA GGG CTT GTT CAC CTG GC -3'. The underlined sequences are adapters for restriction enzyme sites. The mouse PN-1 specific sequences were derived from the GenBank mouse PN-1 sequence of X70296. The upstream primer sequence corresponds to base numbers 206-225 of X70296, the first codon (206-208) is that of Ser, the amino-terminal residue of the mature mouse PN-1 peptide (20). The downstream primer sequence corresponds to base numbers 1,323-1,342, including the termination codon (1,340-1,342). The RT-PCR was performed as described previously (13), using 3 μg of mouse seminal vesicle mRNA as the template. A single cDNA band was amplified. The Taq DNA polymerase was removed by phenol/chloroform extraction, and the cDNA was treated with EcoRI and XhoI under proper buffer conditions. The restriction-modified cDNA was then inserted into the pGEX-6P-1 vector (Amersham Pharmacia Biotech) at the corresponding sites, resulting in a fusion gene construct that encodes GST-mPN-1 (GST: glutathione-S-transferase). The amplified PN-1 portion of the fusion gene was completely sequenced, no error in the PN-1 sequence was found. A human PN-1 cDNA encoding the mature peptide was cloned from the total RNA of the human breast carcinoma cell line MDA-MB-435s (American Type Culture Collection, Manassas, VA) essentially as described above, resulting in the GST-hPN-1 construct. The primers used for the cloning were: upstream: 5'-GGAATTCTCC CAC TTC AAT CCT CTG TC -3'; downstream: 5'-GGAATTC TCA GGG TTT GTT CAT CGG CC-3'. The underlined sequences are adapters for restriction enzyme sites. The human PN-1 specific sequences were derived from the GenBank human PN-1 sequence of A03911. The
upstream primer sequence corresponds to base numbers 82-101 of A03911, the first codon (82-84) is that of Ser, the amino-terminal residue of the mature human PN-1 peptide (23). The downstream primer sequence corresponds to base numbers 1,199-1,218, including the termination codon (1,216-1,218). The GST-mPN-1 and the GST-hPN-1 constructs were then transformed into the TOPP-10 strain of *E. coli* cells (Stratagene, La Jolla, CA). For production of the recombinant fusion proteins, cells harboring the constructs were grown to an optical density of 0.8 (at 600-nm wavelength), and recombinant protein expression was induced with 0.2 mM of IPTG (isopropylthio-β-galactoside) at 37°C with shaking at 250 rpm for 1 h. Cells were collected by centrifugation at 4,000 rpm for 20 minutes at 4°C, washed in 1 x PBS (pH 7.4) and re-centrifuged with the same settings. GST-mPN-1 or GST-hPN-1 was then purified by glutathione-agarose affinity chromatography using protocols recommended by the manufacturer (Amersham Pharmacia Biotech).
Results

Purification of Prostasin-binding Protein from Mouse Seminal Vesicle

The presence of mouse prostasin-binding protein (mPBP) in each purification step was monitored using a prostasin-binding assay as described in "Experimental Procedures". Figure 1A shows the representative purification profiles for each step. Two milliliters of mouse seminal vesicle fluid were applied onto the Q cartridge and eluted with 1 M NaCl/buffer A. Fractions were subjected to the prostasin-binding assay followed by western blotting using a prostasin antibody (12). The mPBP was present in the flow-through fractions (peak a, indicated by the horizontal solid bar), but not the 1 M NaCl eluent (peak b). The mPBP-containing fractions were pooled and applied onto the HTP cartridge. After washing with buffer A, the cartridge was first eluted with 0.2 M sodium phosphate buffer at pH 6.8 (to result in peak d), and then eluted with 0.5 M sodium phosphate buffer at pH 6.8 (to result in peak e). Neither peak c (the flow-through) nor peak d contained any detectable amount of mPBP. The mPBP was detected in peak e (indicated by the horizontal solid bar). Fractions corresponding to peak e were pooled and further separated by using a CM cartridge. The CM cartridge was eluted with a linear NaCl gradient from 0 to 0.75 M in buffer A. The mPBP was eluted at 0.25-0.55 M NaCl/buffer A (peak g, as indicated by the horizontal solid bar). The flow-through fractions (peak f) did not contain mPBP. The purified mPBP was used to generate a polyclonal antibody using rabbit as the host. Proteins from each purification step were subjected to SDS-PAGE/Coomassie blue staining (Figure 1B); or western blot analysis using the mPBP antibody (Figure 1C). As shown in Figure 1B, the purified mPBP (lane 4, 5 µg) migrated at ∼45 kDa in an SDS-PAGE under reducing
conditions. As shown in Figure 1C, lanes 1-4, the mPBP antibody recognized a 45-kDa protein in mouse seminal vesicle fluid, as well as the purified mPBP itself.

Characterization of Mouse Prostasin-binding Protein

The purified mPBP was tested for its biochemical activities using the prostasin-binding assay (12). Complex formation between mPBP and purified prostasin was analyzed by western blotting using the mPBP antibody and a prostasin antibody (12). Both antibodies recognized the complex of prostasin-mPBP at 82 kDa (Figure 2A, lanes 2 & 5). The prostasin antibody also recognized the purified prostasin (Figure 2A, lane 1), unbound prostasin (Figure 2A, lane 2), as expected, but not the purified mPBP (Figure 2A, lane 3). The mPBP antibody recognized the purified mPBP (Figure 2, lane 6), unbound mPBP (Figure 2, lane 5), as expected, but not the purified prostasin (Figure 2, lane 4). Figure 2B shows the time-course of complex formation between prostasin and mPBP. The complex was detected after 30 seconds of incubation and progressed during the incubation time course (60 minutes). As shown in Figure 2C, the complex formation was inhibited in the presence of the serine protease inhibitor aprotinin (lane 3), or PMSF \(^1\) (lane 4), or heparin (lane 5), or the mPBP antibody (lane 1). The complex formation of prostasin and mPBP was used as a control (Figure 2C, lane 2).

To reveal the identity of mPBP, the purified mPBP was subjected to a trypsin digestion and the digested mixture was separated using Tricine/SDS-PAGE. After transferring the resolved samples to the Immobilon-P membrane, one set of the samples was immunodetected with the mPBP antibody. In the sample without trypsin
digestion (Figure 3, lane 1), the mPBP antibody recognized a single band at 45 kDa. With increasing amounts of trypsin added in the digestion mixture, several mPBP immunoreactive bands were detected (Figure 3, lanes 2-5). In particular, a 10-kDa band (indicated by an arrow) was separated furthest in the gel from other bands. The corresponding band in a set of the exact samples transferred to an Immobilon-P membrane, stained with Coomassie blue, was sent for amino acid sequence analysis. The amino-terminal sequence of this fragment was determined to be SLEELGSNTGIQ, which is identical to the sequences between position 26 and position 37 of the GenBank™ mouse protease nexin-1 (PN-1) translated sequence (accession number: X70296). This result suggests that PBP may be identical to PN-1, a serine protease inhibitor (serpin) (20).

It has been known that PN-1 can form complexes with various serine proteases, including thrombin (24). We then tested if our purified mPBP can form a complex with thrombin. Figure 4A shows the complex formation between prostasin-mPBP, and that between thrombin-mPBP. We also tested if the complex formation is pH dependent because prostasin's optimum pH is 9.0 (2). The results showed that the purified mPBP formed a complex with prostasin as well as with thrombin. The complex formation of mPBP and prostasin is increased with higher pH in the binding conditions, while the complex formation of mPBP and thrombin is somewhat decreased with increasing pH. We further tested if heparin may have a different effect on the complex formation between prostasin-mPBP, versus on that between thrombin-mPBP. In Figure 4B we show that heparin, at 0.25 unit/reaction, completely abolished the complex formation

1 PMSF = phenylmethylsulfonyl fluoride
between prostasin-mPBP; but not between thrombin-mPBP.

**Prostasin-binding Protein Inhibits Prostasin’s Activity**

As described previously, the prostasin-binding protein that was identified in the seminal vesicle inhibits prostasin’s activity as determined by membrane-overlay zymography (12). Here, we used QAR-AMC as a substrate for prostasin to test the inhibitory activity of the purified mPBP. Prostasin (0.8 μM) was incubated with 0, 0.05, 0.1, 0.2 or 0.4 μM mPBP at 37°C for 30 min. The reaction mixture was then added to the assay buffer containing a final concentration of 100 μM QAR-AMC substrate (see “Experimental Procedures” for details). As shown in Figure 5, when incubated with mPBP at different concentrations, prostasin’s activity was inhibited in a dose dependent manner.

**Prostasin Forms A Complex with Recombinant Protease Nexin-1**

To establish if mPBP is indeed protease nexin-1, mouse and human protease nexin-1 (PN-1) cDNA were cloned into the pGEX-6P-1 expression vector. The recombinant protein products have the schistosomal glutathione-S-transferase (GST) fused to the N-terminus of the PN-1. The GST fusion proteins were affinity-purified using glutathione-conjugated agarose-beads. For each type of recombinant protein, cleared supernatant of cell lysate from one liter of culture was incubated with 1 ml of 50% glutathione-beads. The beads were eluted with 1 ml of fresh 10 mM glutathione in 50 mM Tris-HCl, pH 8.0. Twenty microliters of the eluent were incubated with 0.5 μg of
recombinant prostasin at 37°C for 60 min in the absence or presence of aprotinin. Both the GST-mPN-1 (Figure 6, lane 1, alone at 64 kDa) and the GST-hPN-1 (Figure 6, lane 4, alone at 64 kDa) formed a 100-kDa complex when incubated with prostasin (Figure 6, lanes 2 & 5). The complex formation was inhibited by the serine protease inhibitor aprotinin (Figure 6, lanes 3 & 6). These results further indicate that the mPBP that we had purified is the serpin protease nexin-1. For this immunoblot, both the prostasin antibody and the mPBP antibody were used as the primary antibody, and a goat anti-rabbit IgG conjugated with HRP was used as a secondary antibody. An immunoreactive band at 30 kDa, and two other minor immunoreactive bands at 42 kDa and 60 kDa were likely the products of non-specific degradation of the recombinant PN-1, since no protease inhibitors were added in the cell lysate during purification.
Discussion

In the present study, we have characterized a previously identified prostasin-binding protein following purification from mouse seminal vesicle. The prostasin-binding protein was further confirmed to be a serpin, previously identified as protease nexin-1 (PN-1). The purified mouse prostasin-binding protein was shown to inhibit prostasin's serine protease activity.

A prostasin-binding protein (PBP) was first identified when extracts of a number of mouse tissues were subjected to a prostasin-binding assay (12). The results indicated that a high level of a functional PBP appeared to be present only in the seminal vesicle. To reveal the identity of PBP, we used mouse seminal vesicle as the source for purification. By means of liquid chromatography, mPBP was purified to homogeneity as determined by SDS-PAGE (Figure 1). The purified mPBP migrated at 45 kDa and formed a covalent complex with prostasin as analyzed by SDS-PAGE under reducing conditions. The complex formation was fast, detected after 30 seconds of incubation, and was inhibited by the serine protease inhibitor aprotinin or PMSA, and by heparin (Figure 2). We also tested if mPBP binds to heparin by applying mouse seminal vesicle fluid to heparin-agarose. Prostasin-binding activity was found in the proteins eluted from heparin-agarose in the 0.3 – 0.6 M NaCl range, indicating that mPBP binds to heparin directly (data not shown). We have generated a polyclonal antibody against mPBP, developed an enzyme-linked immunosorbent assay to detect mPBP in tissues. Again, seminal vesicle was shown to contain the highest amount of mPBP (~5 μg mPBP/mg total protein), confirming our previous findings (12). The level of mPBP in other tissues was at nanograms per milligram total protein (data not shown). The tissue
distribution of mPBP is consistent with that of mouse PN-1 mRNA reported previously (20). The results of the amino acid sequence analysis of a trypsin-digested fragment of mPBP, and of binding assays using the mouse or human recombinant PN-1 with prostasin had indicated that the PBP is identical to PN-1 (Figures 3 & 6).

PN-1 is a serpin with a broad spectrum of target serine proteases, such as thrombin, trypsin, plasmin, and urokinase-type plasminogen activator (uPA) (23). We provided evidence herein that PN-1 also inhibits prostasin. Several synthetic substrates were used by Yu et al. (2) for testing prostasin's activity in an in vitro enzymatic assay, such as D-Pro-Phe-Arg-AMC, D-Phe-Phe-Arg-AMC, D-Val-Leu-Arg-AMC, and Z-Gly-Pro-Arg-AFC. We also tested other substrates, including N-t-Boc-Gln-Ala-Arg-AMC (QAR-AMC), MeOSuc-Ile-Gly-Arg-AFC, N-Benzoyl-Val-Gly-Arg-PNA, and MeOSuc-Ala-Ala-Ala-Arg-PNA. None of these substrates seems to be the best substrate for prostasin, as the $K_m$ was high for all of these substrates (data not shown, also see ref. 2). We chose QAR-AMC for our study to test mPBP's inhibitory activity on prostasin. Since the QAR-AMC or any other substrate listed above is not the best substrate for prostasin, resulting in a low, and slowly-progressing velocity of prostasin-catalyzed hydrolysis, we were not able to determine the $K_{ass}$ of mPBP with prostasin. As a control, we used QAR-AMC, an excellent trypsin substrate (25), to test the inhibitory activity of mPBP/PN-1 toward trypsin, the $K_{ass}$ of mPBP/PN-1 to trypsin was at a range of $10^5$ to $10^6$ M$^{-1}$S$^{-1}$, similar to the previously published results for protease nexin-1 (23). Using the QAR-AMC substrate, we did, however, observe the inhibition of prostasin by mPBP in a dose-dependent manner (Figure 5), demonstrating that mPBP/PN-1 is an

2 AFC = 7-amido-4-trifluoromethyl coumarin
inhibitor of prostasin serine protease.

A heparin-binding site has been mapped in PN-1 (26). In the presence of heparin, the inhibitory activity of PN-1 to several serine proteases, such as thrombin and factor Xa, is enhanced (26). In the present of heparin, however, the binding between prostasin and PN-1 is abolished (Figure 4B). Also, in an enzymatic assay using the QAR-AMC substrate, pre-incubation of mPBP and heparin was able to prevent prostasin inhibition by mPBP (data not shown). This is a novel finding of PN-1’s serine protease inhibition mechanism, having potentially profound implications, especially in cancer biology. PN-1 can bind to heparin-like molecules, or heparan sulfate proteoglycans (HSPG), on the cell surface and this binding apparently accelerates thrombin inhibition by PN-1 (27). The HSPG, as a component of the extracellular matrix (ECM), is suggested to play a major role in cell-matrix signaling (28). As we described previously, prostasin is a GPI-anchored membrane protease (12) which has an anti-invasion activity in vitro (13-14). It is likely that prostasin’s anti-invasion activity is regulated by PN-1 and the ECM in the tissue microenvironment. Both the membrane-bound and the secreted prostasin can bind to and be inhibited by mPBP (12). The membrane-bound prostasin may be a proteolytic regulator of cell surface events, but may also serve as a receptor or a ligand in ECM signaling or tissue remodeling under physiological or pathological conditions. The complex formation between PN-1 with two of its target enzymes, prostasin and thrombin, is affected by pH (Figure 4). Changes in intracellular pH have been shown to be a mechanism of cell signaling (29), our finding may have significant implications to the control of the active prostasin serine protease.

\[^{3}\text{PNA} = \text{p-nitroanilide}\]
inside the cell (12). On the other hand, extracellular pH change may also affect the signaling mechanisms for the plasma membrane-bound active prostasin.

There has been a large body of literature addressing the various functions of the serpin PN-1, especially for its roles in promoting the growth of neurites (30). The investigation of prostasin's functions, though still at its beginning, has indicated a number of possibilities, these include anti-invasion and epithelial sodium channel (ENaC) activation (6-14). Identifying an interaction between prostasin and PN-1 will undoubtedly facilitate further understanding of the biological functions of both prostasin and PN-1. Expression of serpin molecules has been linked to protection against tumor invasion (31-32), but non-protease-inhibition mechanisms are also suggested for serpin's roles in tumor invasion and metastasis (33). We now have identified a serpin that inhibits a serine protease that reduces in vitro invasiveness of prostate and breast cancer cells. In our continued research, we will investigate the tissue and cell-type specific expression of this serpin in relation to the expression of prostasin. Another important aspect of this present finding is that the reactive site sequence of the serpin PN-1, in particular, its P1-P4 residues Leu-Ile-Ala-Arg, may very well reveal sequence or structure information about the natural substrates of the prostasin serine protease. It has been shown with the serpin kallistatin (34), that its reactive site sequence was also the best for a substrate (35). Identification of prostasin's natural substrates will further the understanding of this protease's role in normal physiology and pathological conditions.

In the kidney, both prostasin and PN-1 are expressed (2, 36). While prostasin seems to activate ENaC, and the activation seems dependent on prostasin's serine
protease activity (10-11); PN-1 then, can serve the role of regulating this proteolytic activation process. In this role, PN-1 may be a potential therapeutic agent for diseases that involve activated ENaC as part of the mechanism. This idea is also potentially applicable to diseases of the respiratory system since there is recent evidence that prostasin may be involved in ENaC activation in the airway (9); and PN-1 is also expressed in the lung (37). Investigation of the spatial and temporal control of the coordinated expression of these two counteracting molecules will be of great importance for interests in renal and respiratory diseases. Alternatively, for potential therapeutic applications, inhibition of prostasin serine protease may also be accomplished by using synthetic inhibitors containing the sequences derived from the PN-1 reactive center.

PN-1 deficient mice display significant defects in fertility, evident through altered semen protein composition, inadequate semen coagulation, and deficient vaginal plug formation (38). Previously, the expression of prostasin and of PN-1 in the semen has been noted separately (2, 20). The findings of the present study suggest that prostasin and PN-1 may play an interactive role in the functions of male fertility.

Yet another tissue site for a potential prostasin/PN-1 interaction to have a profound effect to the body is the liver. Prostasin expression is noted in the liver (2). PN-1, though apparently not expressed in the liver (37), but has been shown to covalently bind factor Xa on the surface of hepatoma cells (39). As active factor Xa activates thrombin (40), while the latter can be inhibited by PN-1, the introduction of prostasin into this complex multi-player system must change or add to the views on how these players are regulated in a concerted way. The role of heparin in this complex
multi-player system will also need to be investigated as we have shown that heparin inhibits the interaction between prostasin and PN-1, but it enhances the interaction between thrombin and PN-1 (27).
References


Figure Legends:

Figure 1. Purification of mouse prostasin-binding protein (mPBP). Two milliliters of mouse seminal vesicle fluid were fractionated in sequence on a Q-Cartridge (anion exchange), an HTP (hydroxylapatite), and a CM cartridge (cation exchange). A: a representative purification profile. Protein contents in fractions were monitored at 280 nm with different AUFS (Absorbance Units Full Scale) as indicated. Fractions containing prostasin-binding activity were determined with the prostasin-binding assay (Experimental Procedures), and indicated by the horizontal solid bars. B: Coomassie blue staining of proteins of crude mouse seminal vesicle fluid (lane 1, 50 µg), flow-through fractions of Q-Cartridge (lane 2, 50 µg), 0.5 M sodium phosphate eluent of HTP-Cartridge (lane 3, 25 µg), and the purified mPBP from the CM-Cartridge (lane 4, 5 µg). C: Western blot analysis of samples from B using the polyclonal antibody against mPBP.

Figure 2. Complex formation between prostasin and mouse prostasin-binding protein. Purified recombinant human prostasin (0.5 µg) (12) was incubated with purified mPBP (0.5 µg) at 37°C for 60 min. The binding mixtures were resolved in 10% SDS-PAGE under reducing conditions and were examined by western blot analysis using either a prostasin antibody (12) or the mPBP antibody. A: Lanes 1 & 4: prostasin alone; lanes 2 & 5: the binding mixtures; and lanes 3 & 6: purified mPBP alone. The blot shown in the left panel was detected with the prostasin antibody (IB: Prostasin) and that in the right panel was detected with the mPBP antibody (IB: mPBP). B: Prostasin was
incubated with mPBP at 37°C for various time periods as indicated. The samples were examined on a western blot with the prostasin antibody. The complex can be observed at as early as 30 sec after incubation. C: Prostasin was incubated with mPBP in the presence of aprotinin (lane 3, 1 μg), PMSF (lane 4, 5 mM), heparin (lane 5, 5 units), and the mPBP antibody (lane 1, 0.5 μl). The samples were examined on a western blot with the prostasin antibody. The 50-kDa band indicated by the asterisk in lane 1 is the mPBP antibody (IgG) recognized by the secondary antibody. The complex formation of prostasin-mPBP was inhibited by serine protease inhibitors, heparin, and the mPBP antibody.

**Figure 3. Trypsin digestion of mPBP.** Purified mPBP (6 μg) was incubated with various amounts of trypsin (lane 1, zero μg; lane 2, 2.5 μg; lane 3, 5.0 μg; lane 4, 10 μg; and lane 5, 20 μg) at 37°C for 60 min. The digested mixtures were analyzed in 16.5% Tricine-SDS/PAGE and immunoblotted with the mPBP antibody. The band at ~ 10 kDa (indicated by the arrow) was cut from a stained duplicate membrane and sent for amino-terminal sequencing.

**Figure 4. Effects of pH and heparin on complex formation.** Prostasin (0.3 μg) or thrombin (0.2 μg) was incubated with mPBP (0.5 μg) at different pH as indicated (A), or in the presence of various amounts of heparin (B) at 37°C for 1 hour. The binding mixtures (20 μl) were analyzed in 10% SDS-PAGE followed by immunoblotting. Prostasin-binding assay was analyzed with a prostasin antibody (12) and labeled as IB:
Prostasin-binding Protein

Prostasin, while thrombin-binding assay was analyzed with the mPBP antibody and labeled as IB: mPBP. The amount of heparin in each reaction is as follows: lanes 1 & 5, zero unit; lanes 2 & 6, 0.25 unit; lanes 3 & 7, 0.5 unit; and lanes 4 & 8, 1.0 unit. The complex formation of prostasin-mPBP is increased with increasing pH, and that of thrombin-mPBP is somewhat decreased. Heparin abolished complex formation between prostasin-mPBP, but not between thrombin-mPBP.

Figure 5. mPBP/PN-1 inhibits prostasin’s activity. Prostasin’s serine protease activity was measured using a synthetic substrate, QAR-AMC as described in “Experimental Procedures”. When prostasin (0.8 μM) was first incubated with mPBP (0, 0.05, 0.10, 0.20, and 0.40 μM) for 30 min at 37°C, then added to the QAR-AMC (100 μM) solution, prostasin’s activity was inhibited in a dose-dependent manner. The residual prostasin activity was determined by the fraction of velocity of the inhibited prostasin reaction versus velocity of the uninhibited prostasin reaction. The experiment was repeated for 3 times.

Figure 6. Recombinant mouse or human PN-1 forms a complex with prostasin. GST-mPN-1 and GST-hPN-1 were cloned, expressed, and purified as described in “Experimental Procedures”. The purified GST-fusion PN-1 proteins were incubated with prostasin at 37°C for 60 min without (lanes 2 & 5) or with aprotinin (lanes 3 & 6, 1 μg); or examined alone without incubation with prostasin (lanes 1 & 4). The binding mixtures were analyzed in 10% SDS-PAGE followed by immunoblotting with both prostasin and
mPBP antibodies. The complex of prostasin-GST-mPN-1 or prostasin-GST-hPN-1 migrated at 100 kDa (labeled as "Complex"). Unbound prostasin is labeled as "Prostasin".
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Residual Activity (100%) vs. mPBP (μM)
Mouse | Human
---|---
118 K| Complex
82 K| GST-PN-1
50 K| Prostasin
33 K| 27 K|

1 2 3 4 5 6

Figure 6
Appendix 6

The Prostasin Gene Promoter Is Hypermethylated

in Invasive Human Prostate Cancer Cells

Li-Mei Chen and Karl X. Chai*

Department of Molecular Biology and Microbiology, University of Central Florida

Orlando, Florida 32816

Short Title: Prostasin Methylation in Prostate Cancer

*Correspondence to: Department of Molecular Biology and Microbiology, University of Central Florida, 4000 Central Florida Boulevard, Orlando, Florida 32816-2360, Phone: (407) 823-6122; Fax: (407) 823-3095; E-mail: kxchai@mail.ucf.edu
ABSTRACT

We have shown recently that prostasin serine protease is down-regulated in high-grade prostate cancers, and inhibits invasiveness of prostate and breast cancer cell lines upon enforced re-expression. Further, prostasin expression in breast cancer cells is regulated by DNA methylation in the prostasin gene promoter-exon 1 region. In the present study, normal human prostate epithelial cells, and human prostate cancer cell lines (LNCaP, DU-145, and PC-3) were investigated for prostasin gene promoter methylation. The methylation pattern of the prostasin gene promoter correlates with prostasin expression in these cells. Demethylation coupled with histone deacetylase inhibition resulted in reactivated expression of the prostasin mRNA in DU-145 and PC-3 cells. Prostasin gene promoter methylation may be explored as a marker for invasiveness of prostate cancer.

Keywords: Prostasin, Serine Protease, Invasion Suppressor, Prostate Cancer, DNA Methylation
INTRODUCTION

Prostasin serine protease has recently been suggested as an invasion suppressor for human prostate and breast cancers (1-2). Its expression is down-regulated in high-grade (Gleason 4/5) prostate cancers (1) and also absent in highly invasive human prostate (1) and breast cancer cells (2). Prostasin is a glycosylphosphatidylinositol (GPI)-anchored active serine protease and can also be secreted (3). In the kidney and the airway epithelia, prostasin has been shown to be a sodium channel (ENaC) activator (4-5), most likely through its serine protease activity (6). The ENaC activation function of prostasin requires its GPI-anchorage (6). The invasion suppression by prostasin is also dependent on its membrane-anchorage (1), but it remains to be determined whether invasion suppression requires prostasin's serine protease activity.

The prostasin gene promoter-exon 1 regulatory region was shown to be methylated in the highly invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s (2). This methylated state is causal to prostasin's absence in these cell lines, suggesting that prostasin promoter methylation may be explored as a marker for invasiveness (2). We have also shown that two highly invasive human prostate cancer cell lines DU-145 and PC-3 do not express prostasin protein or mRNA, while normal human prostate epithelial cells and a non-invasive human prostate cancer cell line LNCaP express both the prostasin mRNA and protein (1). In the present study, we examined the methylation state of the prostasin gene promoter-exon 1 regulatory region in normal human prostate epithelial cells, and LNCaP, DU-145, and PC-3 cell lines.
MATERIALS AND METHODS

Cell culture maintenance

A normal human prostate epithelial cell (PrEC) primary culture (Catalog Number CC-2555) was obtained from Clonetics (San Diego, CA), and maintained as described previously (1). Human prostate cancer cell lines LNCaP, DU-145, and PC-3 were obtained from the American Type Culture Collection (ATCC, Manassas, VA), and maintained as described previously (1).

RNA preparation and analysis by RT-PCR/Southern blot

Cells grown to 80% confluence (in 60-mm tissue culture dish) were used for RNA isolation as described previously (2). The human prostasin-specific RT-PCR (reverse transcription-polymerase chain reaction)/Southern blot analysis was performed as described previously (1-2).

Genomic Southern blot analysis of prostasin promoter methylation

High molecular weight genomic DNA was isolated from the cell lines as described previously (7). Genomic DNA from each cell line was digested with restriction enzymes (methylation sensitive and non-sensitive) for Southern blot analysis as described previously (2).

Demethylation of prostasin gene promoter and reactivation of prostasin expression

DU-145 and PC-3 cells were seeded in 60-mm dishes at 80% confluence and cultured in the presence of 500 nM 5-aza-2'-dC for 24 hr, and were then treated for an additional 24 hr with either 1 μM trichostatin A (TSA, Sigma-Aldrich Co.) or an equal volume of 95% ethanol used to dissolve TSA. RNA was isolated for prostasin-specific RT-PCR/Southern blot analysis as described.
RESULTS AND DISCUSSION

Prostasin gene promoter is hypermethylated in invasive prostate cancer cell lines

In this study, we examined, in the human prostate epithelial cells and prostate cancer cell lines, the prostasin promoter and exon 1 region which was shown to be hypermethylated in invasive human breast cancer cell lines (2). This region is defined by an Xho I-BamH I fragment and contains multiple CpG dinucleotides. The sites being investigated were identical to those examined for the breast cancer cell lines previously. These are, an Hha I site at base number 615/-807 (relative to the transcription initiation site, same below), an Aci I site at 1,102/-320, a BsaA I site at 1,156/-266, an Hpa II site at 1,326/-96, and an Aci I site at 1,445/+24. The results of the genomic Southern blot analysis are presented in Figure 1 and summarized in Table 1.

In all three prostate cancer cell lines and the PrEC, Xho I/BamH I/Hha I digestion yielded a 1,275-bp prostasin promoter band seen in the Xho I/BamH I digestion (Figure 1, upper panel), indicating that the -807 Hha I site-CpG is homogeneously methylated.

In the PrEC, digestion with Xho I/BamH I/Aci I yielded a 1,072-bp, a 727-bp, and a 345-bp band, but no 1,275-bp band, indicating that the -320 Aci I site-CpG is heterogeneously methylated, but the +24 Aci I site-CpG is homogeneously unmethylated. In LNCaP and DU-145, digestion with Xho I/BamH I/Aci I yielded only the 1,072-bp band, indicating that the -320 Aci I site-CpG is homogeneously methylated, but the +24 Aci I site-CpG is homogeneously unmethylated. In PC-3, digestion with Xho I/BamH I/Aci I yielded the 1,072-bp band, and to a lesser extent the 1,275-bp band, indicating that the -320 Aci I site-CpG is homogeneously methylated, while the +24 Aci I site-CpG is heterogeneously methylated.

In the PrEC and LNCaP, digestion with Xho I/BamH I/BsaA I yielded a 782-bp and a 493-bp band, indicating that the -266 BsaA I site-CpG is homogeneously unmethylated. In DU-145, digestion with Xho I/BamH I/BsaA I yielded the 782-bp and the 493-bp bands, but also the
A 1,275-bp band, indicating that the -266 BsaA I site-CpG is heterogeneously methylated. In PC-3, digestion with Xho I/BamH I/BsaA I yielded only the 1,275-bp band, indicating that the -266 BsaA I site-CpG is homogeneously methylated.

In the PrEC and LNCaP cells, the 1,275-bp Xho I-BamH I band can be digested by the methylation-insensitive Msp I as well as by the methylation-sensitive Hpa II, yielding a 951-bp band (Figure 1, lower panel), indicating that the CpG at the -96 M/H restriction site is homogeneously unmethylated. In DU-145 and PC-3, the 1,275-bp band can be fully digested by Msp I, but only partially by Hpa II (Figure 1, lower panel), indicating heterogeneous methylation of the -96 M/H site-CpG.

The PrEC express both the prostasin mRNA and protein (1), and is the least methylated in the prostasin promoter-exon 1 region (methylation is only observed at beyond -266, relative to the transcription initiation site). The prostasin gene promoter-exon 1 region in LNCaP cells is methylated to a higher extent than that in the PrEC. In LNCaP, which also express both the prostasin mRNA and protein (1), methylation is only observed at beyond -96. In DU-145, which does not express either the prostasin protein or mRNA (1), methylation is observed at the -96 position and beyond. In PC-3, which also does not express either the prostasin protein or mRNA (1), the promoter-exon 1 region is the most heavily methylated. While in DU-145 the methylation is limited to the 5'-flanking region, all CpG sites examined, including one of exon 1 (+24 Aci I site-CpG) show heterogeneous to homogeneous methylation in the PC-3 cells. The prostasin gene promoter-exon 1 region CpG methylation patterns correlate with the absence of prostasin expression in the human prostate cells.

The methylation state of the prostasin promoter region may be examined for a potential diagnostic application to indicate prostate cancer invasiveness. The prostasin gene promoter methylation state at the -96 M/H CpG site, for example, is seen methylated only in invasive cell types (Figure 1, lower panel, and Table 1).
Prostasin expression was reactivated by demethylation and histone deacetylase inhibition in DU-145 and PC-3 cell lines

We next investigated if DNA methylation in the promoter is causal to the lack of prostasin gene expression in the prostate cancer cell lines DU-145 and PC-3. Treatment of these cell lines for 8 days with the DNA methyltransferase inhibitor 5-aza-2'-dC resulted in significant level of demethylation, but no prostasin mRNA expression was detected in an RT-PCR/Southern blot analysis of the DNA-demethylated cells (data not shown). Treatment of the cells with the combination of 5-aza-2'-dC and trichostatin A (TSA), an inhibitor of histone deacetylase (8), however, restored prostasin mRNA expression in DU-145 and PC-3 (Figure 2). We further examined whether the prostasin protein was expressed in the 5-aza-2'-dC/TSA-treated cells by western blot analysis, the result was negative (data not show). It appears that, although promoter DNA methylation is causal to absence of prostasin expression in the invasive prostate cancer cells, the reactivated expression represents only the basal expression, similar to what we have observed previously in breast cancer cells (2).
ACKNOWLEDGEMENTS

This work was supported by Department of Defense Prostate Cancer Research Program Grant No. DAMD17-98-1-8590.
REFERENCES


FIGURE LEGENDS

Figure 1. Genomic Southern blot analysis of DNA from PrEC and human prostate cancer cell lines. Panels of genomic DNA Southern blot analysis results are as indicated for each cell type. Restriction endonucleases used in each digestion mixture are identified as follows: X = Xho I, B = BamH I, Hh = Hha I, A = Aci I, Bs = BsaA I, M = Msp I, and H = Hpa II. Hha I, Aci I, BsaA I, and Hpa II only cut unmethylated DNA while Msp I, an isoschizomer of Hpa II, cuts unmethylated or methylated DNA. Genomic DNA (10 μg) from each cell type was cut with X/B, or with X/B/M to serve as controls for the detection of differential methylation. In the upper panel, prostasin promoter DNA will yield a 1,275-bp X/B fragment. When Hha I was added to the X/B digestion mixture, a fragment of 1,037 bp was expected if the –807 Hha I site-CpG was not methylated. When Aci I was added to the X/B digestion mixture, three smaller bands might be expected depending on CpG methylation states at –320 and +24 Aci I sites. They are 1,072 bp (from Xho I to +24 Aci I), 727 bp (from Xho I to –320 Aci I), and 345 bp (from –320 Aci I to +24 Aci I) in length, respectively. When BsaA I was added to the X/B digestion mixture, two smaller bands might be expected depending on CpG methylation state at the –266 BsaA I. They are 782 bp (from Xho I to BsaA I) and 493 bp (from BsaA I to BamH I) in length, respectively (indicated by asterisks in the figure). In the lower panel, the upper arrow points to the X/B fragment, while the lower arrow points to the fragment that is generated by Msp I, regardless of DNA methylation; or by Hpa II, only when DNA is unmethylated.

Figure 2. Reactivation of prostasin expression in DU-145 and PC-3 cells. Cells treated with 5-aza-2'-dC (500 nM) for 24 hr were treated with TSA (1 μM) for an additional 24 hr, before being harvested for total RNA isolation and RT-PCR/Southern blot analysis as described. Cells treated with 5-aza-2'-dC and 95% ethanol (indicated as EtOH) were used as controls.
Table 1. CpG methylation in the prostatin gene promoter-exon 1 region in human prostate cells.

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Prostatin Expression</th>
<th>Hha I (-807)</th>
<th>Aci I (-320)</th>
<th>BsaA I (-266)</th>
<th>Msp I/Hpa II (-96)</th>
<th>Aci I (+24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PrEC</td>
<td>Yes</td>
<td>Methyl</td>
<td>Hetero-Methyl</td>
<td>Un-Methyl</td>
<td>Un-Methyl</td>
<td>Un-Methyl</td>
</tr>
<tr>
<td>LNCaP</td>
<td>Yes</td>
<td>Methyl</td>
<td>Methyl</td>
<td>Un-Methyl</td>
<td>Un-Methyl</td>
<td>Un-Methyl</td>
</tr>
<tr>
<td>DU-145</td>
<td>No</td>
<td>Methyl</td>
<td>Methyl</td>
<td>Hetero-Methyl</td>
<td>Hetero-Methyl</td>
<td>Un-Methyl</td>
</tr>
<tr>
<td>PC-3</td>
<td>No</td>
<td>Methyl</td>
<td>Methyl</td>
<td>Methyl</td>
<td>Hetero-Methyl</td>
<td>Hetero-Methyl</td>
</tr>
</tbody>
</table>

Table Legend: Methyl = homogeneously methylated. Hetero-methyl = heterogeneously methylated. Un-methyl = homogeneously unmethylated.
PrEC LNCaP DU-145 PC-3

Figure 1
Figure 2
Appendix 7

Genetic Analysis of the *Drosophila melanogaster* Stubble-stubbloid locus During Leg Imaginal Disc Morphogenesis: A Potential Role for a Type II Transmembrane Serine Protease in RhoA Signaling.

Cynthia A. Bayer *, Susan R. Halsell †‡, Daniel P. Kiehart ‡ and Laurence von Kalm*

* Department of Biology, University of Central Florida, Orlando, FL 32816-2368
† Department of Biology, Department of Biology, James Madison University, Harrisonburg, VA 22807
‡ DCMB Group, Department of Biology, Duke University, Durham, NC 27708-1000
Key Words: actin, myosin, zipper, Rho kinase, cell shape changes

Corresponding Author: Laurence von Kalm
Department of Biology
4000 Central Florida Blvd.
Orlando, FL 32816-2368
Phone: (407) 823-6684
FAX: (407) 823-5769
email: lvonkalm@mail.ucf.edu
ABSTRACT

The Drosophila Stubble-stubbloid (Sb-sbd) locus encodes a member of the type II transmembrane serine protease family. Sb-sbd function is required for cell shape changes that control leg elongation in prepupal imaginal discs. Here we demonstrate that Sb-sbd mutants act as genetic enhancers of mutant leg defects associated with mutations in RhoA and several members of the RhoA signaling pathway. Over-expression of Sb-sbd in prepupal leg discs results in a malformation phenotype that is suppressed by reducing the gene dosage of RhoA suggesting that RhoA acts downstream of Sb-sbd as leg disc cells change their shape. We propose that induction of Sb-sbd by ecdysone in leg discs triggers RhoA signaling leading directly to cell shape change. To identify additional components of a hypothetical Sb-sbd-RhoA signaling pathway in leg discs we have characterized six mutations identified as enhancers of zipper (myosin II heavy chain) mutant leg defects. The enhancer of zipper mutants show significant interactions with Sb-sbd and RhoA mutants. Three of these genes encode known members of the RhoA signaling pathway suggesting that the remaining genes also encode gene products with functions related to Sb-sbd-RhoA signaling to the actin cytoskeleton. Our results provide evidence that the type II transmembrane serine proteases, a class of proteins strongly associated with human developmental abnormalities and pathology, can regulate an intracellular signaling pathway required for normal development.
INTRODUCTION

METAMORPHOSIS in Drosophila is a remarkable developmental process mediated by the steroid hormone 20-OH ecdysone (hereafter referred to as ecdysone; ANDRES and THUMMEL 1992; RIDDIFORD 1993; FRISTROM and FRISTROM 1993). Ecdysone regulates two distinct developmental programs during metamorphosis. In one program, most larval tissues such as the salivary glands, fat body, and gut undergo programmed cell death and histolysis. Concurrently in the second program, the precursors of adult structures -- the imaginal discs, imaginal rings, imaginal islands, and histoblast nests -- undergo dramatic morphogenetic changes. The imaginal discs, which form the adult eyes, antennae, legs, and wings, as well as the adult epidermis, develop from small clusters of epithelial cells set aside in the embryo (FRISTROM and FRISTROM 1993; COHEN 1993). During the larval period imaginal disc development is characterized by rapid cellular proliferation to form a highly-folded sac attached via a stalk to the larval epithelium. The rapid increase in ecdysone titer associated with the onset of metamorphosis triggers unfolding of the imaginal disc epithelium and dramatic changes in tissue shape. Within a few hours structures resembling the adult appendages are formed and evert to the outside of the animal. Subsequent fusion of the disc epithelia gives rise to the adult head and thoracic epidermis.

Leg imaginal discs are a particularly useful system for the study of epithelial tissue shaping and morphogenesis. Leg imaginal disc morphogenesis has been extensively characterized at a cell biological level, providing a solid foundation for further genetic and molecular analyses (CONDIC et al. 1991; FRISTROM and FRISTROM 1993). Distal portions of the leg, including all tarsal segments and the distal portion of the tibia, form during the 12-
hour prepupal period. Final morphogenesis of the proximal portion of the tibia and the femur occurs later during the pupal period. Prepupal leg development is characterized by elongation of the presumptive leg as the disc epithelium unfolds, and concurrent eversion to the outside of the animal, a morphogenetic process collectively referred to as evagination. The prepupal elongation of leg discs to form presumptive leg segments is of particular interest because it is primarily driven by apical cell shape changes (CONDIC et al. 1991). Before elongation, leg disc cells are highly anisometric. They are wide in the presumptive circumferential axis and short in the proximal-distal axis. In fully elongated legs, these cells become isometric, having decreased in width and increased in length. The number of cells encircling each segment remains unchanged. Thus, the change in cell shape from anisometric to isometric results in the elongation and narrowing of the leg segments and is a major morphogenetic force in the shaping of the adult leg.

The current model describing the mechanical forces driving cell shape changes and elongation in leg discs is based on studies in vertebrate and invertebrate epithelia (reviewed in FRISTROM and FRISTROM 1993). Cells within the epithelium of leg imaginal discs are linked via sub-apically localized adherens junctions. The cytoplasmic side of each adherens junction is connected to an actin-myosin contractile ring. In response to the rise in ecdysone titer at the onset of metamorphosis the heavy chain of non-muscle myosin II becomes activated. The head domains of activated myosin dimers bind to and slide actin filaments past each other within the contractile ring. The result is a “purse string” effect whereby contraction of the actin-myosin ring causes the apical surface of the disc cell to adopt an isometric shape. The contractile force in one cell is transmitted to neighboring cells via adherens junctions, causing all of the cells of the epithelial sheet to change shape in a concerted manner and coordinating elongation of the presumptive leg (ODELL et al. 1981; FRISTROM 1988).
Mutations affecting prepupal leg disc elongation have been identified in a number of genes including Stubble-stubbloid (Sb-sbd), the Broad-Complex (BR-C), zipper (zip), RhoA, DRhoGEF2, spaghetti squash (sqh), blistered, dachsous, E74, crooked legs, vulcan and bancal (see Table 1). These mutants have a characteristic malformed leg phenotype in which some or all leg segments are thicker and shorter than normal, and often twisted or kinked (Figure 1). Confocal microscopic analysis of the leg imaginal disc cells of Sb-sbd and BR-C mutants shows that these cells fail to undergo proper cell shape changes at the beginning of metamorphosis, suggesting that inability to control cell shape changes underlies the malformed leg phenotype (CONDIC et al. 1991; VON KALM et al. 1995). Thus the malformed leg phenotype has proven to be a valuable tool to genetically identify regulators of cell shape changes during leg elongation.

Genetic regulators of cell shape changes during leg elongation can be divided into two classes based on their response to ecdysone. The Sb-sbd, BR-C, E74, crooked legs, vulcan, and bancal loci are all transcriptionally induced in response to ecdysone at the onset of metamorphosis (ANDRES et al. 1993; APPEL et al. 1993; BAYER et al. 1996; BURTIS et al. 1990; D’AVINO and THUMMEL 1998; GATES and THUMMEL 2000), whereas the zip, sqh, RhoA, and DRhoGEF2 loci are not induced in response to ecdysone (WARD and THUMMEL 2002; A. HAMMONDS and J. FRISTROM, pers. comm.). Thus, control of cell shape changes during prepupal leg imaginal disc elongation requires the coordinated activities of both ecdysone inducible and non-inducible proteins. Because leg morphogenesis is triggered by ecdysone, it is likely that the activities of ecdysone insensitive proteins are directed by one or more ecdysone inducible gene products at the onset of morphogenesis.
The *Sb-sbd* locus is of particular interest for understanding how leg morphogenesis is controlled because it is transcriptionally induced by ecdysone at the onset of metamorphosis. In addition, *Sb-sbd* mutations interact genetically with mutant alleles of genes known to have important roles in prepupal leg morphogenesis. These genes include the *Broad-Complex*, which encodes a family of transcriptional regulators, and *zipper*, which encodes the heavy chain of non-muscle myosin II (hereafter referred to as myosin; DIBELLO *et al.* 1991; GOTWALS and FRISTROM 1991; YOUNG *et al.* 1993). Upon induction by ecdysone, the Sb-sbd protein is localized to the apical surface of leg disc epithelial cells (VON KALM *et al.* 1995). The *Sb-sbd* locus encodes a typical member of an unusual family of membrane-associated serine proteases, the type II transmembrane serine proteases (TTSPs; APPEL *et al.* 1993). All TTSP family members have an intracellular N-terminus and an extracellular C-terminus that ends in a trypsin-like serine protease domain (HOOPER *et al.* 2001). To date nine members of the TTSP class of serine proteases have been described. A striking feature of these proteases is their association with changes in cellular morphology, differentiation, and physiology, as well as pathologies including viral infection, and cancer, heart, and respiratory disease. Although the TTSPs have obvious developmental and clinical significance little is known about their cellular mode of action.

*Sb-sbd* mutants are commonly known for their effects on bristle morphogenesis. Bristles form as apical extensions of specialized imaginal disc cells. As the bristle cell develops, actin microfilament bundles appear around the cortex of the cell in a regular arrangement of 15-18 actin bundles associated with the plasma membrane (OVERTON 1967; APPEL *et al.* 1993). The bristle grows at its tip by continuous polymerization of short actin bundles that are joined end to end with the distal tips of previously synthesized bundles (LEES and PICKEN 1944; TILNEY
et al. 1996). The Sb-sbd protease is essential for bristle extension. Both recessive loss-of-function (sbd) and dominant (Sb) mutations have been identified at the locus on the basis of their shortened bristle phenotype and genetic and gene structure analyses indicate that many Sb-sbd mutants lack protease activity (LINDSLEY and ZIMM 1992; APPEL et al. 1993). Interestingly, defects in the organization of the actin cytoskeleton appear to underlie the shortened bristle phenotype associated with both Sb and sbd mutations. In homozygous recessive sbd mutants microfilament organization in bristles is initially normal. However, the actin bundles become frayed and disorganized at their tips as the bristle develops (APPEL et al. 1993). In dominant Sb mutants the number of actin bundles is increased to 25-30 per bristle, and their arrangement is irregular with some bundles located in the core of the bristle. In either type of mutant (Sb or sbd), extension of the actin microfilaments ceases prematurely. Thus, the Sb-sbd protease appears to regulate the organization of the actin cytoskeleton during bristle extension.

The role of the Sb-sbd serine protease in leg disc morphogenesis is less well understood. Interestingly, both Sb and sbd mutations behave as recessive alleles in the context of leg morphogenesis, suggesting a fundamental difference in the function of the Sb-sbd protease in bristle versus leg development. The observation that exogenous application of trypsin to Sb-sbd mutant leg discs in in vitro culture leads to rapid elongation of the discs initially suggested that the Sb-sbd protease might function in leg disc elongation by cleaving apical extracellular matrix proteins to facilitate cell shape changes (APPEL et al. 1993). However, the discovery that Sb-sbd mutants act as genetic enhancers of leg morphogenesis defects associated with zipper mutations (GOTWALS and FRISTROM 1991) raises the possibility that Sb-sbd regulates actin cytoskeletal dynamics in elongating legs via by inducing contraction of the apical actin-myosin belt.
Recent evidence has shown that mutations in *Drosophila RhoA* and *DRhoGEF2* also act as genetic enhancers of *zipper* with respect to leg malformation (HALSELL et al. 2000). The Rho family of small GTPases regulate actin cytoskeletal dynamics in a variety of vertebrate and invertebrate systems via activation of myosin (reviewed in TAPON and HALL 1997; VAN AELST and D’SOUZA-SCHOREY 1997; HALL 1998). The observation that *Sb-sbd* is also a genetic enhancer of *zipper* leg malformation defects (GOTWALS and FRISTROM 1991) lead us to investigate the possibility that the Sb-sbd protease is involved in RhoA signaling in leg imaginal discs. We find that significant genetic interactions occur between *Sb-sbd* mutations and *RhoA* mutations and between *Sb-sbd* mutations and mutations in other RhoA signaling pathway members. We also find that a reduction in the dosage of *RhoA* suppresses the penetrance of the leg malformation phenotype associated with over-expression of the Sb-sbd protease. Our data are consistent with the possibility that the Sb-sbd protease regulates myosin activation and actin cytoskeletal dynamics via RhoA signaling during leg imaginal disc morphogenesis, perhaps acting as an ecdysone inducible trigger to control the timing of RhoA pathway activation.

In order to identify additional genes encoding products that participate in a hypothetical Sb-sbd/RhoA signaling pathway required to regulate cell shape changes in elongating leg imaginal discs, we analyzed mutations in six genes on the second chromosome that enhance *zipper* mutant leg defects. We find that mutations in these *enhancer of zipper* genes -- *en(zip)* -- show significant interactions with *Sb-sbd* and *RhoA* mutants. Three of the *en(zip)* mutations have been identified as new alleles of the *RhoA*, *DRhoGEF2*, and *zipper* loci. This strongly suggests that the remaining 3 uncharacterized genes identified in our screen encode products with roles in Sb-sbd-RhoA regulation of actin cytoskeletal dynamics during leg imaginal disc morphogenesis.
MATERIALS AND METHODS

**Stocks:** The genotypes of all stocks tested and the molecular nature of mutant lesions (where known) are described in Table 2.

**Genetic complementation analysis:** To ensure that the viability of emerging progeny classes was not distorted by environmental factors (e.g. overcrowding) the following crossing regimen was established empirically in preliminary experiments. In each cross 4 virgin females (1-7 days old) were mated to 3-5 males. All crosses were set up in triplicate on standard cornmeal medium. Cultures were incubated for 3 days at 25°C followed by transfer of adults to fresh medium. Subsequent cultures were incubated for 2 days at 25°C generating a total of nine cultures for each cross. The legs of all emerging F1 progeny classes were scored for malformation. F1 progeny were scored for 19 days from the date parental adults were first placed in each vial.

Second-site non-complementation (SSNC) assays were conducted by mating animals heterozygous for the mutant genes of interest. Leg malformation was scored in the doubly heterozygous F1 progeny class. Genotypes needed to test for dominant interactions were obtained by first mating animals carrying the mutant of interest, e.g. */CyO, to CyO, P[sevRas1.V12]FK1/Sco; red sbd^{201} e/TM6B, Tb Hu e animals. F1 male progeny heterozygous for both mutations, e.g. */CyO, P[sevRas1.V12]FK1; red sbd^{201} e/+ , were mated to virgin female sbd' ro e ca homozygotes. Leg malformation was scored in the F2 progeny class heterozygous for the mutation of interest and transheterozygous for the sbd'/sbd^{201} mutations (i.e. */+; sbd'/sbd^{201}). For both SSNC and dominant interaction tests, sibling progeny classes were also scored, e.g. +/+; sbd'/sbd^{201}, and the highest percentage of leg malformation observed in
any sibling class was subtracted from the percent malformation observed in progeny classes being tested for interaction.

**Heat-induced induction of hs-Stubble transgene:** 30 Rho^{720}/CyO females were crossed to 20 w^{118}; hs-Stubble males in bottles at 25°C, and turned into fresh bottles every 3 days. The progeny were picked as 0h white prepupae and transferred to food vials. They were either immediately subjected to a 1 hour heat shock by immersion in a 37°C water bath (= HS 0h AP), or allowed to develop for 3 hours at 25°C before being heat shocked (= HS 3h AP). Treated animals were allowed to continue development at 25°C. Eclosed animals were sorted into 2 progeny classes, CyO/+; hs-Stubble/+ or Rho^{720}/+; hs-Stubble/+, and scored for leg malformation. The induction of hs-Stubble at either of these times in development affects 2^nd and 3^rd leg pairs differently, so the 2^nd and 3^rd pairs of legs of each animal were scored separately. An animal was scored as malformed if either the left or right leg of a pair was malformed.

**Enhancer of zipper mutations:** Mutations in six second chromosome genes that behave as enhancers of zipper mutant leg defects were previously identified by Dr. Jim Fristrom (U.C. Berkeley). Prior to testing these mutations for interactions with Sb-sbd and RhoA mutants they were outcrossed to Canton S flies for 3 generations to remove recessive lethal mutations linked to but independent of the enhancers of zipper. Outcrossed chromosomes were recovered and balanced over SM5, CyO or CyO, P[sevRasl.V12]FK1.

**Mounting of adult legs:** Adult flies were transferred to 80% glycerol for at least 24 hours. Legs were dissected from the preserved animals and mounted in a drop of glycerol under of coverslip sealed with nail polish. The legs were observed by brightfield microscopy using a 4x Acroplan objective on a Zeiss Axiophot MC80 microscope. Images were acquired into Adobe Photoshop 6.0 software to crop and montage using a Kodak DC290 Zoom digital camera.
Molecular lesions associated with RhoA and Sb-sbd mutant alleles used in this study:

All of the RhoA mutations used in these studies have been characterized at a molecular level (Table 2). RhoA$^{E310}$ is a CAAX box missense mutation (C to Y), while RhoA$^{J38}$ is a deletion of the 13 C-terminal amino acids, including the CAAX box (HALSELL et al. 2000). These mutations are likely to be loss-of-function alleles since the CAAX box motif is required for RhoA association with the plasma membrane (ZHANG and CASEY 1996; SEABRA 1998). The RhoA$^{E2F}$ and RhoA$^{J2O}$ mutations are P-element excision mutants and are also likely null mutations (STRUTT et al. 1997). Df(2R)Jp8 is a small deficiency that uncovers RhoA but does not uncover the nearby myosin light chain kinase gene (HALSELL et al. 2000). Five of the Sb and sbd mutant alleles used in this study have also been characterized to varying degrees at a molecular level. The Sb$^{63b}$ mutation is associated with a transpositional blood element insertion close to the junction of the extracellular stem region and the proteolytic domain (APPEL et al. 1993; A. HAMMONDS and J. FRISTROM, pers.comm). Sequence analysis indicates that translation would be terminated a few nucleotides into the blood element insertion effectively truncating the proteolytic domain from the Sb-sbd protein. The Sb$^j$ and Sb$^{70}$ mutations are also associated with transpositional insertions (APPEL et al. 1993), although the precise molecular locations of these insertions have not been determined. The sbd$^{201}$ mutation is associated with a histidine to arginine substitution of residue 572 in the proteolytic domain (A. HAMMONDS and J. FRISTROM, pers.comm). The affected residue is adjacent to a conserved cysteine in the substrate binding pocket. The resulting protease is likely to have defective substrate binding capabilities and/or reduced proteolytic activity. The sbd$^{105}$ mutation is associated with a large deficiency that removes the entire Sb-sbd locus and flanking genomic DNA (APPEL et al. 1993).
Finally, the $sbd^2$ mutation is not associated with coding region defects and is presumed to be regulatory in nature (A. HAMMONDS and J. FRISTROM, pers. comm.).
RESULTS

*RhoA* mutations show significant second-site non-complementation and dominant genetic interactions with *Sb-sbd* alleles: Mutations in Drosophila *RhoA* exhibit second-site non-complementation (SSNC) with mutations in the heavy chain of non-muscle myosin (*zipper*), with 100% of heterozygous double mutant animals (i.e. *RhoA* +/+ *zip*) exhibiting a leg malformation phenotype (HALSELL *et al.* 2000). The observation that *Sb-sbd* is also a genetic enhancer of *zipper* with respect to leg malformation (GOTWALS and FRISTROM 1991) lead us to investigate the possibility that *Sb-sbd* mutations interact genetically with *RhoA* mutations in elongating leg imaginal discs. In Table 3 and subsequent tables we define interactions as strong when greater than 40% of animals have at least one malformed leg, moderate when 20-40% of animals are malformed, and weak when 5-19% malformation is observed. In almost all cases, “background” leg malformation in animals heterozygous for only one mutant allele (e.g. *Sb*/+) ranged from 0-2%. Thus, a moderate interaction indicates that animals have malformation frequencies 10-20 times background, while a strong interaction indicates that the frequency is greater than 20-fold above background. Molecular lesions associated with *RhoA* and *Sb-sbd* mutants used in this study are described in the Materials and Methods.

Leg malformation genetic interaction data for *Sb-sbd* and *RhoA* mutant alleles are shown in Table 3. The *Sb*63b and *Sb*70 alleles interact very strongly with *RhoA* mutant alleles and the *RhoA* deficiency *Df(2R)Jp8* in SSNC assays, with the frequency of animals with leg malformation ranging from 59% to 96% (see also Figure 1). The interactions with the *RhoA*13.8 and *RhoA*E3.10 mutations are particularly strong. In our experiments we find these particular *RhoA* alleles to be the most genetically sensitive in leg malformation assays with *Sb-sbd* mutants. Many of the *RhoA*/+; *Sb-sbd*/+ double mutant animals exhibit malformation of both second and
third legs, a phenotype associated with severe malformation. In the cases where $RhoA^{E3.8}$, $RhoA^{E3.10}$, and $Df(2R)Jp8$ were tested for interactions with $Sb^{63b}$ and $Sb^{70}$ almost all animals exhibited severe malformation. In contrast, only weak SSNC interactions are observed between the $Sb^{l}$ and $Sb^{spike}$ and $RhoA$ alleles. The $Sb^{l}$ and $Sb^{spike}$ alleles have also been previously reported to interact weakly in SSNC assays with the historically interactive zipper allele $zip^{Ebr}$, and $Broad-Complex$ allele $br^{l}$ (BEATON et al. 1988; GOTWALS and FRISTROM 1991).

The $sbd^{105}$ mutation exhibits moderate levels of SSNC interaction with the $RhoA^{E3.8}$ and $RhoA^{E3.10}$ alleles (Table 3). No interactions were observed with the $sbd^{201}$ allele. The $sbd^{105}$ and $sbd^{201}$ alleles have previously shown only weak to moderate interactions with $Broad-Complex$ and zipper mutants in SSNC assays (BEATON et al., 1988; GOTWALS and FRISTROM, 1991). Therefore we asked if $RhoA$ mutants interact dominantly with $sbd$ alleles. Because $sbd^{105}$ homozygotes are inviable and $sbd^{201}$ homozygotes have reduced viability and exhibit 100% malformation, we tested the transheterozygotes $sbd^{201}/sbd^{l}$ and $sbd^{201}/sbd^{2}$ which exhibit malformation rates of 10% and 1% respectively. The $RhoA^{E3.10}$, $RhoA^{E3.8}$, and $Df(2R)Jp8$ alleles all show very strong dominant interactions with $sbd^{201}/sbd^{l}$ transheterozygotes. In contrast, weak to moderate interactions are observed between $sbd^{201}/sbd^{l}$ transheterozygotes and the $RhoA^{E3.10}$, $RhoA^{E3.8}$, and $Df(2R)Jp8$ alleles. Therefore, in subsequent tests for dominant interactions with $sbd$ alleles we used the $sbd^{201}/sbd^{l}$ combination. Collectively, our data show that $Sb$-$sbd$ mutations interact strongly with mutations in $RhoA$ and raise the possibility that $Sb$-$sbd$ proteolytic activity plays a role in the $RhoA$ signaling pathway during leg morphogenesis.

$Sb$-$sbd$ mutants interact with $RhoA$ signaling pathway mutants. We extended our analysis by asking if $Sb$-$sbd$ mutations interact with mutations in other known components of the $RhoA$ signaling pathway. Mutations in the gene encoding the guanine nucleotide exchange factor
$DRhoGEF2$ have been previously reported to affect RhoA-mediated cell shape changes during Drosophila gastrulation (BARRETT et al. 1997). These $DRhoGEF2$ mutants show weak to moderate interactions in leg discs with $zip^{Ebr}$ in SSNC genetic assays (HALSELL et al. 2000), and moderate to strong interactions with $RhoA$ mutations (C. BAYER and L. VON KALM, data not shown). Three $DRhoGEF2$ alleles, $DRhoGEF2^{1.1}$, $DRhoGEF2^{4.1}$, and the P-element insertion mutant $DRhoGEF2^{04291}$, show mostly weak interactions with $Sb-sbd$ alleles in SSNC and dominant interaction assays (Table 4). These findings initially suggested that $DRhoGEF2$ might not be involved in a hypothetical $Sb-sbd-RhoA$ signaling pathway in leg imaginal discs. However, we have identified a new allele of $DRhoGEF2$ (see below). This new allele, $DRhoGEF2^{11-3}$, was tested with $Sb-sbd$ alleles in SSNC and dominant interaction assays (Table 4). $DRhoGEF2^{11-3}$ interacts strongly with $Sb^{63b}$ and $Sb^{70}$, and moderately in a dominant interaction assay with $sbd^{201/sbd^{d}}$ transheterozygotes. The apparent allele-specific nature of genetic interactions involving $DRhoGEF2$ in our leg malformation assays is consistent with other reports (e.g. BEATON et al. 1988; GOTWALS and FRISTROM 1991; HALSELL and KIEHART 1998). A striking example of an allele-specific interaction is the observation that null alleles of $zipper$ fail to enhance $BR-C$ or $Sb-sbd$ mutant leg defects in SSNC assays, whereas high percentages of animals are malformed when the $zip^{Ebr}$ allele is tested in similar assays with $BR-C$ or $Sb-sbd$ mutants. The $zip^{Ebr}$ mutation is associated with a missense alteration in the myosin ATP-binding pocket and may encode a weakly dominant negative allele of myosin with the potential to form unproductive dimers with wild-type myosin molecules (HALSELL et al. 2000). Consistent with the possibility of dominant negative activity we observe up to 4% leg malformation in $zip^{Ebr}/+$ animals, suggesting that $zip^{Ebr}$ heterozygotes are highly sensitized to further genetic perturbations affecting the actin cytoskeleton. In contrast, the complete loss of
one copy of the zipper locus apparently does not reduce myosin levels sufficiently to interfere with actin cytoskeletal dynamics during leg morphogenesis. Thus, by analogy, even though although only one of the DRhoGEF2 mutants tested interacts significantly with Sb-sbd alleles in our assays, the strength of the interactions between Sb-sbd mutants and DRhoGEF2\(^{1/-3}\) clearly implicates DRhoGEF2 function in leg imaginal disc morphogenesis.

Previous reports have indicated that the downstream RhoA effector kinase, Rho kinase, plays an important role in actin cytoskeletal dynamics in vertebrates via phosphorylation of the myosin regulatory light chain (AMANO et al., 1996; BURRIDGE and CHRZANOWSKA-WODNICKA 1996; RIDLEY 1996). A recent report demonstrates that the Drosophila homolog of Rho kinase (Drok) is also a RhoA effector kinase in wing imaginal discs (WINTER et al., 2001). In this study Drok was shown to be involved in the control of planar cell polarity in a Frizzled-mediated signaling pathway to the actin cytoskeleton via phosphorylation of the Drosophila myosin regulatory light chain protein, Spaghetti Squash. We therefore tested two alleles of drok for interactions with Sb-sbd mutations (Table 4). \(drok^1\) and \(drok^2\) show strong interactions with \(Sb^{70}\), and weak to moderate interactions with \(Sb^{63b}\). In contrast, both \(drok\) mutants show weak dominant interactions with \(sbd\) alleles. None-the-less, the strength of the SSNC interaction of both \(drok\) alleles tested with the \(Sb^{70}\) mutation strongly indicates that Rho kinase acts as a downstream effector of RhoA in the control of cell shape changes in leg imaginal discs.

The second chromosome deficiency \(Df(2R)Jp1\) uncovers the cytogenetic interval 51C3-52F8/9 and therefore should delete the myosin light chain kinase gene located at 52D11/E1 (CHAMPAGNE et al. 2000; KOJIMA et al. 1996; TOHTONG et al. 1997; www.Flybase.org). In vertebrate systems the myosin light chain kinase functions in conjunction with other effector kinases such as Rho kinase to activate myosin via phosphorylation of the myosin regulatory light
chain (reviewed in TAN et al. 1992). We find that \textit{Df(2R)Jp1} shows strong and moderate interactions respectively with \textit{Sb}^{63b} and \textit{Sb}^{70} in SSNC assays, and interacts very strongly in a dominant genetic interaction test with \textit{sbd}^{201}/\textit{sbd}^d transheterozygotes (Table 4). \textit{Df(2R)Jp1} has been previously reported to interact genetically in leg malformation assays with the \textit{RhoA} alleles used in this study (HALSELL et al. 2000). If the published right breakpoint for \textit{Df(2R)Jp1} is correct this deficiency might also uncover the \textit{RhoA} locus recently placed in cytogenetic region 52F8-9 by deficiency mapping analysis (HALSELL et al. 2000). However, although lethal recessive \textit{RhoA} mutations show SSNC interactions with \textit{Df(2R)Jp1}, they are viable over this Deficiency in doubly heterozygous combinations. In contrast, the same \textit{RhoA} alleles are inviable over \textit{Df(2R)Jp8} which does uncover \textit{RhoA}, indicating that \textit{Df(2R)Jp1} does not uncover \textit{RhoA}. Further evidence that \textit{Df(2R)Jp1} uncovers a \textit{RhoA} signaling pathway member distinct from \textit{RhoA} comes from our observation that SSNC genetic interactions between \textit{Sb-sbd} mutants and \textit{Df(2R)Jp4}, a deficiency predicted to uncover both \textit{RhoA} and \textit{MLCK}, are stronger than those observed for \textit{Sb-sbd} and \textit{Df(2R)Jp1} or \textit{Sb-sbd} and \textit{Df(2R)Jp8} (data not shown). Thus, our observation of strong genetic interactions between \textit{Sb-sbd} mutants and \textit{Df(2R)Jp1} are consistent with the possibility that \textit{Sb-sbd} mutants interact genetically with loss-of-function \textit{MLCK} alleles and provide additional evidence that the \textit{Sb-sbd} protease participates in \textit{RhoA} signaling to myosin to control cell shape changes in prepupal leg imaginal discs.

We also tested mutant alleles of the myosin regulatory light chain gene, \textit{spaghetti squash} and Drosophila \textit{Pkn} for interactions with \textit{Sb-sbd} alleles. We observe no interaction between \textit{Sb-sbd} alleles and the strongly hypomorphic \textit{sqh}^I or amorphic \textit{sqh}^2 (data not shown; KARESS et al. 1991; EDWARDS and KEIHART 1996). However, \textit{sqh} null alleles also fail to interact with \textit{zipper} mutations including \textit{zip}^{Ebr} in SSNC assays even though biochemical evidence clearly demonstrates a direct physical interaction between these proteins. Here, one dose of the wild-
type myosin regulatory light chain gene in sqh/+; zip/+ animals produces sufficient protein to drive cell shape changes in elongating leg imaginal discs. Thus we are not surprised by the failure of strong loss-of-function sqh mutations to interact with Sb-sbd mutants. Drosophila Pkn binds specifically to GTP-activated RhoA and is required for epidermal cell shape changes during dorsal closure in the embryo (LU and SETTLEMAN 1999). We therefore asked if Pkn mutants interact with Sb-sbd alleles. We find that Pkn\textsuperscript{3} and the P-element insertion mutant Pkn\textsuperscript{06736} fail to interact with Sb\textsuperscript{63b} or Sb\textsuperscript{70} in SSNC assays and exhibit weak dominant enhancement of leg malformation with sbd\textsuperscript{201/sbd\textsuperscript{d}} transheterozygotes (data not shown). Thus we conclude that our data do not support a major role for Pkn in Sb-sbd-RhoA mediated cell shape changes during leg morphogenesis.

**Leg malformation associated with over-expression of Sb-sbd is suppressed by reducing RhoA gene dosage.** In experiments aimed at characterizing and rescuing Sb-sbd mutations we generated transgenic flies carrying a full length Sb-sbd cDNA placed under the control of a heat-inducible promoter in the transposon pCaSpeR-hs (Thummel and Pirrotta, 1992). We have used this hs-Sb-sbd transgene (hs-Stubble) to rescue leg defects associated with homozygous sbd\textsuperscript{201} mutations by inducing the transgene with a 1 hour 37\textdegree heat shock in staged 0hr or 3hr prepupae. In the course of these experiments we discovered that induction of hs-Stubble in wild-type 0hr or 3hr prepupae results in a high percentage of severe leg malformation in adults involving second as well as third legs. In contrast, we find that over-expression of Sb-sbd either 12hr before or 10hr after pupariation does not effect leg morphogenesis. Thus, the leg malformation associated with over-expression of Sb-sbd is highly specific to a critical period of leg development.
We took advantage of the leg defect associated with Sb-sbd over-expression at the beginning of the prepupal period to test the hypothesis that RhoA acts downstream of Sb-sbd in elongating leg discs. We asked if reducing the gene dosage of RhoA to one copy could suppress the leg phenotype associated with over-expression of Sb-sbd. We find that in RhoA^{720}/+; hs-Stubble/+ animals heat-shocked as 3hr prepupae, second leg malformation is reduced 2.7-fold, from 69% to 25% (Table 5). When RhoA^{720}/+; hs-Stubble/+ animals are heat-shocked as 0hr prepupae, 2nd leg malformation is reduced 2-fold, from 17% to 8%. A similar degree of suppression is also seen for third leg malformation (Table 5). Similar results to those shown in Table 5 were obtained in experiments using the RhoA^{E1.10} allele (data not shown). The observation that hs-Stubble induced leg malformation can be suppressed by reducing RhoA gene dosage strongly suggests that RhoA functions downstream of Stubble in a signaling pathway regulating myosin as cells change their shape during leg elongation.

*Enhancer of zipper mutations interact genetically with Sb-sbd and RhoA mutations during leg elongation.* In order to identify additional genes encoding products that participate in a hypothetical Sb-sbd/RhoA signaling pathway required to regulate cell shape changes in elongating leg imaginal discs, we analyzed mutations in six genes on the second chromosome that enhance zipper mutant leg defects. These mutations were originally identified by Dr. Jim Fristrom in an EMS based genetic screen (unpublished data). These mutations, referred to as enhancers of zipper, en(zip), were outcrossed to Canton S flies for three generations to remove recessive lethal mutations linked to but independent of the enhancers. We tested the en(zip) mutations for interaction with Sb-sbd and RhoA mutants. Five of the six en(zip) mutations are homozygous lethal. The one exception is 31-6 which is semi-lethal with approximately one quarter of viable animals exhibiting leg malformation. Of the six mutants, three are alleles of
known genes. One mutant, 11-3 (described in Table 4), fails to complement \( DRhoGEF2^{1-1} \), \( DRhoGEF2^{4-1} \), and \( DRhoGEF2^{04291} \), indicating that 11-3 is a new allele of \( DRhoGEF2 \). Another mutant, 12-6, fails to complement \( RhoA^{12-6} \) and \( RhoA^{E3.10} \) mutants and \( Df(2R)Jp8 \) which uncovers \( RhoA \). Thus we conclude that 12-6 is likely to be a new \( RhoA \) allele. A third mutant, 33-1, fails to complement \( zipper \) null mutations and \( Df(2R)ES1 \) which uncovers \( zipper \), and is therefore likely to be a new allele of \( zipper \). \( zip^{33-1} \) is semi-viable over \( zip^{Ebr} \) and these animals have severe leg malformation (see Table 6). It is possible that one or more of the non-complementation results we have observed are due to lethal SSNC interactions rather than non-complementation between two alleles of the same gene. We are therefore currently initiating rescue experiments with full length cDNAs or cosmids carrying genomic clones for each of the genes involved to confirm our genetic complementation data.

With the exception of the moderately interacting 31-6 mutant, the \( en(zip) \) alleles all show strong interactions with \( zip^{Ebr} \) (Table 6). The strongest interactions are seen with the \( DRhoGEF2^{11-3} \), \( RhoA^{12-6} \), and \( zip^{33-1} \) alleles. We find that \( RhoA^{12-6} \) interacts very strongly with \( zip^{Ebr} \) with reduced viability. Similar results were reported by HALSSELL et al. (2000) for interactions between \( RhoA^{13.8} \) or \( RhoA^{E3.10} \) and \( zip^{Ebr} \). In contrast, our \( DRhoGEF2^{11-3} \) allele is considerably more interactive with \( zip^{Ebr} \) than the previously reported \( DRhoGEF2^{04291} \), \( DRhoGEF2^{1-1} \), and \( DRhoGEF2^{4-1} \) alleles (HALSSELL et al. 2000). The combination \( zip^{33-1}/zip^{Ebr} \) exhibits 97% malformation with greatly reduced viability. As stated above, \( zip^{33-1} \) fails to complement \( zip \) null alleles and a deficiency that uncovers \( zipper \). The six \( en(zip) \) alleles also interact to varying degrees with \( Sb-sbd \) mutants (Table 6). \( DRhoGEF2^{11-3} \) and \( RhoA^{12-6} \) exhibit strong SSNC with \( Sb^{63b} \) and \( Sb^{70} \), while the remaining \( en(zip) \) alleles interact moderately with at least one of these \( Sb \) alleles. All of the \( en(zip) \) alleles show moderate to strong dominant interactions with \( sbd^{201}/sbd^{1} \) transheterozygotes.
The en(zip) mutations exhibit universally strong SSNC interactions with RhoA alleles and Df(2R)Jp8 (Table 6). As stated above, RhoA^{12-6} fails to complement the two RhoA alleles and deficiency tested. The strongest interactions are seen between RhoA mutants and DRhoGEF2^{11-3} and zip^{33-1} which exhibit 93-100% malformation and in the case of DRhoGEF2^{11-3} greatly reduced viability in combination with all RhoA alleles tested. The uncharacterized en(zip) alleles, 12-5, 18-5, and 31-6, also interact strongly with RhoA mutants. The viability of animals doubly heterozygous for 12-5 and RhoA^{13.8} or RhoA^{E3.10} is reduced. Somewhat surprisingly the en(zip) mutants fail to interact with DRhoGEF2^{04291}, DRhoGEF2^{1.1}, DRhoGEF2^{4.1}, drok^{1}, drok^{2}, or Df(2R)Jp1. There are two exceptions to these observations. First, RhoA^{12-6} exhibits 20% malformation with the drok^{1} and drok^{2} alleles, and 13% malformation with Df(2R)Jp1 (data not shown). Second, DRhoGEF2^{11-3} is lethal with all DRhoGEF2 alleles tested, and exhibits 17% malformation with Df(2R)Jp1 (data not shown). As positive controls we tested all DRhoGEF2 and drok alleles for interaction with RhoA and zipper alleles. The DRhoGEF2^{04291}, DRhoGEF2^{1.1}, and DRhoGEF2^{4.1} alleles exhibit moderate to strong interactions ranging from 21-64% malformation with RhoA^{13.8}, RhoA^{E3.10}, and zip^{Ebr} in SSNC assays (data not shown and HALSELL et al. 2000). The drok mutants also exhibit moderate to strong interactions with RhoA^{13.8}, RhoA^{E3.10}, and zip^{Ebr} in SSNC assays (48-68% malformation for drok^{1} and 19-38% malformation for drok^{2}).

We have tested the three uncharacterized en(zip) mutants (12-5, 18-5, and 31-6) for non-complementation with mutations in second chromosome genes thought to have a role in RhoA signaling, and with genes reported to exhibit the malformed leg phenotype in the mutant condition. Genes tested include Drosophila Pkn (LU and SETTLEMAN, 1999), blistered (GOTWALS and FRISTROM, 1991), vulcan and bancal (GATES and THUMMEL, 2000), and crol (D'AVINO and THUMMEL, 1998). Other mutants tested include Df(2R)Jp1 which
putatively uncovers the myosin light chain kinase gene, concertina which has been proposed to act as an upstream regulator of RhoA signaling leading to cell shape changes during Drosophila gastrulation (BARRETT et al. 1997), and the protein 4.1 family members coracle, inscuteable, and expanded (FEHON et al. 1994; BOEDIGHEIMER and LAUGHON 1993; KRAUT and CAMPOS-ORTEGA, 1996). The 12-5, 18-5, and 31-6 alleles are fully viable over all of these mutations and exhibit wild-type leg morphology.

The *en(zip)* mutants interact with each other but not with the *br"* allele of the Broad-Complex: We also asked if the *en(zip)* alleles interact with each other in SSNC assays. As seen in Table 7 there are significant genetic interactions between *en(zip)* alleles in these assays. Of particular interest are the uncharacterized 12-5, 18-5, and 31-6 mutants. The 12-5 mutant exhibits moderate to strong interactions with all *en(zip)* mutants tested. A very strong interaction is observed with 18-5. In addition to severe malformation, 12-5+/+ 18-5 animals have reduced viability. A significant interaction (35% malformation) is also observed between the 18-5 and 31-6 mutants. With the exception of *DRhoGEF2"* , the semi-viable 31-6 mutant interacts at moderate to strong levels with all *en(zip)* mutants tested. In addition, approximately one quarter of 31-6 homozygotes have malformed legs, an observation fully consistent with a role for the 31-6 gene product in leg morphogenesis.

Finally we asked if the *br"* allele of the Broad-Complex (BR-C) interacts with RhoA pathway members and the *en(zip)* mutants. The *br"* mutant is highly interactive in leg malformation assays and has previously been shown to interact strongly with *Sb-sbd* and *zipper* mutations (BEATON et al. 1988; GOTWALS and FRISTROM 1991). The *br"* allele also exhibits temperature sensitivity with typically greater penetrance of leg malformation observed at 18° as compared to 25° (BEATON et al. 1988). The *br* genetic function of the BR-C is
essential for prepupal leg development. Animals carrying amorphic mutations that affect this 
BR-C function completely fail to elongate and evert their leg imaginal discs (KISS et al. 1988; 
BAYER et al. 1996). At a molecular level the br genetic function is strongly associated with the 
Z2 zinc-finger transcription factor product of the BR-C (DIBELLO et al. 1991; BAYER et al. 
1997). To date little is understood of the role played by this critical regulator of imaginal disc 
morphogenesis. We find that RhoA mutants interact dominantly with brI mutants at both 18° and 
25° with stronger interactions observed at 18° (Table 8). Weak to moderate interactions are also 
observed between brI and Df(2R)Jp1. However, the brI allele fails to show significant 
interactions with DRhoGEF2, drok, Df(2R)Jp1, or the en(zip) mutants, including zip33-1.
DISCUSSION

The Drosophila Sb-sbd locus is required for normal cell shape changes in prepupal elongating leg imaginal discs (CONDIC et al. 1991; VON KALM et al. 1995). Genetic interactions between Sb-sbd and the Drosophila gene encoding non-muscle myosin II (zipper) suggest a role for the Sb-sbd protease in regulating contractility of the apical actin-myosin belt found in imaginal disc epithelia (GOTWALS and FRISTROM 1991). Zipper mutations also interact genetically with mutations in the small GTPase RhoA indicating that phosphorylation of the myosin regulatory light chain (Sqh) is a necessary pre-requisite to myosin activation in developing leg imaginal discs (HALSELL et al. 2000). In order to learn more about the relationships between the molecules encoded by the Sb-sbd, zipper and RhoA loci we asked if Sb-sbd and RhoA mutations interact genetically during prepupal leg development. We observe very strong SSNC and dominant interactions between mutant alleles of these genes. In addition, we find that Sb-sbd alleles show significant interactions with members of the RhoA signaling pathway including a new allele of DRhoGEF2, Rho kinase, and a deficiency, Df(2R)Jp1, that uncovers the gene encoding the myosin light chain kinase. In addition, we have shown that leg malformation associated with over-expression of Sb-sbd during leg elongation is suppressed by reducing the gene dosage of RhoA. Taken as a whole these data strongly implicate Sb-sbd in RhoA signaling and suggest that Sb-sbd acts upstream of RhoA to regulate cell shape changes in elongating leg discs.

Previous studies have clearly established a connection between signaling by the small GTPase RhoA and regulation of actin cytoskeletal dynamics (reviewed in HALL 1998). Evidence from both vertebrate and invertebrate systems indicate that RhoA signaling serves to activate non-muscle myosin and thereby control the assembly and contractility of actomyosin-
Based on the strength of the SSNC interactions we have observed between \textit{Sb-sbd} and \textit{RhoA} mutants, and \textit{Sb-sbd} and \textit{RhoA} pathway members we favor a linear signaling pathway from \textit{Sb-sbd} to \textit{RhoA} as a likely explanation of our data. We propose a model in which ecdysone-mediated induction of the \textit{Sb-sbd} locus is required to activate the \textit{RhoA} signaling pathway in late larval leg discs (Figure 2). Following induction by ecdysone the \textit{Sb-sbd} zymogen is secreted to the apical surface of leg disc cells. At the cell surface \textit{Sb-sbd} is activated, possibly by auto-proteolytic cleavage (APPEL \textit{et al.} 1993), and signals to DRhoGEF2 via an unknown mechanism. Signaling to DRhoGEF2 could involve cleavage of another extracellular protein (pathway 1 in Figure 2), or signaling via the Stubble cytoplasmic domain (pathway 2 in Figure 2). \textit{RhoA} is then cycled into the active GTP-bound form via interaction with DRhoGEF2 leading to downstream effector kinase signaling, myosin assembly, and changes in actin dynamics. Genetic interactions between \textit{Sb-sbd} and members of the \textit{RhoA} pathway can be interpreted in ways other than a linear signaling pathway. For example, \textit{Sb-sbd} and \textit{RhoA} might act in parallel pathways. These pathways might converge to activate myosin, or regulate different components of the contractile apparatus. Alternatively, the \textit{Sb-sbd} protease may facilitate cell shape changes via cleavage of apical extracellular matrix while \textit{RhoA} signals to activate myosin. We have also
considered the possibility that \textit{Sb-sbd} could be a transcriptional target of RhoA signaling in leg imaginal discs. This latter possibility seems unlikely in view of the fact that \textit{Sb-sbd} is rapidly induced in response to ecdysone (APPEL et al. 1993), and to date no ecdysone responsive member of the RhoA signaling pathway has been identified (WARD AND THUMMEL 2002; see below.). Ultimately, molecular genetic and biochemical approaches will be required to resolve the mechanism underlying the genetic interactions between \textit{Sb-Sbd} and the RhoA signaling pathway.

Our initial experiments to investigate the mechanism underlying the genetic interactions between \textit{Sb-Sbd} and the RhoA signaling pathway do not support a role for the \textit{Sb-sbd} 58 amino acid cytoplasmic domain in signaling. We have constructed transgenic animals expressing the cytoplasmic domain with or without its associated transmembrane region under heat-inducible control. We hypothesized that over-expression of the cytoplasmic domain might result in a dominant negative effect on leg development by sequestration of a gene product critical for RhoA signaling if the cytoplasmic domain is required for intracellular signaling events. However, over-expression of cytoplasmic domain with or without the transmembrane region in white prepupae and 3 hour prepupae has no discernable effect on leg development and these animals are fully viable. Thus, if a linear signaling model is correct, \textit{Sb-sbd} proteolytic activity on the apical surface of elongating leg disc cells is a more likely mechanism to trigger RhoA signaling.

In addition to \textit{Sb-sbd} the ecdysone-inducible \textit{Broad-Complex (BR-C)} and \textit{E74} genes are good candidates to regulate RhoA signaling in leg imaginal discs. The \textit{BR-C} and \textit{E74} are both active in leg imaginal discs during early prepupal development. Amorphic mutations in the \textit{br} genetic function of the \textit{BR-C} completely block leg development (KISS \textit{et al.} 1988). The \textit{br}
genetic function encodes the Z2 zinc-finger transcription factor product of the \textit{BR-C} and Z2 is essential for normal leg development (DIBELLO \textit{et al.} 1991; BAYER \textit{et al.} 1997). \textit{In vitro} and \textit{in vivo} analyses show that Z2 RNA and protein are strongly induced by ecdysone in imaginal discs at the onset of metamorphosis (EMERY \textit{et al.} 1994; BAYER \textit{et al.} 1996). A small percentage of animals carrying mutations specific to the E74A and E74B isoforms develop far enough into pupal development to permit assessment of leg morphology (FLETCHER \textit{et al.} 1995). Those animals that do reach the later stages of the pupal period exhibit malformed legs. However, the\textit{ BR-C} and E74 loci both encode families of transcription factors (BURTIS \textit{et al.} 1990; DIBELLO \textit{et al.} 1991). Thus, if \textit{BR-C} or E74 gene products are required to initiate RhoA signaling it is very likely that one or more components of the RhoA signaling pathway will be transcriptionally induced by \textit{BR-C} or E74 gene products. The RhoA pathway genes targeted by \textit{BR-C} or E74 transcription factors should therefore behave as ecdysone responsive genes. However, to date none of the genes encoding RhoA signaling pathway members have been shown to be ecdysone responsive at a transcriptional level. Genes tested for ecdysone responsiveness include \textit{RhoA, DRhoGEF2, drok, RhoGAPs, guanine nucleotide dissociation inhibitors (GDIs), and zipper} (WARD AND THUMMEL 2002; C. BAYER and J. FRISTROM, unpublished data). Until a \textit{BR-C} or E74-dependent ecdysone inducible gene is identified, other ecdysone responsive genes, such as \textit{Sb-sbd}, that do not encode transcription factors are more probable candidates to initiate RhoA signaling.

We have identified three potentially novel genes likely to have important roles in a hypothetical \textit{Sb-sbd-RhoA} signaling pathway. These genes, \textit{12-5, 18-5, and 31-6}, were originally identified as EMS mutations on the second chromosome that behaved genetically as enhancers of \textit{zipper} mutant leg defects (J. FRISTROM, pers. comm.). All three mutant genes also show
significant interactions with Sb-sbd and RhoA mutations. However, the 12-5, 18-5, and 31-6, mutants fail to interact with several DRhoGEF2 alleles tested, drok\(^1\), drok\(^2\), or Df(2R)Jp1. In addition 31-6 does not interact with the new DRhoGEF\(^{11-3}\) allele described in this study (12-5 and 18-5 show moderate and weak interactions respectively with DRhoGEF\(^{11-3}\); Table 7). Because we have only one allele of each of the uncharacterized en(zip) mutations the lack of interactions with members of the RhoA signaling pathway may be attributable to the specific nature of the mutations in each of these genes. The fact that known components of the RhoA signaling pathway (RhoGEF2\(^{11-3}\); RhoA\(^{12-6}\), and zip\(^{33-1}\)) were also isolated in the original enhancer of zipper screen gives us confidence that molecular characterization of the protein products encoded by the 12-5, 18-5, and 31-6 genes will provide new insights into Sb-sbd-RhoA signaling in leg imaginal discs.

The role of the BR-C in prepupal leg development remains unclear. BR-C mutants interact genetically with both Sb-sbd and zipper mutations during leg development (BEATON et al. 1988; GOTWALS AND FRISTROM, 1991). In addition, the br\(^l\) allele of the BR-C interacts with mutations in RhoA and Df(2R)Jp1 (Table 8; see also WARD AND THUMMEL 2002). However, the br\(^l\) allele does not interact with DRhoGEF2, drok, or en(zip) mutations. Clearly the BR-C has a critical role in leg morphogenesis (see above). Characterization of genes identified in a recent large genetic screen for enhancers of br\(^l\) leg malformation (WARD AND THUMMEL 2002) will likely shed light on the role of this important master regulator of metamorphosis in prepupal leg development.

The Sb-sbd protease has been strongly implicated in the regulation of the actin cytoskeleton during bristle development (see Introduction). However, three observations indicate that interactions between Sb-sbd and the actin cytoskeleton proceed via different mechanisms in bristles and leg imaginal discs. First, all Sb-sbd mutants behave as recessive alleles during leg
development. In contrast Sb alleles behave as dominant mutations during bristle development. Second, The genetic interactions between Sb-sbd, the BR-C, zipper, and RhoA described here and elsewhere (BEATON et al. 1988; GOTWALS AND FRISTROM 1991; HALSELL et al. 2000) are observed only in legs. Animals exhibiting SSNC for mutant alleles of these genes have wild-type bristles. These differences in Sb-sbd function during leg disc and bristle development are not surprising given that there is no cell biological evidence for any form of actin-myosin contractile apparatus in bristles. Our data also indicate that RhoA signaling plays no role in actin dynamics during bristle development. Third, the $Sb^{63b}$ mutation interacts genetically with mutations in two other genes required for bristle morphogenesis, singed (sn) and forked (f). singed and forked encode actin bundling proteins related to echinoderm fascin and mammalian espin, respectively (BRYAN et al. 1993; CANT et al. 1994; PETERSON et al. 1994; TILNEY et al. 1995; BARTLES et al. 1996). Compared to sn, f, or Sb-sbd mutants, sn; Sb-sbd and f; Sb-sbd double mutants have extremely reduced bristles that appear as small nubs barely extending beyond the exoskeleton. However, the sn; Sb-sbd or f; Sb-sbd double mutant combinations do not exhibit any increase in the frequency of malformed legs above that found in Sb-sbd mutants (L. von Kalm, unpublished data). These data suggest that actin bundling proteins other than sn or f are expressed in developing legs.

Finally, our data suggest that type II transmembrane serine proteases (TTSPs) have the potential to activate intracellular signaling pathways during development. Vertebrate members of the TTSP family have been linked to developmental abnormalities and a variety of pathologies. The human TTSP Hepsin controls hepatocyte morphology and growth (TORRES-ROSADO et al. 1993). Over-expression of this protease is linked to ovarian, kidney, and prostate cancer (TANIMOTO et al. 1997; ZACHARSKI et al. 1998; LUO et al. 2001; MAGEE et al. 2001; DHANASEKARAN et al. 2001). MAGEE et al. (2001) reported that hepsin RNA over-
expression correlates with neoplastic transformation in the prostate, and that hepsin is expressed specifically in the transformed epithelial cells rather than the adjacent stroma. DHANASEKARAN et al. (2001) extended these findings to a study of the Hepsin protein and concluded that expression of Hepsin in prostate cancer correlates inversely with measures of patient prognosis. At least three other TTSPs, MT-SP1, TMPRSS2, and TMPRSS4 are associated with malignancy (TAKEUCHI et al. 1999; LIN et al. 1999; WALLRAPP et al. 2000). For example, TMPRSS4 is strongly over-expressed in pancreatic cancer when compared to normal pancreatic tissue (WALLRAPP et al. 2000). In this study the level of TMPRSS4 expression was shown to correlate with the metastatic potential of SUIT-2 pancreatic cancer cell lines. Human HAT, which is expressed in the lung, is potentially associated with chronic airway diseases (YAMAOKA et al. 1998), while the influenza virus surface protein neuraminidase is essential for viral infection (JONES et al. 1985). Corin, a candidate for the human TAPVR gene associated with congenital heart defects, is highly expressed in the region of the mouse embryonic heart where outflow tracts form and has been hypothesized to play a role in cellular differentiation in the early stages of human and mouse heart development (YAN et al., 1999). Recent evidence suggests that Corin also plays a role in the regulation of blood pressure via activation of the cardiac hormone pro-atrial natriuretic peptide (YAN et al. 2000; WU et al. 2002).

In addition to Sb-sbd two other members of the TTSP family may be involved in “outside-in” signaling events, suggesting that these proteases are anchored in the membrane for this purpose rather than for cleavage of extracellular matrix. Enteropeptidase and MT-SP1 activities are potentially linked to intracellular signaling via activation of the proteolytically-activated G protein-coupled receptor PAR2 (KONG et al. 1997; TAKEUCHI et al. 2000; HOOPER et al. 2001). These observations raise the possibility that other members of the TTSP
family participate in signal transduction events and that aberrant intracellular signaling may underlie their association with pathology and developmental abnormalities. The entereopeptidase, MT-SP1, and Sb-sbd proteases all have extracellular domains in addition to the proteolytic domain that could potentially be involved in protein-protein interactions required to interact with cleavage targets (HOOPER et al. 2001). The Sb-sbd TTSP has an extracellular disulfide knotted domain (APPEL et al. 1993) and in vitro studies indicate that this domain is capable of mediating protein-protein interactions (KELLENBERGER et al. 1995). In vivo mutational analysis of the knotted domain in the Drosophila snake serine protease which is secreted into the perivitelline space of early embryos clearly demonstrates that it is essential for normal function of the snake protease (SMITH et al. 1992; 1994).

In future studies the Sb-sbd protease will provide an excellent model system in which to elaborate the molecular mechanisms underlying the developmental and pathological phenotypes associated with aberrant expression of type II transmembrane serine proteases.
ACKNOWLEDGMENTS

We thank Ann Hammonds, Jim Fristrom, Rob Ward, and Carl Thummel for communicating results prior to publication. We are grateful to Greg Winter and Liquin Luo for providing us with drok mutants prior to publication, Ann Hammonds for flies carrying hs-Stubble, and the Bloomington Stock Center for numerous fly stocks. We are indebted to David Kuhn and Jim Fristrom for critical reading of the manuscript. This work was supported by grants from the Department of the Army Prostrate Cancer Research Program (DAMD17-98-1-8590) and the Florida Hospital Gala Endowed Program for Oncologic Research to LvK.


Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2.


FIGURE LEGENDS

FIGURE 1. Defects in cell shape changes during leg imaginal disc morphogenesis result in malformed legs. (A) A Sb$^{63b+/}$ heterozygote leg showing the long, slender shape of a normal femur and tibia from the 3rd leg pair of an adult. Both Sb and sbd alleles behave as recessive mutations in the context of prepupal leg development. Note the dominant bristle phenotype in the trochanter (arrow). (B) A mildly malformed 3rd leg taken from an animal of the genotype RhoA$^{J3.8+/}$; Sb$^{63b+/}$. Note the abnormally short and thick tibia and dent in the femur. (C) A severely malformed leg taken from an animal of the genotype RhoA$^{J3.8+/}$; Sb$^{63b+/}$. Note the abnormally short and thick femur and tibia and associated twisting of the leg segments.

### TABLE 1. Genes that display the malformed leg phenotype in the mutant condition.

References indicate publications in which the malformed leg phenotype was first described. (1) BEATON et al. 1988; (2) KISS et al. 1988; (3) GOTWALS and FRISTROM 1991; (4) HALSELL et al. 2000; (5) EDWARDS and KEIHART 1996; (6) CLARK et al. 1995; (7) FLETCHER et al. 1995; (8) D’AVINO and THUMMEL 1998; (9) GATES and THUMMEL, 2000.

### TABLE 2. Mutant alleles and genotypes of stocks used in this study. Where appropriate the Bloomington Stock number is indicated. Alleles are defined as gain-of-function (gof) or loss-of-function (lof) except in cases where genetic testing has determined that alleles are amorphic, or hypomorphic. (1) BEATON et al. 1988; (2) APPEL et al. 1993; (3) A. HAMMONDS and J. FRISTROM pers. comm; (4) DOBZHANSKY 1930; (5) HALSELL et al. 2000; (6) STRUTT et al. 1997; (7) SAXTON et al. 1991; (8) BARRETT et al. 1997; (9) Berkeley Drosophila Genome Project; (10) WINTER et al. 2001; (11) KARESS et al. 1991; (12) EDWARDS and KEIHART 1996; (13) KONEV et al. 1994; (14) GOTWALS and FRISTROM 1991; (15) YOUNG et al., 1993; (16) MORGAN et al. 1925; (17) KISS et al. 1988.
TABLE 3. RhoA mutations enhance Sb-sbd leg malformation. Animals are either doubly heterozygous, e.g. RhoA\textsuperscript{J3.8}/+; Sb\textsuperscript{63b}/+, or transheterozygous for the sbd\textsuperscript{20l}/sbd\textsuperscript{d} mutations, e.g. RhoA\textsuperscript{J3.8}/+; sbd\textsuperscript{20l}/sbd\textsuperscript{d}. The numbers shown indicate the percentage of animals with malformed legs, with the total number of animals scored indicated in parenthesis. In this and all following tables, the highest percentage of malformation observed in other progeny classes (e.g. RhoA\textsuperscript{J3.8}/+; +/- or +/-; Sb\textsuperscript{63b}/+) has been subtracted from the data. n.d. = not determined.

TABLE 4. Mutations in DRhoGEF2, drok, and Df(2R)Jpl enhance Sb-sbd leg malformation. Animals are either doubly heterozygous, e.g. DRhoGEF2\textsuperscript{1.1}/+; Sb\textsuperscript{63b}/+, or transheterozygous for the sbd\textsuperscript{20l}/sbd\textsuperscript{d} mutations, e.g. DRhoGEF2\textsuperscript{1.1}/+; sbd\textsuperscript{20l}/sbd\textsuperscript{d}. The numbers shown indicate the percentage of animals with malformed legs, with the total number of animals scored indicated in parenthesis. n.d. = not determined.

TABLE 5. Leg malformation associated with over-expression of Sb-sbd is suppressed by reducing RhoA gene dosage. All animals carry one copy of the third chromosome hs-Stubble transgene. The transgene was induced by heat-shocking 0hr or 3hr prepupae for 1 hour at 37°C. The numbers shown indicate the number of animals exhibiting at least one malformed second or third leg and the total number of animals scored. The percentage of animals with malformed legs is indicated in parenthesis. Data are averaged across two independent experiments. +/- indicates that animals carry two wild-type RhoA alleles.
TABLE 6. *en(zip)* mutations enhance *zip*<sup>Ebr</sup>, *Sb-sbd*, and *RhoA* leg malformation. Animals are either doubly heterozygous, e.g. *DRhoGEF<sup>11-3</sup>-/+; *Sb<sup>53b</sup>/+, or transheterozygous for the *sbd<sup>201</sup>/sbd<sup>I</sup>* mutations, e.g. *DRhoGEF<sup>11-3</sup>-/+; *sbd<sup>201</sup>/sbd<sup>I</sup>*. The numbers shown indicate the percentage of animals with malformed legs, with the total number of animals scored indicated in parenthesis. *a* = reduced viability relative to sibling classes.

TABLE 7. *en(zip)* mutations interact genetically with each other. All animals are doubly heterozygous for the alleles indicated, e.g. *DRhoGEF<sup>11-3</sup>-/+ + *sbd<sup>201</sup>/sbd<sup>I</sup>*. The numbers shown indicate the percentage of animals with malformed legs, with the total number of animals scored indicated in parenthesis. *a* = reduced viability relative to sibling classes.

TABLE 8. Interactions between *br<sup>I</sup>* and *RhoA* mutants, mutations in RhoA pathway members, and *en(zip)* alleles in legs. 25°C and 18°C interaction data for males are shown. All animals are hemizygous for the X-linked *br<sup>I</sup>* allele and heterozygous for the other allele tested. n.d. = not determined.
Fig. 1. The presence of a RhoA mutation enhances the frequency of malformed legs in Stubble mutant animals. Most $Sb^{63b/+}$ animals exhibit normal, long, thin legs (a), 97% of $RhoA^{13.8/++; Sb^{63b/+}}$ animals exhibit either weak (b) or severe (c) leg malformation. The femur and tibia are shorter and fatter than wild type, and in the more severe cases, are kinked or dented. The examples shown in these panel are from the third pair of legs. Often, if one leg is weakly malformed, the other leg of the pair is normal, but when severe malformation is seen, usually both legs of the pair are affected similarly.

Note in the text that only the proximal-most portion of the femur and coxa have the shortened bristles that are so obvious on the thorax and head of $Sb^{63b/+}$ animals.
Figure 2. Model for Sb-sbd signaling to RhoA in Drosophila leg imaginal discs.

Sb-sbd protease → cell surface receptor

<table>
<thead>
<tr>
<th>Rho-GEF</th>
</tr>
</thead>
<tbody>
<tr>
<td>RhoA - GDP → RhoA - GTP</td>
</tr>
<tr>
<td>Rho-GAP ↓</td>
</tr>
</tbody>
</table>

myosin light chain kinase

Rho kinase (Drok) → myosin light chain phosphatase

myosin regulatory light chain (Sqh)

myosin II heavy chain (Zipper) → actin cytoskeleton
TABLE 1

Genes that display the malformed leg phenotype in the mutant condition.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Protein Product</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stubble-stubbloid</td>
<td>Type II transmembrane serine protease</td>
<td>(1)</td>
</tr>
<tr>
<td>Broad-Complex</td>
<td>Zinc-finger transcription factors</td>
<td>(2)</td>
</tr>
<tr>
<td>zipper</td>
<td>Non-muscle myosin II heavy chain</td>
<td>(3)</td>
</tr>
<tr>
<td>blistered</td>
<td>Drosophila serum response factor</td>
<td>(3)</td>
</tr>
<tr>
<td>RhoA</td>
<td>Small GTPase</td>
<td>(4)</td>
</tr>
<tr>
<td>DRhoGEF2</td>
<td>RhoA-specific guanine nucleotide exchange factor</td>
<td>(4)</td>
</tr>
<tr>
<td>spaghetti squash</td>
<td>Myosin regulatory light chain</td>
<td>(5)</td>
</tr>
<tr>
<td>dachsous</td>
<td>Cadherin</td>
<td>(6)</td>
</tr>
<tr>
<td>E74</td>
<td>ETS transcription factors</td>
<td>(7)</td>
</tr>
<tr>
<td>crooked legs</td>
<td>Zinc-finger transcription factor</td>
<td>(8)</td>
</tr>
<tr>
<td>vulcan</td>
<td>SAPAP</td>
<td>(9)</td>
</tr>
<tr>
<td>bancal</td>
<td>hnRNP K</td>
<td>(9)</td>
</tr>
<tr>
<td>Mutant allele</td>
<td>Genotype of stock</td>
<td>Mutation</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Sf'</td>
<td>Sf' ry'TM6B, Tb Ha</td>
<td>transpositional insertion</td>
</tr>
<tr>
<td>Sf''</td>
<td>red Sf'' e'TM6B, Tb Ha e ca</td>
<td>transpositional insertion</td>
</tr>
<tr>
<td>Sf'0</td>
<td>Sf'0 TM6B, Tb Ha e</td>
<td>transpositional insertion</td>
</tr>
<tr>
<td>Sf'1</td>
<td>Sf'1 TM6B, Tb Ha e</td>
<td>X-ray</td>
</tr>
<tr>
<td>shd'</td>
<td>shd' re e ca</td>
<td>spontaneous</td>
</tr>
<tr>
<td>shd''</td>
<td>shd'' e e e ca</td>
<td>X-ray</td>
</tr>
<tr>
<td>shd''0</td>
<td>red shd''0 e'TM6B, Tb Ha e</td>
<td>EMS</td>
</tr>
<tr>
<td>Rhoc19'</td>
<td>Rhoc19'CyO</td>
<td>EMS</td>
</tr>
<tr>
<td>Rhoc19-1</td>
<td>pr Rhoc19-1 CyO, ft-lacZ</td>
<td>EMS</td>
</tr>
<tr>
<td>Rhoc19''</td>
<td>Rhoc19''CyO, ft-lacZ</td>
<td>P-element</td>
</tr>
<tr>
<td>Rhoc19'''</td>
<td>Rhoc19'''CyO, ft-lacZ</td>
<td>P-element</td>
</tr>
<tr>
<td>Rhoc19''''</td>
<td>Rhoc19''''CyO, ft-lacZ</td>
<td>P-element</td>
</tr>
<tr>
<td>Df(2R)Jp8 (BL1520)</td>
<td>w' Np'; Df(2R)Jp8 w' CyO</td>
<td>X-ray</td>
</tr>
<tr>
<td>Df(2R)Jp1 (BL1518)</td>
<td>w' Np'; Df(2R)Jp1 w' CyO</td>
<td>X-ray</td>
</tr>
<tr>
<td>RhoGEF2''</td>
<td>w'; RhoGEF2'' CyO, act-lacZ</td>
<td>EMS</td>
</tr>
<tr>
<td>RhoGEF2'''</td>
<td>w'; RhoGEF2'' CyO, act-lacZ</td>
<td>EMS</td>
</tr>
<tr>
<td>RhoGEF2'''''</td>
<td>RhoGEF2'''' CyO, ft-lacZ</td>
<td>P-element insertion</td>
</tr>
<tr>
<td>drk''</td>
<td>w drk'' FRT80M3</td>
<td>EMS</td>
</tr>
<tr>
<td>drk'''</td>
<td>w' drk''' FRT80M3</td>
<td>EMS</td>
</tr>
<tr>
<td>sqh''</td>
<td>yw sqh'' 9 FRT80M3</td>
<td>EMS</td>
</tr>
<tr>
<td>sqh'''</td>
<td>yw sqh'' 9 FRT80M3</td>
<td>EMS</td>
</tr>
<tr>
<td>Phe' (BL 5523)</td>
<td>Phe'CyO</td>
<td>X-ray</td>
</tr>
<tr>
<td>Phe'''' (BL12322)</td>
<td>Phe''''CyO, ft''''CyO; ry''''</td>
<td>P-element insertion</td>
</tr>
<tr>
<td>zip''''</td>
<td>b pr cn sp zip''''/SMS</td>
<td>EMS</td>
</tr>
<tr>
<td>br''</td>
<td>br''</td>
<td>spontaneous</td>
</tr>
<tr>
<td></td>
<td>RhoA&lt;sup&gt;13.8&lt;/sup&gt; / +</td>
<td>RhoA&lt;sup&gt;E3.10&lt;/sup&gt; / +</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Sb&lt;sup&gt;23b&lt;/sup&gt; / +</td>
<td>94% (344)</td>
<td>89% (272)</td>
</tr>
<tr>
<td>Sb&lt;sup&gt;70&lt;/sup&gt; / +</td>
<td>91% (383)</td>
<td>95% (253)</td>
</tr>
<tr>
<td>Sb' / +</td>
<td>8% (350)</td>
<td>4% (343)</td>
</tr>
<tr>
<td>Sb&lt;sup&gt;16i&lt;/sup&gt; / +</td>
<td>15% (455)</td>
<td>8% (277)</td>
</tr>
<tr>
<td>sbd&lt;sup&gt;201&lt;/sup&gt; / +</td>
<td>0% (395)</td>
<td>0% (260)</td>
</tr>
<tr>
<td>sbd&lt;sup&gt;105&lt;/sup&gt; / +</td>
<td>28% (230)</td>
<td>32% (391)</td>
</tr>
<tr>
<td>sbd' / +</td>
<td>2% (344)</td>
<td>1% (193)</td>
</tr>
<tr>
<td>sbd&lt;sup&gt;201&lt;/sup&gt; / sbd'</td>
<td>86% (244)</td>
<td>89% (164)</td>
</tr>
<tr>
<td>sbd&lt;sup&gt;201&lt;/sup&gt; / sbd&lt;sup&gt;2&lt;/sup&gt;</td>
<td>18% (272)</td>
<td>40% (215)</td>
</tr>
</tbody>
</table>

*TABLE 3*

*RhoA mutants enhance Sb-sbd leg malformation*
### TABLE 4

Mutations in DRhoGEF2, drok, and Df(2R)Jp1 enhance Sb-sbd leg malformation

<table>
<thead>
<tr>
<th></th>
<th>GEF2&lt;sup&gt;1/1&lt;/sup&gt; / +</th>
<th>GEF2&lt;sup&gt;4/1&lt;/sup&gt; / +</th>
<th>GEF2&lt;sup&gt;b201&lt;/sup&gt; / +</th>
<th>GEF2&lt;sup&gt;11-3&lt;/sup&gt; / +</th>
<th>drok&lt;sup&gt;1&lt;/sup&gt; / +</th>
<th>drok&lt;sup&gt;2&lt;/sup&gt; / +</th>
<th>Df(2R)Jp1 / +</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sb&lt;sup&gt;53b&lt;/sup&gt; / +</td>
<td>11% (211)</td>
<td>2% (277)</td>
<td>11% (232)</td>
<td>45% (382)</td>
<td>11% (186)</td>
<td>28% (176)</td>
<td>43% (165)</td>
</tr>
<tr>
<td>Sb&lt;sup&gt;70&lt;/sup&gt; / +</td>
<td>12% (273)</td>
<td>3% (287)</td>
<td>9% (297)</td>
<td>41% (373)</td>
<td>65% (330)</td>
<td>57% (201)</td>
<td>28% (213)</td>
</tr>
<tr>
<td>sbd&lt;sup&gt;201&lt;/sup&gt; / +</td>
<td>1% (244)</td>
<td>0% (196)</td>
<td>0% (282)</td>
<td>1% (555)</td>
<td>2% (246)</td>
<td>0% (178)</td>
<td>n.d.</td>
</tr>
<tr>
<td>sbd&lt;sup&gt;105&lt;/sup&gt; / +</td>
<td>0% (186)</td>
<td>0% (187)</td>
<td>0% (228)</td>
<td>0% (139)</td>
<td>9% (140)</td>
<td>8% (136)</td>
<td>n.d.</td>
</tr>
<tr>
<td>sbd&lt;sup&gt;201&lt;/sup&gt; / sbd&lt;sup&gt;1&lt;/sup&gt;</td>
<td>24% (206)</td>
<td>14% (192)</td>
<td>12% (222)</td>
<td>32% (163)</td>
<td>10% (243)</td>
<td>15% (259)</td>
<td>71% (149)</td>
</tr>
</tbody>
</table>
TABLE 5
Leg malformation associated with over-expression of Sb-sbd is suppressed by reducing RhoA gene dosage

<table>
<thead>
<tr>
<th></th>
<th>HS 0h AP</th>
<th></th>
<th>HS 3h AP</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+/-</td>
<td>RhoA^{720}/+</td>
<td>+/-</td>
<td>RhoA^{720}/+</td>
</tr>
<tr>
<td>2^{nd} legs</td>
<td>17/97 (17%)</td>
<td>10/121 (8%)</td>
<td>75/108 (69%)</td>
<td>42/165 (25%)</td>
</tr>
<tr>
<td>3^{rd} legs</td>
<td>56/97 (58%)</td>
<td>35/121 (29%)</td>
<td>91/108 (84%)</td>
<td>91/165 (55%)</td>
</tr>
<tr>
<td>Enviroment</td>
<td>zip&lt;sup&gt;Ebr&lt;/sup&gt; / +</td>
<td>Sb&lt;sup&gt;E3b&lt;/sup&gt; / +</td>
<td>Sb&lt;sup&gt;b&lt;/sup&gt; / +</td>
<td>sbd&lt;sup&gt;201&lt;/sup&gt; / sbd&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>----------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>GEF&lt;sup&gt;II.3&lt;/sup&gt; / +</td>
<td>81% (186)</td>
<td>45% (382)</td>
<td>41% (373)</td>
<td>32% (163)</td>
</tr>
<tr>
<td>I2-5 / +</td>
<td>71% (186)</td>
<td>17% (229)</td>
<td>39% (257)</td>
<td>21% (185)</td>
</tr>
<tr>
<td>RhoA&lt;sup&gt;12-6&lt;/sup&gt; / +</td>
<td>83% (165)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>61% (292)</td>
<td>74% (163)</td>
<td>52% (163)</td>
</tr>
<tr>
<td>I8-5 / +</td>
<td>41% (311)</td>
<td>34% (388)</td>
<td>37% (299)</td>
<td>26% (177)</td>
</tr>
<tr>
<td>31-6 / +</td>
<td>22% (486)</td>
<td>16% (427)</td>
<td>26% (382)</td>
<td>41% (193)</td>
</tr>
<tr>
<td>zip&lt;sup&gt;33.1&lt;/sup&gt; / +</td>
<td>97% (123)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8% (274)</td>
<td>36% (264)</td>
<td>44% (163)</td>
</tr>
</tbody>
</table>

**TABLE 6**

*en(zip)* mutants enhance *zip<sup>Ebr</sup>, Sb-sbd, and RhoA leg malformation*
TABLE 7

*en(zip)* mutations interact genetically with each other

<table>
<thead>
<tr>
<th></th>
<th>GEF2&lt;sup&gt;11-3&lt;/sup&gt;</th>
<th>12-5</th>
<th>RhoA&lt;sup&gt;12-6&lt;/sup&gt;</th>
<th>18-5</th>
<th>31-6</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEF2&lt;sup&gt;11-3&lt;/sup&gt;</td>
<td>lethal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-5</td>
<td>30% (311)</td>
<td>lethal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RhoA&lt;sup&gt;12-6&lt;/sup&gt;</td>
<td>73% (229)</td>
<td>46% (267)</td>
<td>lethal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-5</td>
<td>15% (453)</td>
<td>89% (85)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>27% (296)</td>
<td>lethal</td>
<td></td>
</tr>
<tr>
<td>31-6</td>
<td>3% (452)</td>
<td>37% (259)</td>
<td>44% (102)</td>
<td>35% (249)</td>
<td>24% (224)</td>
</tr>
</tbody>
</table>
TABLE 8

Interactions between br and RhoA mutants, mutations in RhoA pathway members, and en(zip) mutants in legs

<table>
<thead>
<tr>
<th></th>
<th>br&lt;sup&gt;1&lt;/sup&gt; / Y 25°C</th>
<th>br&lt;sup&gt;1&lt;/sup&gt; / Y 18°C</th>
</tr>
</thead>
<tbody>
<tr>
<td>RhoA&lt;sup&gt;13.8&lt;/sup&gt; / +</td>
<td>26% (99)</td>
<td>29% (40)</td>
</tr>
<tr>
<td>RhoA&lt;sup&gt;E3.10&lt;/sup&gt; / +</td>
<td>45% (80)</td>
<td>63% (69)</td>
</tr>
<tr>
<td>Df(2R)Jp8 / +</td>
<td>4% (295)</td>
<td>48% (93)</td>
</tr>
<tr>
<td>GEF2&lt;sup&gt;1.1&lt;/sup&gt; / +</td>
<td>1% (195)</td>
<td>1% (163)</td>
</tr>
<tr>
<td>GEF2&lt;sup&gt;4.1&lt;/sup&gt; / +</td>
<td>1% (175)</td>
<td>4% (241)</td>
</tr>
<tr>
<td>GEF2&lt;sup&gt;o429&lt;/sup&gt; / +</td>
<td>4% (76)</td>
<td>1% (185)</td>
</tr>
<tr>
<td>drok&lt;sup&gt;1&lt;/sup&gt; / +</td>
<td>0% (224)</td>
<td>n.d.</td>
</tr>
<tr>
<td>drok&lt;sup&gt;2&lt;/sup&gt; / +</td>
<td>0% (195)</td>
<td>n.d.</td>
</tr>
<tr>
<td>Df(2R)Jp1 / +</td>
<td>28% (169)</td>
<td>13% (70)</td>
</tr>
<tr>
<td>GEF2&lt;sup&gt;11.3&lt;/sup&gt; / +</td>
<td>5% (182)</td>
<td>9% (125)</td>
</tr>
<tr>
<td>12-5 / +</td>
<td>0% (163)</td>
<td>2% (100)</td>
</tr>
<tr>
<td>RhoA&lt;sup&gt;12.6&lt;/sup&gt; / +</td>
<td>4% (237)</td>
<td>4% (204)</td>
</tr>
<tr>
<td>18-5 / +</td>
<td>0% (296)</td>
<td>0% (130)</td>
</tr>
<tr>
<td>31-6 / +</td>
<td>0% (136)</td>
<td>0% (212)</td>
</tr>
<tr>
<td>zip&lt;sup&gt;33.1&lt;/sup&gt; / +</td>
<td>0% (195)</td>
<td>n.d.</td>
</tr>
</tbody>
</table>
MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

PHYLIS M. RINEHART
Deputy Chief of Staff for Information Management